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Abstract
A longitudinal seroepidemiological cohort study of Epstein-Barr virus (EBV) in the Edinburgh student
population was conducted between 1999 and 2003. During this time 60 cases of infectious
mononucleosis (IM) were recruited at the University Health Centre to join a case control study to
investigate the symptoms of IM and its impact on daily activities.
In the longitudinal cohort study a total of 2006 students (1258 female and 748 male) commencing four
year degree courses in 1999 or 2000 had their EBV serology determined and completed a lifestyle
questionnaire. Overall 1499 (75%) were EBV seropositive at recruitment. Female students were
more likely than male students to be seropositive (79% vs. 69%, p<0.001), as were, students with
siblings (75%, compared to those without 66%, p=0.023), and those reporting prior residence in a
tropical country (81%, p=0.003). Students reporting a prior sexual relationship were more likely to be
seropositive (83%, p<0.001). Repeat serological testing of 241 initially seronegative students
undertaken at the start of their fourth year of study showed that 110 (54%) had seroconverted over the
intervening three year period. The proportion experiencing IM was 25%.
Of the 60 IM cases recruited to the case control study, the great majority 56/60 (93%) had either sore
throat or complaints relating to lymphadenopathy when presenting to their GP. Few students
complained of fever (13%), and some had presentations that included atypical symptoms including
gastrointestinal complaints 8% (predominantly vomiting), headache 10%, fainting 10% or cough 7%.
Fatigue was experienced by all cases during the period of their most severe symptoms, although the
severity and duration varied considerably. Female students experienced more severe and prolonged
fatigue (median 125 days) than males (median 54 days, p=0.002). Overall 73% of students missed
university classes because of IM. Female students were more likely to miss timetabled university
classes (median 17 hours) than males (median 2 hours, p=0.004) and were more likely to discontinue
their studies completely (16% vs. 0%, p=0.055). All cases, but only 66% of the control group
students reported any sexual contact, including kissing, in the preceding three months (p<0.001).
Analysis of lymphocyte subsets in IM cases and controls demonstrated prolonged perturbations of
some subsets following IM, with elevated natural killer and gamma delta T-cell populations 5 or more
months after diagnosis.
Strain typing was performed on EBV DNA obtained from IM cases and their partners, friends and
flatmates. Matching strains were found in 9/11 (82%) IM and partner pairs, but in only 3/17 (18%) of
non-sexual contacts of IM cases (p=0.001).
The study demonstrates that students with IM are likely to be sexually active, and may therefore have
additional health care needs. IM in university students is associated with prolonged clinical,
immunological, and social consequences. Female students are more likely than males to experience a
protracted fatigue state and to miss university classes.
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Aim
The present study was undertaken to investigate the current epidemiology of EBV infection
in a student population, the risk factors for symptomatic seroconversion and the clinical and
social impact of symptomatic infection.
Introduction
1 Herpes Viruses
1.1 Herpes Virus Family
Herpes viruses are widespread animal viruses found in diverse species ranging from
molluscs to man. Membership of the family is based on the distinct virus morphology and
shared biological features, which include, the ability to remain latent in their hosts,
destruction of the infected cell when virus progeny are produced, synthesis of viral DNA and
assembly of the viral eapsid in the host cell nucleus, and the production of a large number of
viral enzymes (Minson et al, 2000; Pellet & Roizman, 2007). There is marked sequence
diversity between the viruses of homoiothermic (warm blooded birds and mammals) and
poikilothermic (cold blooded) animals, although the herpesvirus structure is conserved.
The herpes viruses have large double stranded DNA genomes encased in an icosohedral
nucleocapsid, composed of 162 capsomers, which varies little in size between host species,
despite the variable size of the enclosed genome. The capsid is coated with a layer of
proteins known as the tegument and this is surrounded by a lipid bilayer envelope, derived
from the host cell which contains virus-encoded glycoproteins. Interactions between cellular
receptors and viral glycoproteins trigger envelope-membrane or cell-cell fusion. Three
glycoproteins, designated gB, gH and gL, are thought to be essential for fusion in all herpes
viruses, although additional viral glycoproteins may be required as fusion ligands (e.g. gD)
and as binding ligands (e.g. gC) (Spear & Longnecker, 2003).
1.2 Classification ofHerpes Viruses
The family Herpesviridae is divided into three subfamilies- alpha, beta and gamma which all
share features of herpes virus (HV) biology, including a high incidence of asymptomatic
infections, thought to reflect the long co-evolution with their respective hosts, and, the
establishment of latency with episodes of reactivation, which allows horizontal transmission
to new hosts. The host-virus relationship is finely balanced and disease states may occur,
particularly in situations of impaired host immunity or if infection of an unusual host occurs.
Initially the classification was based upon biological properties e.g., permissive cell types,
length of the reproductive cycle in cell culture and oncogenic potential, however,
classification is now based on the organisation and content of the genome. Generally alpha
and beta herpes viruses are not oncogenic, although notable exceptions exist, particularly
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Marek's Disease HV of chickens. Gamma herpes viruses establish latent infection in
lymphocytes and are associated with lymphoproliferative disease.
1.3 Evolution of Gamma Herpes Viruses in Primates
Prior to the year 2000 EBV-like B-lymphotropic gamma herpes viruses had been found only
in Old World primates. The discovery of EBV-like sequences in the peripheral blood of
squirrel monkeys, Saimiri sciureus, (Wang et al, 2001) and in spontaneous B-cell
lymphomas ofNew World common marmosets, Callithrix jacchus, (Cho et al, 2001; Ramer
et al, 2000), implied that primates and EBV-like gamma-herpes viruses had been evolving
together prior to the split ofNew and Old world primates which occurred 35 - 47 million
years before the present day (Kumar & Hedges, 1998; McGeoch, 2001).
Comparison of conserved herpes virus genes permits classification into subfamilies and the
study of phylogenetic relationships. Gamma herpes viruses are subdivided into two genera
the lymphocryptoviruses (y-1), found only in primates, and rhadinoviruses (y-2) which are
found in a broader range of mammalian species. Both genera share aspects of genome
organisation and some y-herpes virus specific genes, including the transcriptional activator
known as BRLF1 in EBV; an anti-apoptotic Bcl-2 homologue; integral membrane proteins
that in EBV are designated latent membrane proteins 1 and 2 (LMP1 and LMP2); and, genes
that are analogous in function e.g., Epstein-Barr virus nuclear antigen 1 (EBNA1) and
latency-associated nuclear antigen (LANA) which allow the persistence of the genome as an
episome in latently infected cells (Kieff& Rickinson, 2007; McGeoch, 2001).
Lymphocryptoviruses, unlike rhadinoviruses, immortalise B-lymphocytes and to this end y-1
viruses share genes associated with cell immortalisation. Both y-1 and y-2 have homologues
of cellular genes e.g. the interleukin (IL)-10 homologue in EBV and the IL-6 homologue in
Human Herpes Virus 8 (HHV8).
1.4 Human Herpes Viruses
The human herpes viruses (HHVs) are a group, currently numbering eight, endemic in
human populations (Table l). EBV was the fourth member of the group to be discovered,
which also includes herpes simplex viruses 1 and 2, varicella zoster virus, cytomegalovirus,
HHV6A, HHV6B and HHV7, aetiological agents of erythema subitum, and HHV8 or
Kaposi's Sarcoma associated herpes virus (KSHV). Human herpes viruses are represented
in all three subfamilies (alpha, beta and gamma) of the Herpesviridae. Following primary
infection they all establish persistent infection resulting in periodic reactivation and shedding
of infectious virus. The extent of reactivation is influenced by the host immune system.
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The prevalence of the individual viruses varies from universal infection at an early age, as is
seen with HHV6B, to being an infection which mainly affects restricted geographical, ethnic
or behavioural groups with HHV8. Infection with HHVs occurs via mucosal surfaces,
although other routes of transmission are also seen. Cytomegalovirus (CMV), varicella
zoster virus (VZV) and herpes simplex viruses (HSV) 1 and 2 are associated with vertical
infection of the foetus; and EBV, CMV and HHV8 have been transmitted by blood
transfusion and / or organ donation.
1.5 The Discovery of EBV
Denis Burkitt, a surgeon working in Uganda after the Second World War, became interested
in an unusual tumour of the maxilla or mandible in young children in equatorial Africa. The
tumour was often multifocal at presentation, with deposits in the liver, adrenals or kidneys,
and responded poorly to surgery although appeared to regress with chemotherapy, which was
in short supply. Following a number of "medical safaris" he recorded that the tumour was
geographically restricted and related this to altitude, temperature and rainfall (Burkitt, 1958;
Burkitt, 1962a; Burkitt, 1962b; Burkitt, 1983; Olweny & Nkrumah, 1985). In 1961 he
presented his early findings at a lecture in The Middlesex Hospital London where Anthony
Epstein, a virologist, was in the audience. Surmising that the tumour might be caused by an
insect-vectored oncogenic virus he asked Burkitt to send tumour samples to his laboratory.
For the next two years Epstein, together with Bert Achong and a PhD student, Yvonne Barr,
tried to grow the samples in tissue culture at The Middlesex Hospital without success.
Epstein relates the delayed arrival of one tumour specimen which appeared turbid, and
thinking this would represent bacterial contamination, he decided to examine the specimen
microscopically before discarding it. Instead of bacterial contamination he found large
numbers of viable-looking tumour cells which reminded him of the successful culture of
murine lymphoid cells he had seen previously at Yale University. Thus the sample instead
of being discarded became the first Burkitt's Lymphoma (BL)-derived continuous cell line.
After almost three months of culture there was sufficient material to allow a portion to be
prepared for electron microscopy which revealed virus particles with the characteristic
morphology of a herpesvirus (Epstein, 1999; Epstein et al, 1964; Epstein, 1985).
Collaboration with Gertrude and Werner Henle in Pennsylvania confirmed that the newly
discovered virus was distinct from the then known human herpes viruses HSV, VZV and
CMV (Henle & Henle, 1966). Later when EBV was shown to be an almost universal
infection of humankind, additional co-factors were sought to explain the association of EBV
with BL. This led to the observation of the correlation between malaria intensity and tumour
incidence (Burkitt, 1983).
In the US, shortly after the description of EBV, the Henles were screening sera from patients
with unidentified viral infections when one of their research technicians contracted infectious
mononucleosis (IM), a disease then of unknown aetiology, characterised by sore throat,
lymphadenopathy and fever (see 2.1.1). Investigation showed evidence of seroconversion to
Epstein's newly discovered virus (Henle et al, 1968).
1.6 Epidemiology of EBV
1.6.1 Socio-economic and Geographical Factors
After the finding of EBV in cell lines derived from BL it became apparent that, unlike BL,
EBV infection was in fact widespread, although the timing of primary infection showed
marked geographical and socio-economic variation. Seroepidemiological studies in Africa
demonstrated very early EBV acquisition with 80-100% of infants infected by their first
birthday (Biggar et al, 1981; Kafuko et al, 1972). Urban African children residing in more
affluent homes showed slightly more delayed EBV acquisition, in some cases until the third
birthday (Biggar et al, 1981). Studies in Europe and the USA have shown later acquisition
of EBV with only 39% of children aged between 5 and 14 having serological evidence of
infection in a laboratory based UK study (Pereira et al, 1969) and 50% acquisition by 2 years
of age in a hospital based study in Philadelphia (Fleisher et al, 1979). A Danish study found
an association between positive EBV serology and the occupation of the head of the
household. Where the head of the household followed an "unskilled" occupation or was
unemployed 54% of children had antibodies as opposed to 34% of children from a "skilled"
or "professional" background (p<0.05) (Hesse et al, 1983).
Persistence of EBV seronegativity into the teenage years has been associated with higher
socio-economic status as assessed by the occupation of the head of the household (Dan &
Chang, 1990), the income of the household (Hallee et al, 1974) or residing in owner-
occupied housing (Dan & Chang, 1990). The association of earlier EBV seroconversion
with the presence of siblings has not been a constant finding; Dan and Chang (1990) and
Hallee et al (1974) found no association, whilst an Australian study found an excess of
seroconversions amongst siblings (Lai et al, 1975). A study based in Edinburgh primary
schools, using a salivary antibody detection method, also failed to find a significant
association with numbers of children in the home, but did find significant associations
between seropositivity and unemployment or manual occupation of the head of the
household; sharing a bedroom; or attending a school in an area with predominantly rented
housing estates (Crowcroft et al, 1998). The finding of an excess of IM, which reflects
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delayed EBV acquisition, in young people from higher socio-economic groups was
confirmed in a small study in London which compared the occupation of the head of the
household where an IM case arose, with the socio-economic grouping of the surrounding
population (Nye, 1973).
1.6.2 Serological Status by Age and Gender
Seroprevalence increases with age, the rapidity of acquisition depending on the affluence of
the household and community. In affluent communities where seroconversion is delayed,
two peaks of acquisition are seen; one in children under 5 years and a second in the teenage
years (Lai et al, 1975; Morris et al, 2002). A recent UK based study, based on serological
samples submitted for diagnostic purposes, showed 35% of children aged 1-4 years old, 54%
of 10-14 year olds and 72% of 15-19 year olds had evidence of past EBV infection (Morris
et al, 2002). In adolescents aged 10-14 years EBV seroprevalence increased at a younger
age in females, than males; a finding corroborated by an earlier community-based survey of
IM in the US, where the peak incidence of IM in girls occurred two years younger than in
males (Heath et al, 1972). It has been proposed that the epidemiology of EBV is currently
changing in the UK, in parallel with similar changes occurring in the epidemiology of HSV-
1, with more EBV seroconversions being delayed into later childhood and adolescence
(Morris et al, 2002). Similar delays in the acquisition ofEBV have recently been described
in Japan (Takeuchi et al, 2006).
1.6.3 Epidemiology of EBV and Infectious Mononucleosis in Students and Military
Populations
The association of EBV seroconversion and IM observed at the Henles' laboratory was
confirmed by testing serum samples that had been collected from students at Yale University
prior to, and after the onset of IM (Niederman et al, 1968). IM was recognized as an
important cause of ill-health in populations with large numbers of young people, including
universities and the military. In the 1960s IM was noted to be the third most common cause
of days lost to hospitalization in the US Air Force and fourth most common in the Navy
(Evans, 1970). In the 1960s and '70s the epidemiology in military recruits and students was
further investigated. Low seroconversion rates were found in US marine recruits and
students at The University of Hong Kong (2-7% per year, (Dan & Chang, 1990; Lehane,
1970)) whilst high rates were observed at Yale University (43-65% per year (Niederman et
al, 1970; Sawyer et al, 1971)). Rates of IM varied from zero in Peace Corps Volunteers and
Hong Kong Students (Dan & Chang, 1990; Niederman et al, 1970) to 13% ofEBV
seronegative students per year at Yale University (Sawyer et al, 1971). The proportion of
EBV seroconversions that resulted in documented illness also varied widely; from none (Dan
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& Chang, 1990; Niederman et al, 1970) to 74% (Sawyer et al, 1971). These prospective
studies are summarised in Table 2.
A study of 19 universities in the US showed a particularly low incidence of 1M at the
University of Hawaii which was not thought to be adequately explained by the low (13%)
prevalence of EBV-seronegative students. Possible additional explanatory factors were the
high proportion ofAsian students, the high proportion of students living with parents or
relatives, which resulted in low use of the university student health facilities, and which may
also have resulted in other social, sexual or health-care seeking behavioural differences in
the students, although these were not explored (Chang et al, 1979). A study amongst
Chinese students in Hong Kong showed that a large majority (93%, 71/1039) of students
were seropositive at university entry, and that all 16 subsequent EBV seroconversions in the
study were asymptomatic (Dan & Chang, 1990). Factors associated with seronegativity at
university entrance in this study were non-manual occupation of the head of the household,
and, residing in privately owned, as opposed to public housing. Seroconversion occurred in
26% (16/62) of the seronegative of students in one year, ofwhom 14/16 (88%) had not
engaged in "deep kissing that resulted in the exchange of saliva" (See 1.9.4 and 1.9.5). In
fact only three seronegative students admitted to kissing, and of these 2 seroconverted. Later
sociological studies have highlighted differences in the sexual behaviour of Asian and
Caucasian students (Huang & Uba, 1992; Meston et al, 1996).
At West Point Military Academy race was found to be a significant determinant of
seropositivity at entrance with 81% of black cadets and 62% ofwhite cadets being
seropositive (Hallee et al, 1974). Income of the family was also significant, with cadets
from the lowest income families more likely to be seropositive than those from the highest.
The study by Sawyer et al at Yale differs from other IM studies in that all EBV
seroconversions were associated with some symptoms, and of these 17/23 (74%) fulfilled a
very strict case definition for IM (Sawyer et al, 1971).
Hallee et al (1974) and Sawyer et al (1971) were unable to demonstrate an increased
incidence of IM or EBV infection amongst susceptible roommates of IM cases.
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1.7 Epidemiology of HSV and CMV
The other human herpes viruses share aspects of epidemiology with EBV. The
epidemiology of herpes simplex viruses and cytomegalovirus, in particular, has been
extensively studied. These viruses show horizontal transmission amongst young children,
which is mostly asymptomatic, and evidence of sexual transmission in adults.
1.7.1 Herpes Simplex Viruses
HSV-1 and HSV-2 are usually transmitted by different routes and typically affect different
areas of body. Like EBV, HSV-1 is usually acquired horizontally in childhood, through
contact with oral secretions, and early seroconversion is associated with poor socio¬
economic status (Whitley & Roizman, 2001). Oral or genital lesions may arise with HSV-1
depending on the mode of transmission. In the UK, the seroprevalence of HSV-1 has been
falling in children and in student populations (Best et al, 1994; Vyse et al, 2000), and the
proportion of symptomatic sexually acquired HSV-1 has been rising (Scoular et al, 2002). It
has been proposed that similar epidemiological trends will apply to EBV in view of the oral
salivary transmission route that they both share in childhood (Morris et al, 2002).
HSV-2 is usually sexually transmitted and typically results in genital lesions (Nahmias et al,
1990; Whitley & Roizman, 2001). In a cross-sectional survey ofUS undergraduates
increasing seroprevalence of HSV-1 and HSV-2 were each associated with a longer duration
of sexual activity in years, and with a prior history of sexually transmitted infection (Gibson
et al, 1990). A large cross-sectional survey in the US investigating HSV-2 seroepidemiology
found significant positive associations with female gender, non-Hispanic black ethnicity,
increasing numbers of lifetime sexual partners (Xu et al, 2006). Interestingly this study
reported a fall in HSV-2 seroprevalence in the period 1999-2004 compared with the period
1988-1994 which was concentrated in the younger age groups. The proportion of
participants reporting prior sexual intercourse (oral, anal or vaginal) in the age groups 15-19
years and 20-19 years had decreased in the later time period. A British study that
investigated the seroprevalence of HSV-2 in a sexually transmitted diseases clinic found that
homosexual men had a significantly increased risk of being HSV-2 positive than
heterosexual men, although the results were not stratified by numbers of sexual partners
(Cowan et al, 1994).
1.7.2 Cytomegalovirus
Like EBV, CMV may be transmitted through salivary contact. CMV is also found in semen
and cervical secretions with sexual transmission thought to be a significant route of person-
to-person spread. In addition transmission occurs transplacental^, during birth, via breast
milk, and iatrogenically, by blood transfusion or organ transplantation (Britt, 2005; Ho,
1990; Pass, 2001). The seroprevalence ofCMV infection increases with age although the
age at initial infection varies with living conditions, occurring earlier in developing countries
and in less affluent communities of the developed world. In the USA and Europe rates of
CMV infection are higher in non-white ethnic groups, although this appears to be a result of
socio-economic differences, rather than any true difference in susceptibility (Pass, 2001).
Although early acquisition ofCMV is generally related to poor socio-economic conditions,
Scandinavia and Japan are notable exceptions, because of high rates of perinatal transmission
and group day care of infants (Dollard et al, 2007; Ho, 1990; Pass & Hutto, 1986). Amongst
CMV positive mothers the detection ofCMV DNA in breast milk is almost universal
(Hamprecht et al, 2001), however, the prevalence ofCMV varies as does the acceptance of
breast feeding (Pass & Hutto, 1986) resulting in variations in perinatal acquisition. In the
UK and USA where fewer mothers have had CMV infection and breast feeding is less
consistently practised; only 10% of one year olds have acquired CMV as opposed to a
seroprevalence of 39-56% in infants in Finland, and Japan (Stagno et al, 1980). Group care
of young children appears to facilitate CMV transmission with 80% of children acquiring
CMV in this setting compared with 20% of children from a similar socio-economic
background cared for at home (Pass & Hutto, 1986). Later in life the prevalence ofCMV
infection is affected by sexual behaviour with positive correlations noted with increasing
duration of sexual activity in years, numbers of lifetime partners, and the presence of
sexually transmitted infections (Chandler et al, 1985a; Chandler et al, 1985b; Collier et al,
1990; Sohn et al, 1991; Stanberry et al, 2004). The use of barrier contraception may protect
against the acquisition ofCMV (Chandler et al, 1985a; Collier et al, 1990) although after
regression analysis Chandler et al found only a trend (p=0.06) towards significance.
Dan and Chang (1990) found the likelihood ofCMV seropositivity was positively correlated
with EBV seropositivity in Chinese students in Hong Kong, (p=0.02), although fewer
students had acquired CMV (60%) than EBV (94%) (see Table 3).
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Table 3 Proportions of students with antibodies to EBV and CMV at The Chinese University of Hong
Kong
t EBV- EBV+ Totals
CMV+ 6(2.1%) 167 (57.6%) 173 (59.7%)
CMV- 12 (4.1%) 105 (36.2%) 117(40.3%)
Totals 18 (6.2%) 272 (93.8%) 290
f Data from Dan and C lang (1990)
A British study of EBV in colleges and universities showed that CMV seroprevalence was
30% at college entry and acquisition was less than that of EBV at 1.4% in seven months,
considerably lower than the 12% acquisition rate of EBV during the same period (Anon.,
1971). A similar seroprevalence of 29% was found in 199 first year medical students at St.
Thomas's Hospital, London in the late 1980s (Best et al, 1994).
1.8 EBV Genome
In the infectious virion the DNA is double-stranded and linear, whilst in infected cells the
genome persists as an extra-chromosomal circular episome. This circularisation is mediated
by a terminal repeat sequence at each end of the linear molecule. The exact number of the
500 base pair (bp) repeat sequences is variable, a feature that has been used to assess
clonality of the virus in tumours (Raab-Traub & Flynn, 1986). Within the genome there is
another larger repeat sequence known as the major internal repeat or IRl, which comprises
5-10 copies of a 3072 bp sequence. It contains the Wp promoter for the EBNA genes which
is active when the virus first infects a B lymphocyte. The genes assembled on either side of
IRl are known as the unique short region (Us) and unique long region (UL). The Ul is
further subdivided by an additional three internal repeats. Overall the EBV genome has
coding potential for about 70 proteins of which the latent genes (see 1.8.1 and Table 4) allow
the establishment of a latent infection with limited viral gene expression but without the
production of virions. The EBV genome was sequenced using DNA fragments obtained by
BamHl restriction enzyme digestion (Baer et al, 1984). The BamW \ restriction fragments
are named according to their size, A being the largest. Genes are designated according to the
BamW\ fragment in which they are located e.g. the transcription factor BZLF1 is located in
the first (1) leftward (L) open reading frame of the BamH\ (B) fragment (Z) (Baer et al,
1984).
1.8.1 Latent Gene Expression
EBV possesses genes to facilitate viral survival in the host in order to achieve the state of
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latency. These are the EBV nuclear antigen genes (EBNA) 1, 2, 3A, 3B and 3C, leader
protein (LP), the latent membrane protein genes LMP1, 2A and 2B, EBV encoded RNAs
EBER 1 and 2, and the complementary strand transcripts (CSTs) also known as BamW 1 A
rightward transcripts (BARTs). In EBV-infected cells lytic infection resulting in cell
destruction is unusual in vitro; instead a latent infection is established in which the episomal
viral DNA is replicated and transmitted to the daughter cells. The expression of the latent
genes is tightly regulated by methylation of the gene promoters (Tao & Robertson, 2003) in
order to allow EBV to persist within the host without eradication by the host immune
response. Recently several EBV-encoded microRNAs have been described (Pfeffer et al,
2004). Clustered in two regions of the genome (BHRF1 and BART) these RNAs are thought
to function as host and viral gene regulators, which, unlike proteins, do not elicit an immune
response. Several patterns of expression of the latent genes in EBV associated tumour cells
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Latency type three, as seen in post-transplant lymphoproliferative disease (PTLD), involves
expression of all nine of the latent genes, the non-polyadenylated EBERs 1 and 2, and the
BamW\ A transcripts. Type two latency is typified by Hodgkin's disease, nasopharyngeal
carcinoma and T-cell lymphomas, and shows transcription of EBNA1, LMP1 and 2, EBERs
and BamW\ A transcripts. BL shows the latency type one pattern with expression of
EBNA1, EBERs and BamW\ A transcripts only. The form of latency found in latently
infected resting memory B-cells is debated. EBNA1 is expressed during cell division
(Hochberg et al, 2004; Yates et al, 1985), and there may also be limited transcription of
LMP2A, which prevents cells from entering the lytic cycle, although the extent of this is
contested (Hochberg et al, 2004; Qu & Rowe, 1992; Tierney et al, 1994).
1.8.2 EBV Types 1 and 2
Two types of antigenically distinct EBV exist which differ in the coding regions of EBNA 2,
3A, 3B, 3C and LP (Farrell, 2005; Sample et al, 1990). The type 1 and 2 EBNA2 proteins
share only 56% of amino acids and have differing functional capabilities with type 2 being
less capable of transforming B lymphocytes (Apolloni & Sculley, 1994; Rickinson et al,
1987). The two types are not distributed equally with type 2 strains being more common in
Africa and Papua New Guinea (Young et al, 1987; Zimber et al, 1986). Subsequent PCR
based studies suggested that type 2 strains and simultaneous infections with both types were
more widespread than previously thought (Apolloni & Sculley, 1994; Sixbey et al, 1989).
Infection with type 2 has been associated with high risk sexual behaviour in heterosexual and
homosexual men in both HIV-infected and uninfected individuals (van Baarle et al, 2000).
In contrast, HIV-infected haemophiliac males have a prevalence of type 2 infection that is
closer to that of the general population (Yao et al, 1998). Amongst HIV seropositive
populations type 2 EBV is over represented in the EBV-malignancies that arise in the
context ofHIV related immunosuppression (Powles & Bower, 2000).
1.9 Life Cycle of EBV
1.9.1 B-Cell Biology
A brief outline of normal B lymphocyte development is helpful in understanding the
lifecycle of EBV as the two are inextricably linked. Nai've B-cells (denoted by bearing IgD
and lacking CD27) released from the bone marrow have not responded to antigen, although,
due to the variation in assortment of the immunoglobulin genes, each is already programmed
to bind a specific antigen, known as their cognate antigen, via their B cell receptor (BCR).
The B-cells circulate in the periphery and secondary lymphoid organs, although cells arising
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in the tonsil and adenoids appear to preferentially traffic back to the lymphoid tissue of
Waldeyer's ring (Laichalk et al, 2002). When naive B-cells meet an antigen which attaches
to their BCR they become activated and home to the T-cell zone of lymphoid organs. If they
interact with dendritic cells and T-helper cells they will either differentiate into short-lived
plasma cells, producing low affinity, predominantly IgM antibody, or, migrate into B cell
follicles and start to proliferate and differentiate into centroblasts, in what becomes a
germinal center. Centroblasts undergo somatic hypermutation in the variable region of their
immunoglobulin genes which produces cells with variants of their original BCR, some of
which will have a higher affinity for the antigen. Class switching of the immunoglobulin
heavy chain occurs under the influence of cytokines and CD40 ligand (McHeyzer-Williams
& McHeyzer-Williams, 2005). The centroblasts differentiate into resting centrocytes and
those with a BCR which has a high affinity are selected to avoid apoptosis, by receiving
survival signals from germinal center T-cells and dendritic cells. These include interaction
of the BCR with cognate antigen on dendritic cells and ligation ofCD40 on the B-cell with
CD40 ligand on T-cells. Finally the B-cells exit the germinal center as antigen-specific
CD27+ memory cells or long-lived plasma cells for a life of antigen surveillance in
peripheral blood and secondary lymphoid organs. Following re-challenge with their cognate
antigen they differentiate into plasma cells and secrete antibody.
1.9.2 In vitro Study of EBV Infection
EBV attaches to the receptor for the complement component C3d, also known as CD21, on
B-cells via its glycoprotein (gp) 350/220, an analogue of gC (Fingeroth et al, 1984).
Thereafter gp42 (an analogue of gD, but without homology) attaches to HLA class II at
specific amino acid sites, which triggers fusion of the virus envelope with the cell membrane
via gpl 10 (gB), gp85 (gH) and gp25 (gL) (Spear & Longnecker, 2003). Epithelial cells lack
HLA class II and generally CD21 is also absent, and in these cells binding of EBV is
mediated by gp85 and gp25 to an as yet unidentified cellular receptor , and by another virus
glycoprotein, BMRF2, to the cellular a5(31 integrin (Hutt-Fletcher, 2005; Molesworth et al,
2000; Tugizov et al, 2003). Virus derived from B-cells more readily infects epithelial cells
than B-cells due to the trapping of gp42 by HLA II as EBV leaves the cell (Borza & Hutt-
Fletcher, 2002), whereas EBV derived from epithelial cells more readily infected B-cells,
stimulating the debate on cell type initially infected in natural infection. Opinion is divided
as to whether infection of the epithelial occurs prior to infection of B-cells, or whether
infection of B-cells occurs directly via the large surface area of the tonsillar crypts where a
specialised discontinuous epithelium exists (Howie, 1980; Perry & Whyte, 1998; Perry et al,
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1988). Tugizov et al (2003) demonstrated three modes of EBV infection in their in vitro cell
cultures of polarized tongue and nasopharyngeal epithelial cells : 1) direct cell to cell contact
at the apical cell membrane with EBV-infected lymphocytes; 2) entry at the baso-lateral
membranes of cell-free virions; and 3) virus spread across lateral membranes to adjacent
epithelial cells.
Early work found EBV-infected epithelial cells in IM (Lemon et al, 1977; Sixbey et al,
1984), a finding refuted by later studies (Anagnostopoulos et al, 1995; Karajannis et al,
1997; Niedobitek et al, 2000), which may reflect differences in methodology. It is possible
that a transient infection of epithelial cells occurs as prelude to infection of B-cells; this
would occur prior to the onset of IM symptoms and could therefore be missed in studies
involving tonsils excised in acute IM.
1.9.3 A Model of EBV Persistence
The hypothesis espoused by Thorley-Lawson is that EBV uses the normal processes of B-
cell maturation and development to persist in the host, without causing disease, and escapes
elimination by the immune response through maintaining latency in memory cells without
expressing any viral proteins (Hochberg et al, 2004; Thorley-Lawson, 2005).
In this hypothesis EBV infects naive B-lymphocytes in the lymphoid tissue of Waldeyer's
ring where lytic replication takes place as well as proliferation of the infected B-cells with
expression of all latent genes. The EBV activated B-cells migrate into follicles to form a
germinal centre where EBNA2 gene expression is switched off (Thorley-Lawson, 2005).
EBV uses expression of LMP1 (a functional homologue ofCD40) and LMP2A, which is
thought to replace the survival signal normally received from the BCR, to supplant the
normal cell survival signals required in the germinal centre (Caldwell et al, 1998; Gires et al,
1997; Kilger et al, 1998; Uchida et al, 1999; Zimber-Strobl et al, 1996). The infected B-
cells survive and differentiate to be released to the periphery as resting memory cells IgD-
CD27+. Once in the peripheral blood these resting memory cells divide only infrequently,
expressing EBNA1 when they do so, in order to maintain the viral episome (Hochberg et al,
2004; Yates et al, 1985). Otherwise EBV viral gene expression is minimal; several groups
have detected RNA transcripts of LMP2A (Babcock et al, 1999; Miyashita et al, 1997; Qu &
Rowe, 1992; Tierney et al, 1994) and some have also detected transcripts of EBNA1
(Miyashita et al, 1997; Tierney et al, 1994). Single cell analysis by Thorley-Lawson
(Hochberg et al, 2004; Thorley-Lawson, 2005) demonstrated that most memory cells do not
express any EBV latent genes. The memory B-cells are thought to cycle between the
periphery and Waldeyer's ring (Laichalk et al, 2002) and are stimulated into lytic replication
by differentiating into plasma cells (Crawford & Ando, 1986; Laichalk & Thorley-Lawson,
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2005). The signals causing the differentiation into plasma cells are unclear and may be
either the recognition of their cognate antigen, when cross-linking of their BCR occurs, or an
antigen independent process, involving bystander T-cell help, similar to that involved in B-
cell memory (Laichalk & Thorley-Lawson, 2005). This allows the production of infectious
virus, in the oropharynx, which may be transmitted to new susceptible hosts.
Anagnostopoulos et al (1995) propose that inter-individual transmission of EBV occurs via
the transfer of EBV-infected lymphocytes based on their in situ hybridisation study of tonsils
removed during IM.
1.9.4 Transmission
Studies of the epidemiology of IM had failed to show any increased risk of IM amongst
susceptible roommates of cases (Hallee et al, 1974; Sawyer et al, 1971). Hoagland had
retrospectively found a history of intimate oral contact with exchange of saliva amongst
many cases (Hoagland, 1964; Hoagland, 1955). A study of 45 EBV seronegative women,
who were seen every 6 months in a British family planning clinic, reported a median time to
seroconversion of 25 months (range 1-60 months) (Woodman et al, 2005). The authors
reported that "acquisition of infection is rarely contemporaneous with the first exposure to an
infected partner and that considerable time may have to elapse before a woman becomes
infected."
1.9.5 Oral Secretions
Cell free virus, present in throat washings of seropositive individuals may be detected by the
immortalisation of cultured B lymphocytes obtained from a seronegative donor. This
technique, utilised in early studies, demonstrates the presence of EBV in the throat gargles of
14-25% of healthy asymptomatic adults (Chang et al, 1973; Chang et al, 1978; Ferbas et al,
1992; Gerber et al, 1972; Haque & Crawford, 1997). Longitudinal study of EBV-infected
individuals showed that the excretion of cell free virus in throat gargles was present on every
occasion in 25% and intermittently detected in a further 66%, with only 2/24 (8%) not
having detectable EBV on any occasion (Yao et al, 1985). In acute IM 50% of patients had
cell free virus in their throat gargles using the same technique (Gerber et al, 1972). Miller et
al found EBV in 92% of IM cases again by the technique of B-cell transformation but their
sample processing method involved cell lysis, rather than using a cell free filtrate (Miller et
al, 1973). The increased rate of EBV detection after IM persisted for more than three
months following diagnosis (Miller et al, 1973; Niederman et al, 1976). Throat wash
samples obtained from immunosuppressed patients show rates of B-cell immortalisation of
38%-100% (Chang et al, 1978; Ferbas et al, 1992; Strauch et al, 1974). The more sensitive
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technique of PCR has demonstrated EBV DNA in the throat wash samples of 48-62%
asymptomatic individuals (Conacher et al, 2005; Haque & Crawford, 1997) and 97% of IM
cases (Balfour et al, 2005).
1.9.6 Genital Secretions
The possibility of sexual transmission is raised by the finding of cell free virus from cervical
washings in 4/28 (14%) women, and by positive PCR in 28-40% of cervical samples in four
other studies (Bevan et al, 1989; Naher et al, 1992; Sixbey et al, 1986; Taylor et al, 1994;
Voog et al, 1995). Ten of 21 (48%) symptomatic males attending a sexually transmitted
diseases clinic had EBV detected by PCR in cell-free filtrates of their urethral discharge
(Israele et al, 1991). One case report describes the detection ofEBV in genital ulcers in a
female with IM (Portnoy et al, 1984). Additional reports record the temporal association of
genital ulceration and IM, mostly in female patients, although not all had been sexually
active (Eludson & Perlman, 1998; Lawee & Shafir, 1983; Lorenzo & Robertson, 2005;
Wilson, 1993).
1.9.7 Breast Milk
Like CMV, EBV has been detected in breast milk. Junker et al detected EBV DNA in 60 of
132 (46%) of samples donated to a Canadian breast milk bank (Junker et al, 1991). It is not
clear whether breast milk is a source of EBV infection in infants; the transplacental
transmission ofmaternal antibodies to EBV in term infants would appear to protect against
early infection as evidenced by the abrupt onset of seroconversions after 8 months of age
(Chan et al, 2001).
1.9.8 Iatrogenic Acquisition of EBV
EBV may be acquired as a consequence of blood transfusion (Alfieri et al, 1996; Gerber et
al, 1969) or organ transplantation (Cen et al, 1991; Haque et al, 1996).
1.10 The Immune Response to EBV
EBV, a potentially oncogenic virus, elicits a broad array of responses from the immune
system and whilst these on the one hand might be regarded as ineffective, as the virus is not
eradicated, on the other the virus is sufficiently controlled in the vast majority of healthy
individuals so that no disease state ensues. The virus has evolved a number of immune
evasion mechanisms which allow persistence during the lifetime of the host and the
opportunity for transmission to new susceptibles.
Much of the data regarding the immune response to primary EBV infection are gathered
from patients diagnosed with IM as this is a detectable event. IM probably represents an
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exaggerated response to the virus, and subclinical infection is likely to elicit a less marked
cellular immune response.
1.10.1 Innate Immune Response
Natural killer cells form part of the innate response, express the surface marker CD56, show
cytotoxic activity - especially after activation by interferon (IFN)-a or (3 - and may
themselves produce IFN-y, tumour necrosis factor (TNF) and chemokines (Biron & Brossay,
2001). In IM natural killer (NK) cells form a proportion of the population of atypical
lymphocytes (Tomkinson et al, 1987). NK cells are thought to contribute to the control of
EBV, as evidenced by the reports of severe EBV infection in persons with NK cell defects
(Joncas et al, 1989; Merino et al, 1983). Boys with X-linked lymphoproliferative disease
have a defective or absent intracellular protein known as SAP (signalling lymphocytic
activation molecule [SLAM] associated grotein). In health SAP modulates the function of
many immune cells, including NK cells, by receiving signals from surface receptors. It is
thought that defective signalling, as a consequence of altered SAP, results in failure of
activation ofNK cells which are then unable to kill EBV-infected B-cells (Nichols et al,
2005; Parolini et al, 2000).
Gamma-delta T-cells form 2-7% of peripheral blood T-cells (Borst et al, 1988; Hassan et al,
1991; Lanier & Weiss, 1986) and have T-cell receptors composed ofy and 8 chain
heterodimers. They differ from conventional aP-T-cells in that they do not require antigen
processing, respond to non-peptide antigens and may function as antigen presenting cells
(Brandes et al, 2005; Chen & Letvin, 2003). Gamma-delta T-cells proliferate following
recognition of their non-peptide antigen and show a rapid and prolonged response following
re-exposure to the same antigen thus appearing to participate in both innate and adaptive
immune responses. Gamma-delta cells are thought to exert cytotoxicity by both perforin
mediated lysis and Fas-mediated apoptosis, and also to be a source of cytokines including
IFN-y and TNF-a (Kabelitz, 1999). Marked increases in y8 T-cells have been noted in
patients with certain infectious diseases, particularly intracellular pathogens (Bertotto et al,
1993; Ito et al, 1992; Jouen-Beades et al, 1997; Schneider et al, 1997), including EBV (De
Paoli et al, 1990; Hassan et al, 1991).
1.10.2 Adaptive Cell Mediated Immune Response
During IM the most obvious feature of the immune response to EBV is the massive
lymphocytic response, observable on a blood film as atypical lymphocytes. Early studies
determined that these were mainly CD8 T-cells with contributions of CD4+ T-cells and NK
cells (Crawford et al, 1981; Tomkinson et al, 1987). CD8' T-cells recognise the antigen
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specific for their receptor, and may either kill the infected cell directly, by osmotic lysis or
Fas-mediated apoptosis, or, release soluble antiviral factors, including IFN-y and TNF-a.
Some have argued that this exaggerated cytotoxic T-cell response is induced by a
superantigen triggering non-specific T-cell activation and proliferation (Sutkowski et al,
2001; Sutkowski et al, 1996), however, analysis of the T-cell receptors shows an oligoclonal
or clonal response in primary EBV infection (Callan et al, 1996). More recently the use of
HLA-tetramer technology has allowed more detailed dissection of the CD8" T-cell response,
which is surprisingly large with up to 44% of all CD8 cells in a single individual being
specific for one EBV epitope (Callan et al, 1998). The exact epitopes eliciting the CD8+
response varies with the HLA type of the individual. Whilst CD8 expansions to both lytic
and latent antigens is seen, the response to the lytic antigens occurs earlier and is of a greater
magnitude (Callan, 2004; Catalina et al, 2001; Hislop et al, 2002). The response to the lytic
antigens is predominantly directly towards immediate early and early gene products rather
than the late structural proteins (Pudney et al, 2005; Steven et al, 1997). In the response to
EBV latent antigens a distinct hierarchy of EBV antigens is observed; epitopes derived from
EBNA 3A, 3C and 3B are the most prevalent followed by LMP2. CD8+ cells specific for
EBNA2, LP and LMP1 epitopes are less commonly detected (Rickinson & Kieff, 2007). For
many years it was thought that the EBNA1 protein did not elicit a cytotoxic CD8 response
as such cells were not detected in the T-cells responding to EBV-infected B lymphoblastoid
cells (Rickinson and Kieff, 2007). Furthermore this protein contained a glycine-alanine
repeat domain which could not be processed by the proteosome (Levitskaya et al, 1997); the
main method by which epitopes are generated for presentation to cytotoxic lymphocytes on
class I HLA molecules. More recently this sequence has also been shown to reduce its own
translation from EBNA1 mRNA (Yin et al, 2003) further reducing EBNA1 epitope
presentation. In spite of these unusual evasion mechanisms EBNA1 is a frequent CD4" T-
cell target (Leen et al, 2001; Miinz et al, 2000) and now using the more sensitive technique
of IFN-y detection, EBNA 1-specific CD8' T-cells have been detected (Miinz, 2004).
T-cells are also critical in the control of latent EBV infection as evidenced by the rising
numbers of infected B-cells that occur as immunity declines in advanced HIV (Birx et al,
1986) and following organ transplantation (Lucas et al, 1996; Savoie et al, 1994).
Furthermore, EBV-associated B-cell lymphomas arising in settings of immunodeficiency,
such as organ transplantation (Armitage et al, 1991; Ho et al, 1988) may be successfully
treated with infusions of EBV-specific T-cells (Haque et al, 2002; Rooney et al, 1998).
Irrespective of whether the acute response in IM is exaggerated or not, work examining the
frequencies of EBV-specific CD8 cells in healthy volunteers has demonstrated on-going
41
high levels of cells specific for both lytic and latent antigens which can be as prevalent as
5.5% for a single epitope, even in persons without preceding IM (Tan et al, 1999).
The final composition in the epitope specificity of CD8+ and CD4+ cells following IM and
asymptomatic seroconversion has not been formally compared but is thought to result in
similar outcomes (Callan, 2004).
The contribution of the CD4 response to the control of EBV infection is less well defined
but is the subject of on-going study. In IM, the proliferation of CD4+ cells is much less than
that ofCD8 cells (Macallan et al, 2003), however study of other infections including murine
lymphocytic choriomeningitis (LCMV) infection suggests that they are likely to be crucial in
the mounting of an effective immune response (Zajac et al, 1998). In HIV infection,
secretion of IFN-y by EBV-specific CD8 cells was noted to fall with decreasing CD4 counts
(van Baarle et al, 2001). After the institution of highly active antiretroviral therapy detection
of IFN-y increased (Kostense et al, 2002). At the time of diagnosis of IM EBV-specific
CD4^ cells directed against both lytic antigens and the latent antigen EBNA3A are present
(Precopio et al, 2003). Recent in vitro studies have concentrated on EBNA1 -specific CD4+
cells which may be critical in the defence against EBV-associated malignancies (Miinz,
2004). Using overlapping peptides to stimulate IFN-y release, CD4 epitopes within the
latent proteins EBNA3C, LMP1 and LMP2 have also been identified, although CD4+ cells
directed against LMP1 and 2 occur in fewer individuals than those to EBNA1 or EBNA3C
(Leen et al, 2001).
1.10.3 Adaptive Humoral Immune Response
B-cells are the site of latent infection and are also responsible for the humoral response to the
virus, however, the role of antibody in ameliorating primary infection and in preventing
subsequent re-infections is unknown. The early antibody response in IM is characterised by
IgM and IgG to "viral capsid antigen"; actually a mixture of antigens made late in lytic
replication including the nucleocapsid and gpl 10, and early lytic cycle antigens so-called
"early antigen" (Rickinson & Kieff, 2001). Neutralising antibody initially of the IgM class
is produced against the major envelope glycoprotein gp350 with IgG to this antigen rising
relatively late (Rickinson & Kieff, 2007; Thorley-Lawson & Poodry, 1982). There is a
dichotomous antibody response to the nuclear antigens, with those against EBNA2 and 3
being formed early, and those against EBNA1 being delayed (Henle et al, 1987). In the
acute phase of IM a virus-induced polyclonal activation of B-cells occurs and a range of
"heterophile" and autoantibodies (mostly of the IgM class) are produced (Henle & Henle,
1979). Heterophile antibodies that are able to agglutinate horse and sheep erythrocytes form
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the basis of the "monospot" and Paul-Bunnell diagnostic tests used in acute IM (Davidsohn,
1937; Lee et al, 1968a; Paul & Bunnell, 1932) (see laboratory findings 2.1.1).
1.11 Immune Evasion
In order to maintain life-long persistence of EBV without eradication a number of evasion
strategies have evolved. The most important is the ability to remain latent in memory B-
cells with little or no gene expression as described above (see l .9.3). EBNAl is an unusual
protein with a glycine-alanine repeat domain, which reduces its own transcription and
proteosomal degradation as discussed above (see 1.10.2). These factors do not make
EBNA1 invisible to the immune system but are thought to reduce antigen presentation via
class 1 MHC molecules on infected B-cells. EBV has a number of homologues of human
genes which are thought to alter the immune response. Viral IL-10 has 84% homology with
the human gene; a cytokine with diverse anti-inflammatory and inhibitory effects on T-cells,
monocytes, macrophages and NK cells and which also stimulates the growth and
differentiation of B-cells (Cohen, 1997; Moore et al, 2001). EBV also subverts the effects of
class I and II interferons by: synthesising viral receptors which compete with the intended
IFN receptor; generating interfering RNAs which inhibit interferon-directed protein
synthesis; and down-regulating IFN-induced transcription (Cohen & Lekstrom, 1999;
Morrison et al, 2001; Sharp et al, 1999; Tortorella et al, 2000). The survival of EBV-
infected cells is promoted by several anti-apoptotic mechanisms including the production of
two homologues of the human gene Bcl-2, BHRF1 and BALF1; and the up-regulation of bcl-
2 itself by the viral gene LMP1 (Henderson et al, 1991; Henderson et al, 1993; Marshall et
al, 1999). Ressing et al have demonstrated that lytically infected cells secrete soluble gp42,
a glycoprotein that binds HLA class II molecules, which may help to protect EBV-infected
cells from CD4" T-cell recognition (Ressing et al, 2005).
2 Disease Burden
Infection with EBV is a significant public health concern. It is the known aetiological agent
of infectious mononucleosis, oral hairy leukoplakia and the majority of cases of B-cell
lymphoproliferative disease. Furthermore EBV is thought to have a direct role in the
pathogenesis of nasopharyngeal cancer, endemic Burkitt's lymphoma, around 40% of
Hodgkin's disease and 10% of gastric carcinoma, the fourth most prevalent cancer
worldwide. It is also associated with a number of less common tumours, and has a putative
role in several other tumours and immune mediated diseases. Understanding of the host
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immune response, the strategies evolved by the virus to evade immune control and of the
stages involved in oncogenesis are important in devising vaccines, therapies, and public
health measures to reduce the disease burden.
2.1 Diseases of Lymphocyte Origin
2.1.1 Infectious Mononucleosis
Clinical features and complications
After an incubation period of between four and seven weeks the symptoms of IM typified by
fever, sore throat and lymphadenopathy may arise (Hoagland, 1964; Hoagland, 1960;
Johannsen et al, 2005). The illness may be subacute in presentation resulting in difficulty in
pin-pointing the exact day of onset (Hoagland, 1960). Not all cases have pronounced sore
throat or lymphadenopathy; in some fever may predominate, whilst occasionally in others,
the presentation may be with an unusual complication.
Pharyngitis is evident in 85% and exudates may be seen in 22%. Lymphadenopathy
particularly affecting the posterior triangle of the neck is present in most cases; axillary or
groin nodes are detected in around half of cases (McCarthy & Hoagland, 1964).
Splenomegaly is clinically detectable in up to 17%; an ultrasound study demonstrated
splenic enlargement in all of 29 cases (Dommerby et al, 1986). Hepatomegaly is clinically
detectable in 10-15% of cases and in 50% by ultrasound (Dommerby et al, 1986; Johannsen
et al, 2005). Other features include petechiae at the junction of the soft and hard palate, and
eyelid oedema (McCarthy & Hoagland, 1964). Rashes, including macular erythema,
petechiae and urticaria are reported in 3-16% of cases, however, the concurrent
administration of ampicillin results in a rash in around 90% or more (Grotto et al, 2003;
McCarthy & Hoagland, 1964; Pullen et al, 1967), and calculated from Kerns et al (Kerns et
al, 1973). The acute features resolve over 3-4 weeks (Chretien et al, 1977), however
thereafter a fatigue state lasting a median of 8 weeks is common (White et al, 1998) and
occasionally depression may follow (Cadie et al, 1976; Petersen et al, 2006; White et al,
1998). A number of complications are well recognised (see Table 5) particularly hepatitis,
jaundice, thrombocytopenia, haemolytic anaemia, splenic rupture, and fatigue. Rarer
complications include encephalitis, demyelination, arrhythmia, pancreatitis, gastrointestinal
haemorrhage, interstitial nephritis and pulmonary infiltrates (Hickey & Strasburger, 1997;
Johannsen et al, 2005). Death as a result of IM is very rare and may be the result of an
underlying immunological defect, particularly the X-linked Duncan Syndrome (Bar et al,
1974; Mroczek et al, 1987; Purtilo et al, 1975). Other underlying defects resulting in severe
disease are recognised, including defective NK cell function (Joncas et al, 1989), perforin
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gene mutations (Katano et al, 2004) and selective IFN-y deficiency (Andersson et al, 1999).
Even in those without immune defects, fatal outcomes may sometimes occur as a result of
airway obstruction, neurological complications, hepatic failure, splenic rupture, myocarditis,
cardiac arrhythmia, secondary bacterial infection or haemorrhage (Andersson, 1991;
Carrington & Hall, 1986; Farley et al, 1992; Hickey & Strasburger, 1997; Johannsen et al,
2005; Kennard & Swash, 1981; Lukes & Cox, 1958; Markin et al, 1987; Penman, 1970).
Organ/System Complication
Liver Clinical jaundice 5%, fulminant hepatitis (rare)
Skin Rashes 3-16%; following the administration of ampicillin 86-98%
Haematological Thrombocytopenia, haemolytic anaemia, neutropenia
Psychiatric Depression, anxiety
Immunological Secondary infection, streptococcal sore throat, sepsis in association
with neutropenia, mesenteric adenitis, depressed cell mediated
immunity
Spleen Splenic rupture 0.1-0.5% spontaneous or after mild trauma (usually in
males), splenic infarction
Neurological Encephalitis, acute cerebellar syndrome, aseptic meningitis, Guillain
Barre Syndrome, cranial nerve palsy especially VII, transverse
myelitis, seizures, mononeuritis, optic neuritis, cerebral haemorrhage
Gastrointestinal Haemorrhage secondary to mucosal erosion, pancreatitis
Genitourinary Haematuria, interstitial nephritis, glomerulonephritis (rare), genital
ulceration
Cardiac Myocarditis, pericarditis, arrhythmia, electrocardiogram changes
Respiratory Respiratory tract obstruction, interstitial pneumonitis (rare)
Table 5 Complications of acute infectious mononucleosis
Laboratory findings
Prior to the availability of specific serological tests and the recognition of heterophile
antibodies IM was known to be associated with an absolute lymphocytosis and atypical
lymphocytes (Downey & McKinlay, 1923; Sprunt & Evans, 1920). The early studies relied
on strict adherence of the following diagnostic criteria 1) absolute lymphocytosis > 4500 /p.1,
2) relative lymphocytosis >50% and 3) atypical lymphocytes >10%, but after the
development of specific serological tests, and in particular anti-VCA (viral capsid antigen)
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IgM, it was recognised that approximately 60% of acute IM cases would be excluded by
these early criteria if only one blood count observation was performed (Fleisher et al, 1983).
Thus an absolute lymphocytosis is typical but not always present, lymphopenia is rarely
present and atypical lymphocytes are usually present, but often not at the originally
described level of 10%. Mild thrombocytopenia is common and neutropenia less so (Carter,
1965; Carter, 1966a).
Prior to the discovery of EBV as the aetiological agent in IM the production of antibodies to
animal antigens, particularly agglutinins to sheep erythrocytes, recognised in 1932 by Paul
and Bunnell, was used for laboratory confirmation of IM. Davidsohn refined the Paul-
Bunnell test with the use of guinea pig kidney antigen, which improved specificity, by
removing Forssman antibodies (animal erythrocyte agglutinins in human serum not related to
acute EBV infection) (Davidsohn, 1937).
Elevations of one or more liver function tests bilirubin, alkaline phosphatase,
aminotransferases occur in around 80% of IM cases, whilst clinical jaundice is apparent in
up to 5% of patients (Finkel et al, 1964; Paublini et al, 1977). Hyperbilirubinaemia may
result from impaired hepatic clearance or increased red blood cell (RBC) destruction as a
result of haemolysis or a combination of these. Jaundice is more common in older patients
and is a frequent accompaniment of patients that succumb to fulminant infection (Horwitz et
al, 1983; Marking?al, 1987).
Pathogenesis of IM
The exaggerated cytotoxic lymphocyte response and cytokine secretion are thought to
account for the symptoms of IM but the reasons for the development of the exaggerated
immune response are not known (Attarbaschi et al, 2003; Foss et al, 1994; Linde et al,
1992). Why some individuals develop IM on primary EBV infection and others do not is
unexplained, but both host and viral factors may be important. Small studies of HLA types
and the occurrence of IM have not detected any association (Rosdahl & Svejgaard, 1979;
Schiller & Davey, 1974; Ythier et al, 1983). In nasopharyngeal carcinoma an association
has been detected between HLA type and the occurrence of this EBV-related tumour within
families but the HLA type differs between affected family groups (de-The, 2005); an
analogous situation may exist in IM. Genetic polymorphism of the IL-10 gene promoter has
been associated with variation in the amount of cytokine produced; whereby substitution of
G with A at position 1082 results in the production of less IL-10 in vitro (Turner et al, 1997).
A study examining this polymorphism of IL-10, showed that individuals who retained G at
position 1082 were protected against both seroconversion and symptomatic disease
(Helminen et al, 1999), although it has not been possible to replicate these observations (Dr.
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K.McAulay, personal communication). More recently susceptibility to IM and severity of
subsequent illness has been linked to HLA class I polymorphisms (McAulay et al, 2007).
Primary infection in children is not usually accompanied by IM (Fleisher et al, 1979). One
possible explanation for the age related difference in outcome of primary infection was the
suggestion that perhaps young children were infected with a lower dose than young adults.
This has been partially countered with the finding of similar viral loads in adults
experiencing symptomatic and asymptomatic primary infection (Silins et al, 2001). It has
been argued that the immune system of children responds differently to that of the young
adult. Possible explanations include the lack of clonal expansions of the CD8+ cells of
young children, differences in lymphocyte subsets which do not attain adult values until the
second decade, and the greater protection offered by the tonsils of younger children which
regress after around the age of 14 (Bofill et al, 1992; Perry & Whyte, 1998; Selin et al,
1998). Racial or behavioural factors might also be important in disease acquisition; IM was
not observed in studies conducted in Hong Kong and the Philippines, although
seroconversions did occur in young adults (Dan & Chang, 1990; Evans et al, 1967). Others
have pointed to the role of psychological factors in symptomatic seroconverters; military
recruits with high motivation scores combined with poorer academic achievement were more
likely to experience IM rather than silent seroconversion (Kasl et al, 1979).
The relative contribution of the two types of EBV to IM is not known; Gratama and Ernberg
(1995) reported that 7/7 IM cases were cased by type 1 strains. Type 2 is known to have a
lesser ability to transform B-cells in culture in vitro (Rickinson et al, 1987). The current
investigation will investigate the proportion of IM caused by type 2 strains.
Pitfalls in the diagnosis of IM
The typical findings of positive anti-VCA IgG and IgM, positive heterophile antibody and
absent anti-EBNA are not found in every case of EBV-induced IM. Anti-VCA IgG and IgM
are usually present at the onset of symptoms but one or both may be delayed (Balfour et al,
2005; Blake et al, 1976; Fleisher et al, 1983). Rarely anti-VCA IgM is not detected, which
may reflect the low titre of this antibody produced and the screening dilution used (Evans et
al, 1975). Antibodies to EBNA are usually absent in the acute phase, developing in
convalescence, but may occasionally be detected during the first week of illness (Fleisher et
al, 1983; Henleetal, 1974).
Amongst patients with IM, confirmed with specific anti-VCA IgM, only 85-96% will have a
positive heterophile antibody test using horse erythrocytes (Blake et al, 1976; Evans et al,
1975; Fleisher et al, 1983). As with anti-VCA antibodies, the onset of detectable heterophile
antibodies may be delayed (Blake et al, 1976; Fleisher et al, 1983). Children aged less than
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four are much less likely to have detectable heterophile antibody (Sumaya & Ench, 1985).
A more recent review has emphasised that many EBV-induced IM cases will have a normal
total lymphocyte count and only 21% had an atypical lymphocytosis comprising 10% or
more of the total lymphocyte count (Ventura & Etudnall, 2004).
Laboratory investigations, rather than giving clarity, may add to diagnostic difficulty; false
positive heterophile antibody tests have been noted in other infections, notably HIV,
connective tissue diseases, lymphoma and in the absence of any illness (Hendry &
Longmore, 1982; Horwitz et al, 1979; Ridker et al, 1990; Seitanidis, 1969; Vidrih et al,
2001; Wynne Jones et al, 1994). Delayed or atypical serological responses to primary
infection may occur in immunosuppressed patients (Gray et al, 1992; Ho et al, 1985). False
positive anti-VCA IgM results have been noted in the presence of rheumatoid factor (Henle
et al, 1979). This difficulty is further compounded by the fact that rheumatoid factor (IgM to
IgG) may be produced in the acute phase of IM (Carter, 1966b). Lastly patients with EBV-
induced IM may show a positive result in CMV IgM tests, although patients with CMV
apparently do not show positive EBV tests (Horwitz et al, 1977).
2.1.2 X-linked Lymphoproliferative Syndrome
X-linked lymphoproliferative syndrome (XLP or XLPS) is a rare familial fatal form of IM
which has been recognised for over 30 years (Bar et al, 1974; Purtilo et al, 1975). The
typical clinical presentation is of a young male who is well prior to primary EBV infection
but when infected rapidly succumbs to fulminant IM. Death may result from hepatic
necrosis, secondary to massive cytotoxic lymphocyte infiltration and cytokine release,
aplastic anaemia or pancytopaenia, or, in some cases superimposed bacterial or fungal
infection (Mroczek et al, 1987; Seemayer et al, 1995). Haemophagocytosis is a frequent
histological finding (Mroczek et al, 1987; Seemayer et al, 1995). Other phenotypes
including dysgammaglobulinaemia, lymphoproliferative disorders or autoimmune
phenomena, including vasculitis, colitis or aplastic anaemia, may arise before or after EBV
infection (Nichols et al, 2005).
The defective gene is located on the long arm of the X-chromosome and encodes a small
cytoplasmic protein known as SH2D1A (Src homology 2 domain-containing protein) or SAP
(signalling lymphocytic activation molecule [SLAM] associated protein) (Coffey et al, 1998;
Nichols et al, 1998; Sayos et al, 1998). SAP is an adaptor molecule expressed in T-cells and
NK cells which binds to the cytoplasmic end of several cell surface proteins including
SLAM, 2B4, CD84, Ly9, and NK-T-B-antigen. Thus SAP receives signals from the cell
surface and generates cytoplasmic signals, which are thought to regulate aspects of
lymphocyte function, including cytokine production, proliferation, cytotoxicity and antibody
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formation. If SAP is defective or absent it is thought that the SLAM family of receptors will
be unable to signal normally (Nichols et al, 2005). To date over 30 mutations of the SAP
gene have been identified; currently there does not appear to be a correlation between
mutation and phenotype although the complex signalling interactions between SAP and its
receptors are not fully understood (Latour & Veillette, 2004; Nichols et al, 2005).
XLP is usually fatal, however, a few patients have undergone bone marrow transplantation
(Gross et al, 1996) and more recently the anti-CD20 monoclonal antibody, rituximab, has
been used at the onset of EBV infection in two cases (Milone et al, 2005).
2.1.3 Chronic EBV Infection
Chronic active EBV (CAEBV) infection is a rare condition, distinct from chronic fatigue,
that is typified by severe, chronic, or recurrent IM-like symptoms after a well documented
primary EBV infection, in a previously healthy person. An abnormal antibody pattern is
present with greatly increased titres of anti-VCA and early antigen, often accompanied by
persisting IgM and IgA to VCA, together with the failure to mount the convalescent phase
anti-EBNA antibody. In addition, there is a marked increase ofEBV load in the tissues and
peripheral blood, and evidence ofmajor organ involvement (e.g., interstitial pneumonia,
bone marrow hypoplasia, splenomegaly, extensive lymphadenopathy, hepatitis,
meningoencephalitis and uveitis) (Kimura et al, 2001; Okano, 2002; Straus, 1988). CAEBV
has a high morbidity and mortality from severe fever, hepatic failure, lymphoma, sepsis,
cardiac failure or haemophagocytic syndrome. Okano (2002) has proposed diagnostic
criteria, which include clinical features, virological and haematological parameters, and, pre¬
fixing the acronym with "severe", to exclude patients with minor symptoms. The exact
pathogenesis is unclear; a perforin defect has been detected in one Caucasian patient, but was
not found in an earlier Japanese series, however, clonal expansion of EBV-infected T orNK
cells takes place in preference to the infection of B-cells that occurs in normal hosts (Katano
et al, 2004; Kimura et al, 2001; Ma et al, 2001). Severe cases are more common in Japan,
China and Korea, suggesting a genetic predisposition to CAEBV. The disease is difficult to
treat; bone marrow transplantation or adoptive immunotherapy may be helpful (Kuzushima
et al, 1996; Okamura et al, 2000; Savoldo et al, 2002).
2.1.4 Burkitt's Lymphoma
This rapidly growing childhood tumour was first recognised as a distinct entity by Denis
Burkitt in rural wet lowland areas of equatorial Africa, where malaria was present all year
round (Burkitt, 1983). The tumours typically occur in the maxilla or mandible but are
usually multifocal, with the retroperitoneal lymph nodes, liver, gut, ovary, kidney and spine
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being common sites. The spleen and peripheral lymph nodes are not usually involved. BL
with similar clinical and epidemiological features was later recognized in Papua New Guinea
and some regions of South America. Subsequently it became clear that tumours with shared
histological features occurred at a lower incidence throughout the world without malaria
acting as a co-factor (Parkin et al, 1985). These latter cases are referred to as sporadic,
whilst the malaria-associated associated cases are known as endemic BL. Virtually all
(97%) cases occurring where malaria is holoendemic are EBV-associated, and in these areas
BL is the commonest childhood malignancy (de-The, 1985). Increased availability of
chloroquine for treatment ofmalaria, and programmes of chloroquine prophylaxis in
children, appeared to reduce the incidence of BL in endemic areas until chloroquine
resistance developed (Geser et al, 1989).
The exact role ofEBV in the pathogenesis remains unclear despite the strong EBV
association in the endemic regions. The tumours characteristically contain clonal EBV
episomes and a translocation of the long arm of chromosome 8 in the region of the myc
proto-oncogene to one of the immunoglobulin gene regions either chromosome 14 (heavy
chain) in 80% of cases or, 2 or 22 (light chain) in the remainder (Gulley et al, 1992;
Magrath, 1990; Zech et al, 1976). This results in expression of the translocated c-myc which
has multiple effects on the cell including growth promotion, stimulation of cell cycle
progression and immortalisation. In addition mutations in the tumour suppressor genes p53
and retinoblastoma-like 2 are frequently detected (Kiippers, 2003; Young & Rickinson,
2004). During acute malaria increased numbers of EBV-infected B-cells are found in the
circulation accompanied by a reduction in EBV-specific cytotoxic T-cell responses (Lam et
al, 1991; Whittle et al, 1984). It is thought that the increased immunological stimulation of
repeated attacks of malaria that occur in the regions of intense malaria transmission render
errors of the somatic hypermutation process (including translocation of c-myc) in the
germinal centre centroblasts more likely to occur (Young & Rickinson, 2004) (see 1.9.1 B-
Cell Biology).
Sporadic BL is associated with EBV in only about 20% of cases, although in HIV-associated
BL the frequency is 35% (Hamilton-Dutoit et al, 1993; International Agency for Research on
Cancer, 1997). Unlike other forms ofNon-Hodgkin lymphoma (NHL) the incidence of BL
does not rise with immunosuppression, except that due to HIV; a condition which, like
malaria, is associated with chronic polyclonal hypergammaglobulinaemia.
2.1.5 B-Cell Lymphoproliferative Disease
EBV-associated B-cell lymphoproliferative disease (BLPD) occurs mainly in the context of
immunosuppression, particularly organ transplantation, where it is known as post transplant
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lymphoproliferative disease (PTLD). PTLD is thought to arise in at least 1.4% of transplant
recipients, and presents in varied ways including an IM-like illness, and, nodal or extranodal
tumours, the latter often involving the gut, brain or transplanted organ (Nalesnik, 1998).
Risk factors for PLTD include intensive immunosuppressive drug regimes, often in the
context of treating episodes of transplant rejection, primary EBV infection during therapy,
and the type of transplant; the highest risks being seen with heart, heart/lung and intestinal
grafts (Cockfield, 2001; Ho et al, 1985; Nalesnik et al, 1997). A spectrum of lesions is seen
ranging from polyclonal polymorphic lymphoproliferation, which expresses all EBV latent
genes, to biclonal or monoclonal lesions which may present a more restricted pattern of EBV
gene expression (Hopwood et al, 2002; Rea et al, 1994).
Analysis of the heavy chain immunoglobulin genes in PTLD tissue has shown that the
disease can arise in variable stages of B-cell development from naive cells to post germinal
centre cells that have immunoglobulin genotypes normally incompatible with B-cell
survival, suggesting that EBV facilitates the survival of cells that ordinarily would have been
eliminated (Timms et al, 2003). Thorley-Lawson has proposed PTLD may arise when cell
types other than nai've B-cells, so called bystander cells, become infected with EBV. These
cells are unable to differentiate into memory cells, in order to exit the cell cycle, and in the
context of a severely impaired cytotoxic response are not eliminated by the immune response
(Thorley-Lawson & Gross, 2004). In addition to the background of intense T-cell
immunosuppression, the cytokine milieu has also been proposed as important in the
pathogenesis of PTLD with elevated levels of IL-4, 6 and 10 thought to contribute, together
with reduced secretion of IFN-y (Burns & Crawford, 2004).
Treatment is difficult; lesions may regress with reduction in the level of immunosuppression,
although this threatens the survival of the grafted organ (Starzl et al, 1984). As PTLD
usually arises in the context of severely impaired cell mediated immunity, infusions of
cytotoxic T-cells directed against the EBV latent antigens, derived from either the bone
marrow transplant donor, or, a partially HLA-matched blood-donor, have been used in
prophylaxis and treatment (Haque et al, 2002; Rooney et al, 1998). Alternative approaches
include use of the humanised mouse monoclonal antibody, rituximab, which targets CD20,
depleting both normal and malignant pre-B and mature B-cells; surgical excision;
chemotherapy; antibodies to cytokines e.g. anti-IL6; interferon; and radiotherapy (Burns &
Crawford, 2004; Cook et al, 1999; Faye et al, 1998; Haddad et al, 2001; Johnson & Glennie,
2001; Kuehnle et al, 2000).
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2.1.6 Hodgkin's Disease
An involvement ofEBV in the pathogenesis of Hodgkin's Disease (HD) had long been
suspected because the increased risk following IM, the finding of the typical Reed Sternberg
cells ofHD in lymph nodes and tonsil excised during IM and raised levels ofEBV
antibodies prior to diagnosis (Gutensohn & Cole, 1980; Lukes et al, 1969; Mueller et al,
1989; Mueller, 1996). The epidemiology and EBV-association of HD is complex varying
with histological type, socio-economic conditions, geographical location, age and immune
status. For many years a paradox existed that the peak of HD occurring in young adults,
which was predominantly of the nodular sclerosing subtype, was not EBV-related, however,
in 2003 Hjalgrim et al were able to demonstrate that the increased risk ofHD after IM
related specifically to EBV-positive cases of HD, and quantified the risk of developing HD
following IM at around one case per 1000 cases of IM (Hjalgrim et al, 2003). That IM is not
universally followed by HD suggests that other factors, such as the genetic makeup of the
host, play an important role pathogenesis (Diepstra et al, 2005).
The histology ofHD is unusual in that the number ofmalignant cells, known as Reed -
Sternberg and Hodgkin cells (HRS cells) constitute less than 1% of the tumour mass but they
are surrounded by a marked, seemingly ineffectual, inflammatory response (Marshall et al,
2004; Poppema & van den Berg, 2000). Overall about 40% of cases are EBV-associated,
but this figure is much higher for HD occurring at the extremes of age, or in economically-
disadvantaged communities, or in Asian or Hispanic, but not black, racial groups (Glaser et
al, 1997). In the EBV-associated cases clonal EBV episomes are found in the HRS cells
(Anagnostopoulos et al, 1989; Weiss et al, 1989). The rate of EBV positivity varies with
histological subtype being most strongly associated with mixed cellularity (70%), followed
by lymphocyte depleted (55%), nodular sclerosing (23%), and least associated with
lymphocyte predominant (16%), which has now been subdivided into classical and nodular
forms (Glaser et al, 1997; Yung & Linch, 2003). EBV latent gene expression is confined to
EBNA1, EBERs, LMP1 and LMP2 (Pallesen et al, 1991).
Irrespective of EBV-status HRS cells are derived from the clonal proliferation of a single
germinal centre or post germinal centre B-cell, as evidenced by rearrangement of their
immunoglobulin (Ig) genes (Marafioti et al, 2000). The HRS cells do not show lethal, non¬
functional rearrangements of their Ig genes but have lost Ig transcription due to defects in the
regulatory genes (Marafioti et al, 2000). In EBV positive tumours it is likely that by
accident of the presence of EBV these abnormal B-cells, ordinarily destined for apoptosis,
receive survival signals.
In the context ofHIV, HD is not an AIDS-defining diagnosis although the age adjusted
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relative risk for HIV-infected individuals is 11.5 times greater than that of the general
population (Frisch et al, 2001). HD affects 13% of HIV-positive patients and is EBV-
associated in 80-90% of cases (Glaser et al, 2003; Powles & Bower, 2000; Uccini et al,
1989). Within the tumours detection of EBV type 2 is more common than in HIV-negative
patients. HD in HIV generally presents at a more advanced stage and there is a significant
excess of the less favourable histological types, mixed cellularity and lymphocyte depleted
(Frisch et al, 2001; Powles & Bower, 2000). To date HAART has not reduced the incidence
of HD, in fact a recent study suggests that the incidence may be increasing, as a survivor
effect. Effective anti-retroviral therapy has, however, improved survival in HIV-infected
persons that contract HD (Clifford et al, 2005; Hoffman et al, 2004; International
Collaboration on HIV and Cancer, 2000).
2.1.7 AIDS Related Non-Hodgkin Lymphoma
Patients with HIV infection have a risk ofNHL at least sixty times greater than that of the
general population (Beral et al, 1991). The magnitude of the excess risk varies with the
different histological types of tumour; being greatest for NHL that arise in the central
nervous system (CNS), which is 3600 times more common in HIV-infected persons (Cote et
al, 1996; Cote et al, 1997). Prior to the availability of highly active anti-retroviral therapy
(HAART) approximately 16% of HIV-infected patients in the UK had developed a primary
CNS lymphoma by the time of death (Peters et al, 1991). This figure is thought to be much
lower in countries without good supportive medical care, where survival following the onset
ofAIDS is less, although a post-mortem study in Cote d'lvoire showed that 4% of adults
with AIDS had NHL present at the time of death and 1.7% had primary CNS lymphoma
(Lucas et al, 1994). In countries where HAART is available, the incidence of some types of
HIV-associated NHL appears to be falling (Clayton et al, 2006; International Collaboration
on HIV and Cancer, 2000; Kirk et al, 2001; Polesel et al, 2008), although the risk does not
return to the population baseline, and concerns remain that the overall prevalence ofHIV-
associated cancers will increase as survival with HIV improves. In addition, even in
countries where HAART is readily available many patients continue to present late with
advanced immunosuppression.
NHL arising in the context ofHIV are almost always proliferations of B-cells and fall into
three main types - Burkitt-like, small, non-cleaved NHL, which tend to occur earlier in the
course ofHIV infection when the CD4 count is still relatively preserved (median CD4 120-
168 (Kirk et al, 2001)); large cell or diffuse NHL which tend to occur later (median CD4
count 70), often after other AIDS defining conditions have arisen; and, the rare primary
effusion lymphoma which is discussed separately below (2.1.8). The Burkitt-like
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lymphomas are associated with EBV in 34% of cases, whereas 77% of the large
cell/immunoblastic lymphomas contain EBV (Hamilton-Dutoit et al, 1993). Large cell
lymphomas affecting the CNS tend to occur at the lowest CD4 counts (median at
presentation 15) and are almost-always EBV-related (Hamilton-Dutoit et al, 1993; Kirk et al,
2001; MacMahon et al, 1991). In these cases EBV DNA is detectable in CSF and forms a
useful diagnostic test in the evaluation of HIV-positive patients with space occupying lesions
on cerebral imaging (Cinque et al, 1993). The detection of EBV DNA in the CSF may
precede the development of a macroscopic lesion (Al-Shahi et al, 2000), however, more
recent reports have emphasised the low positive predictive value of this test in HIV-infected
patients with neurological disease, including focal brain lesions (Corcoran et al, 2008; Ivers
et al, 2004).
Hodgkin's Disease occurring in the context ofHIV is discussed above (2.1.6).
2.1.8 Primary Effusion Lymphoma
Primary effusion lymphoma predominantly arises in the setting of advanced HIV infection
but occasionally arise in HIV-negative persons (Boshoff& Weiss, 2001). Malignant cells
are found in serosal cavities but without any tumour mass or lymphadenopathy, possibly
because they lack adhesion molecules and lymph node homing markers (Boshoff& Weiss,
2002). Malignant cells show dual infection with HHV8 and EBV in about 70% of cases; the
remainder are infected with HHV8 alone (Boshoff& Weiss, 2002). The EBV pattern of
gene expression resembles that seen in endemic BL, although c-myc is not translocated.
2.1.9 T-Cell Lymphomas
EBV DNA has been detected in different types of T-cell lymphoma. Angioimmunoblastic
lymphadenopathy and sinonasal angiocentric T-cell NHL, previously known as lethal
midline granuloma, show the most consistent EBV association; clonal episomes are detected
in almost every malignant cell with a type 2 pattern of latency (Epstein & Crawford, 2005;
Jones et al, 1988). Approximately 50% of peripheral T-cell lymphomas are EBV associated.
2.2 Diseases ofEpithelial Cell Origin
2.2.1 Oral Hairy Leukoplakia
This corrugated white lesion on the lateral borders of the tongue occurs in states of
significant immunosuppression including advanced HIV infection (Greenspan et al, 1987;
Greenspan et al, 1985), organ transplantation or occasionally systemic glucocorticoid
therapy for other conditions (Fliickiger et al, 1994; Greenspan et al, 1989; Itin et al, 1988).
As it is a productive (lytic) EBV infection (Thomas et al, 1991) it may be controlled with
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oral aciclovir therapy (Resnick et al, 1988). No EBER expression is seen (Gilligan et al,
1990).
2.2.2 Nasopharyngeal Carcinoma
This epithelial cell tumour accounts for 0.7% of the world cancer burden. The distribution
shows marked geographical restriction with 44% of all cases occurring in China and 23% in
SE Asia (Parkin, 1998). Other populations with raised incidence include North African and
Eskimo populations (Wei & Sham, 2005). It is predominantly a tumour ofmales with a
male-female ratio of 3:1 (Le Roux & Joab, 1998). Of the three histological types recognised
undifferentiated (WHO type 3) and non-keratinising (WHO type 2) are the most strongly
EBV-associated, whereas, squamous cell carcinoma (WHO type 1) is less consistently
associated with EBV (Pathmanathan et al, 1995a; Raab-Traub, 2002). The prevalence of the
histological types also varies geographically. In North America around 25% of patients have
type 1, 12% type 2 and 63% have type 3, whereas in South China, the distribution is 2%, 3%
and 95% respectively (Wei & Sham, 2005). Migration studies implicate both environmental
and genetic contributions to pathogenesis (Buell, 1974) with the ingestion of nitrosamine-
containing preserved foods, particularly salted fish, proposed as an environmental risk factor
(Buell, 1974; Yu et al, 1986; Yu & Yuan, 2002). An increased risk ofNPC has been
associated with certain HLA types and for individuals that were homozygous for a particular
cytochrome P450 polymorphism (Le Roux & Joab, 1998). Elevated titres of EBV antibodies
are common in patients with nasopharyngeal carcinoma, with IgA to early antigen and viral
capsid antigen described as being characteristic (Henle & Henle, 1976; Old et al, 1966; Wara
et al, 1975). The rise in EBV antibodies predates tumour onset, however, the cost and risk
benefit of using antibody-based screening on a whole population basis awaits further study
(Chien et al, 2001). Quantitative serum EBV DNA may have a role in early diagnosis and
disease monitoring, although only 67% of patients with local disease recurrence showed a
rise in EBV DNA (Chan et al, 2004; Wei & Sham, 2005). Clonal EBV is consistently
present in malignant cells and is also found in high grade pre-malignant lesions, suggesting
that EBV is involved from an early stage in carcinogenesis, although not necessarily
representing the first step in the pathogenesis (Pathmanathan et al, 1995b; Raab-Traub &
Flynn, 1986).
2.2.3 Gastric Carcinoma
Gastric carcinoma is the fourth most common cancer worldwide and ranks second as a cause
of death from cancer (Parkin et al, 2005). EBV is associated with around 10% of all gastric
carcinomas, although the frequency of this association varies worldwide (Takada, 2000).
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Tumours of the lymphoepithelioma-type with a marked lymphocytic infiltrate show the
closest association with EBV (90%) and in addition around 10% gastric adenocarcinomas
also appear to be EBV-associated (Osato & Imai, 1996; Shibata et al, 1991; Shibata &
Weiss, 1992), although the histological distinction between these types is not always
straightforward (Young & Murray, 2003). In EBV-associated cases all malignant cells
contain clonal EBV. The EBV genes expressed are EBNA1, EBERs, LMP2A, and BARFO
(Iwakiri & Takada, 2005; Niedobitek et al, 2001; Takada, 2000; Young & Murray, 2003).
2.2.4 Other Lymphoepitheliomas
The term lymphoepithelioma refers to malignant epithelial cell tumours with marked
lymphocytic infiltration similar to WHO type 3 NPC. EBV has been associated with
lymphoepitheliomas of the thymus (Dimery et al, 1988; Leywraz et al, 1985), tonsil, salivary
gland (Raab-Traub et al, 1991), lung, and some gastric carcinomas.
2.2.5 Breast Carcinoma
Breast carcinoma is the commonest malignancy in women and its incidence is increasing
(Parkin, 1998). It has been suggested that EBV may be involved in the pathogenesis of some
breast cancers (Bonnet et al, 1999; Labrecque et al, 1995) although this has been refuted by
others (Chu et al, 2001; Glaser et al, 1998; Herrmann & Niedobitek, 2002). In order to
explain the conflicting data it has been suggested that EBER negative breast carcinoma may
occur, analogous to some cases ofNPC, (Magrath & Bhatia, 1999) or that EBV associated
breast carcinoma is restricted to certain epidemiological groups (Glaser et al, 2004).
2.3 Other Disease Associations
2.3.1 Leiomyosarcoma
EBV has been associated with clonal or biclonal tumours of smooth muscle in paediatric
liver transplant recipients (Lee et al, 1995) and in young people with advanced HIV infection
(McClain et al, 1995). Later case reports have described the tumour in cardiac and renal
transplant recipients (Davidoff et al, 1996; Le Bail et al, 1996). Many of the tumours are
multifocal, and develop in unusual sites including gut, lung and liver. The pathogenesis is
unclear; McClain et al (1995) found expression of CD21 on the involved muscle cells.
2.3.2 Multiple Sclerosis
Epstein-Barr virus is one of several agents proposed as having an aetiological role in the
pathogenesis ofmultiple sclerosis (MS). A case-control study in the UK using a population-
based database found preceding IM was associated with an odds ratio of 5.5 for the
subsequent development of MS (Marrie et al, 2000). Distinct subtypes of MS have been
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recognized (Lucchinetti et al, 1996) raising the possibility that the association is restricted to
a subset of cases. A Canadian study identified 27 monozygotic (MZ) twin pairs and 43
dizygotic (DZ) twin pairs with multiple sclerosis. Concordance was 31% for the MZ twins
and 5% for the DZ twins from which the authors concluded that although genetic factors
were important in determining the susceptibility to MS the findings "unambiguously
demonstrates [sic] the powerful effect of non-heritable factors" as the concordance in MZ
twins only reached 30% despite prolonged follow-up (Ebers et al, 1986; Sadovnick et al,
1993). Two years later the same authors published an investigation ofMS in adopted
children and their relatives, finding that the prevalence ofMS among non-biological first-
degree relatives was similar to that in the general population, which led them to dismiss any
contribution in pathogenesis from "a transmissible agent or any familial microenvironmental
factor" (Ebers et al, 1995). More recently a Danish population-based study examined the
subsequent occurrence ofMS amongst over 25 000 patients diagnosed with IM. This study
involved more than 550 000 person-years of follow-up and found a more than 2 fold increase
in the risk ofMS after IM (Nielsen et al, 2007).
2.4 Vaccination
Whilst EBV infects most of the human population and co-exists without causing disease in
the majority, it is an oncogenic virus that is an established factor in the aetiology ofmany
human cancers. In addition, primary EBV infection is a life threatening condition for those
with genetic defects, such as XLP, and for those with profound immunodeficiency following
organ transplantation. Furthermore, IM remains an important cause of morbidity in older
children and young adults, occasionally causing very severe disease, especially in older age
groups. Economic development in Asia, China and South America may result in a rising
incidence of IM due to delays in the age of primary infection.
The traditional approach to immunisation, using a live-attenuated virus, has been avoided by
researchers in view of the known oncogenic potential of EBV. Two main types of
recombinant vaccine are being developed for prophylactic use prior to the occurrence of any
disease. These include the use of the subunit glycoprotein gp350, which is known to induce
neutralising antibody, and, a peptide (epitope) vaccine, so called "polytope" when multiple
peptides are used, designed to induce cytotoxic cellular immunity (Moss et al, 1998). Due to
HLA diversity it is estimated that 25 CD8+ T-cell epitopes would be needed to provide
coverage for >90% of the population in Western countries (Elliott et al, 2008).
The use of gp350 as a subunit vaccine has long been considered, and was previously studied
in the cottontop tamarin primate model. Following intraperitoneal and intramuscular
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injection of EBV these small Colombian monkeys develop large malignant lymphomas
which could be prevented by prior injections with gp350 presented in artificial liposomes.
Only the animals with very high levels of virus neutralising activity in their serum were
protected (Epstein et al, 1985).
A small study in China used vaccinia virus that expressed gp350 to immunise 9 children
prior to primary EBV infection. After 16 months follow-up all ten controls and three of the
vaccine recipients had been infected with EBV (Gu et al, 1995). This illustrates the potential
for an immunogenic vaccine to delay primary infection, however, concerns remain regarding
the widespread use of vaccinia vaccines in view of the relatively high frequency of adverse
events and the potential for person to person spread (Frey et al, 2002; Sepkowitz, 2003).
Gp350 was subsequently expressed in Chinese hamster ovary cells, and after a delay of over
25 years trials have been undertaken in Belgium with a gp350 subunit vaccine with adjuvant
to investigate whether IM can be prevented (Denis et al, 2004; Jackman et al, 1999).
Fortunately there is little sequence variation in this gene between the two EBV types (Lees et
al, 1993). One hundred and eighty one seronegative young adults in Belgium were
randomised to receive either three doses of gp350 with a lipid and aluminium hydroxide
adjuvant, or, three doses of a placebo containing aluminium hydroxide alone. Asymptomatic
primary infection was not reduced by vaccination with gp350, however, the number of cases
of IM was reduced in the gp350 group (2 cases vs. 8 in the placebo group which was
significant by intention to treat analysis) (Sokal et al, 2007). Unfortunately Sokal et al did
not investigate viral load or cytotoxic T-cell responses in either group. In an earlier phase I
study of gp350 with the same adjuvant, one subject, who was already EBV seropositive prior
to study entry, developed oligoarthritis after the second dose of vaccine which might suggest
that vaccination would need to be limited to EBV seronegative subjects to reduce adverse
reactions (Moutschen et al, 2007). A further theoretical concern is that vaccination may
increase the numbers of cases of severe IM in older adults by delaying primary infection in
into middle age, when IM is associated with more severe disease (Horwitz et al, 1983).
To date trials to prevent IM using a polyepitope vaccine have not been conducted. A very
small phase I study using a single EBV epitope mixed with tetanus toxoid and formulated in
a water in oil adjuvant "Monatide ISA 720" has been conducted in 10 HLA B*0801 positive
subjects and 4 controls. Half of the epitope recipients and 2/4 of the placebo recipient
seroconverted to EBV. One case of IM occurred in each group. The study was too small to
estimate vaccine efficacy, however, the authors concluded that the vaccine was safe,
produced epitope specific T-cell responses in 8/9 recipients and was generally well tolerated
(Elliott et al, 2008). The decision to incorporate tetanus toxoid to provide CD4 T cell help
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was questionable as this probably led to increased local adverse reactions to the vaccine and
excluded 45% of potential volunteers, due to pre-exiting high levels of tetanus toxoid
antibodies.
Of the two approaches the gp350 would seem the most promising for further trials at the
present time, although epitope based approaches may find a role as adjuvant therapies in
EBV-associated malignancies (Duraiswamy et al, 2003).
3 EBV-negative Glandular Fever
IM caused by EBV is confirmed in 20-25% of patients where it is clinically suspected and
laboratory investigations are instigated (Blake et al, 1976; Fleisher et al, 1983; Wahren et al,
1969). The remainder have "IM-like" illnesses which are a heterogeneous group and may
include CMV mononucleosis, adenovirus infection, streptococcal infection, influenza, HHV-
6 infection, toxoplasmosis, HSV infection, drug reactions, parvovirus, HIV-seroconversion,
viral hepatitis, rubella and others (Blake et al, 1976; Ho-Yen & Martin, 1981; Rosenberg et
al, 1999; Steeper et al, 1990; Tsaparas et al, 2000; Wahren et al, 1969). There is overlap in
the clinical presentation and haematological features of acute EBV infection and other
conditions, although the likelihood of any individual feature being present varies according
to the diagnosis. For example CMV mononucleosis is characterised by prolonged fever,
lymphocytosis, atypical lymphocytes and abnormal liver function tests. Sore throat and
cervical lymphadenopathy are said not to be characteristic of this illness but they do occur in
around in a third and a fifth of cases respectively (Horwitz et al, 1986; Nankervis & Kumar,
1978; Paublini et al, 1977). Paublini et al (1977) compared the clinical features in patients
with IM, CMV mononucleosis and acute toxoplasmosis; finding that throat involvement,
enlarged nodes, fever and splenomegaly were common to all three conditions.
Toxoplasmosis was characterised by the presence of lymphadenopathy and the absence of
hepatomegaly. Sore throat, fever and splenomegaly occurred only occasionally.
Cytomegalovirus infection was characterised by the presence of fever with the other features
occurring less often.
Like EBV-induced mononucleosis other acute infections including acute HIV, CMV,
toxoplasmosis and hepatitis B may induce severe perturbations of lymphocyte subsets with
inversion of the normal CD4: CD8 ratio (Bossi & Bricaire, 2004; Carney et al, 1981;
Thomas et al, 1982; Tindall et al, 1988).
59
4 Fatigue and its Measurement
Fatigue has been described as a negative feeling experienced in relation to an actual or
anticipated task (although the performance of a task is not a pre-requisite for the feeling)
(Wessely et al, 1999). Fatigue is thought to have a number of dimensions including ability
to sustain physical and mental functions, a feeling state, underlying biochemical,
physiological and psychological mechanisms and its context of cultural factors, social
stressors and physical stressors e.g. temperature and noise. Fatigability when defined as the
inability to sustain power can be measured electrophysiologically, but this is not necessarily
related to the subjective sensation of fatigue. There is no gold standard in fatigue
measurement, indeed many fatigue scales have not been tested in chronic fatigue syndrome
(Friedberg & Jason, 1998). Fatigue intensity is typically measured by one of three main
types of scale: verbal rating (VRS) or Likert-type scale, visual analogue scale (VAS) or
numerical rating scale (NRS). A VRS uses list of adjectives to describe fatigue intensity
such as mild, moderate etc. A VAS consists of a line, usually 10 cm long, whose ends define
the extremes of fatigue "none" to "as bad as it could be". The subject marks the line at the
point which represents their fatigue severity and the distance along the line in mm is the
recorded measure of their fatigue. The NRS is similar, but easier to administer, and
comprises a 0 to 10 or 0 to 100 scale, where 0 is "no fatigue" and 10 or 100 is " as bad as it
could be". These types of scales are used to investigate different aspects of fatigue, for
example, Lee et al used an 18 question/symptom VAS format to investigate fatigue in











EDTA Ethylene diamine tetra-acetic acid
EtBr Ethidium bromide
FCS Foetal calf serum
FITC Fluorescein isothiocyanate
HBSS Hanks balanced salt solution
HCl Hydrochloric acid
KCl Potassium chloride
kh2po4 Potassium di-hydrogen orthophosphate
MgCl2 Magnesium chloride
NaCl Sodium chloride
Na2H P04 Di-sodium hydrogen orthophosphate
PBS Phosphate buffered saline
PE Phycoerythrin
RPMI Rosewell Park Memorial Institute Medium 1640
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TE Tris-EDTA
Tris Tris (hydroxymethyl) aminomethane
Tween-20 Polyoxethylene (20)-sorbitan monolaurate
5.2 Suppliers
British Drug Houses Ltd. VWR International Ltd., Hunter Boulevard, Magna Park,
Lutterworth, Leicestershire, LEI 7 4XN.
Becton Dickinson BD Biosciences, 21 Between Towns Road, Cowley, Oxford,
OX4 3LY.
Bioline Ltd Unit 16, Humber Road, London, NW2 6EW.
Biometra Rudolf-Wissell-StraPe 30, 37079, Goettingen, Germany.
Bion ati atlas ltd., The Grange, Church Road, Chichester, PO20 6JW.
DAKO DakoCytomation, Denmark House, Angel Drove, Ely,
Cambridgeshire, CB7 4ET.
Dynex Technologies Columbia House, Columbia Drive, Worthing, BN13 3HD.
Lalcon Farenheit Laboratory Supplies, 21 Alston Drive, Bradwell
Abbey, Milton Keynes, MK13 9HA.
Fischer Scientific UK Ltd Bishop Meadow Road, Loughborough, Leicestershire, LEI 1
5RG.
GE Healthcare Amersham Place, Little Chalfont, HP7 9NA.
Gibco Invitrogen Ltd., 3 Fountain Drive, Inchinnan Business Park,
Paisley, PA4 9RF.
GraphPad 11452 El Camino Real, #215 San Diego, CA 92130 USA.
Invitrogen 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF.
Machine Shop
Equipment Ltd.
MSE (UK) Ltd., (Henderson Biomedical Ltd.), 97 Avenue
Road, Beckenham, Kent, BR3 4RX.
MP Biomedicals Doornveld 10, 1731 Asse Relegem, Belgium.
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Leitz Leitz, Ernst-Leitz Strasse 17-37, Wetzlar, D-35578, Germany.
Microgen 1 Admiralty Way, Camberley, Surrey, GUI5 3DT.
Minitab Quality Plaza, 1829 Pine Hall Road, State College, PA 16801-
3008, U.S.A.
MWG Research MWG Biotech Ltd, Hibernian House, 80a South Mall, Cork,
Ireland.
Nunc Nalge Nunc International, Unit la, Thorne Business Park,
Hereford, HR2 6JT.
Olympus Vision House, 19 Colonial Way, Watford, WD24 4JL.
Promega Delta House, Chilworth Science Park, Abingdon, Oxon, OX 14
3NB.
Qiagen Qiagen House, Fleming Way, Crawley, RH10 9NQ.
Roche Roche Diagnostics Ltd, Bell Lane, Lewes, BN7 1LG.
Sigma Sigma-Aldrich Co. Ltd., The Old Brickyard, New Road,
Gillingham, SP8 4XT.
Sigma-Genosys Ltd Sigma-Aldrich House, Homefield Business Park, Homefield
Road, Haverhill, CB9 8QP.
Sarstedt Ltd. 68 Boston Road, Leicester, LE4 1AW.
Scientific Laboratory
Supplies
Unit 17, Coatbridge Business Centre, 204 Main Street,
Coatbridge, Lanarkshire, ML5 3RB.
Sterilin Sterilin Ltd., Angel Lane, Aberbargoed, Bargoed, Caerphilly,
CF81 9FW.
Stratagene 11011 North Torrey Pines Road, La Jolla, CA 92307, US.
Sysmex UK Ltd Sunrise Parkway, Milton Keynes, MK14 6QF.
Ultra Violet Products Ltd Unit 1, Trinity Hall Farm Estate, Nuffield Road, Cambridge,
CB4 1TG.
5.3 General Plastic Ware
Plastic ware was supplied by Scientific Laboratory Supplies or Sterilin unless otherwise
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stated, except for cryovials (Nunc) and eppendorfs (Sarstedt).
5.4 Recruitment to Longitudinal Cohort Study
Students commencing four year courses at Edinburgh University in October 1999 and
October 2000 were invited to join a longitudinal study to investigate the epidemiology of
EBV. An information leaflet and posters were produced. Students registering at the
University Elealth Centre (UHC) at the start of their university course who agreed to join the
study were given further verbal explanation regarding the study aims and requirements, and
were allocated a unique study number. Thereafter each student signed a consent form,
completed an anonymised family and lifestyle questionnaire and gave a venous blood
sample. A few students preferred to donate a smaller capillary blood sample. All students
were sent a letter of thanks informing them of their serology result. Seronegative students
were advised to contact the UHC if they developed symptoms of IM. Students who
developed IM during their course were asked to attend for follow-up to document their
illness in more detail; these students additionally joined the case-control study. At the end
the autumn term in their final year at university (December 2002 and 2003) all students
participating in the longitudinal cohort study (LCS) were invited to re-attend the UHC to
complete a further anonymised lifestyle questionnaire and to donate a further venous or
capillary blood sample. Students were contacted by personal email and additional publicity
was generated by means of posters and articles in the student newspaper. In order to
maximise follow-up students were offered a cinema ticket or book token as a thank you
gesture for attending the follow-up session.
5.5 Questionnaires
The anonymous questionnaires were formulated jointly with Professor Anthony Swerdlow
and Craig Higgins, epidemiologists at The London School of Hygiene, taking account of the
approaches used by the successful National Survey ofSexual Attitudes and Lifestyles
(Wellings et al, 1994). Data were gathered on family background and living circumstances,
ethnicity, previous illness, life events, sexual relationships, smoking, alcohol and exercise
history. The questionnaires are in the appendix (12.1). A further questionnaire was
administered if a student developed IM and collected information about living
circumstances, life events and illnesses, sexual relationships, travel and immunisations,
smoking, alcohol and exercise history at university. The questionnaire at the end of the
study was similar to that used if a student developed IM and concentrated on information
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relating to the period of time at university. Additionally questions relating to possible
undetected glandular fever illness were included.
5.6 Recruitment of IM Cases to the Case Control Study
At recruitment to the LCS students were asked to contact the study if they developed
glandular fever. The EBV negative students were also reminded to do this in the letter that
they received informing them of their serology result at the start of the study. Additionally a
diagnostic serology service for suspected IM was provided to the general practitioners at the
UHC, where most of the students in the LCS received their health care. Students with
diagnostic serology compatible with acute IM who had already been recruited to the LCS
were invited to attend for clinical follow-up. Additional students with acute IM who were
not already recruited to the LCS were given a study information sheet by their general
practitioner (GP) at the UHC and invited to attend for clinical follow-up. Seronegative
students from the LCS matched for gender, age and year of study were selected by random
number by Craig Higgins to act as controls for the IM cases.
Acute IM blood samples were drawn at the time of diagnosis. Convalescent samples were
taken at follow-up visits after the diagnosis of IM was made. Where possible a concurrent
sample was sent for determination of the total lymphocyte count at The Royal Infirmary of
Edinburgh haematology laboratory. Liver function tests were measured at the first visit.
Students with abnormal liver function test (LFT) results had these followed up until
recovered. Clinical data was recorded on the "Clinical assessment" sheets (see Appendix
12.1) at the time of clinical review, and entered into an encrypted and password protected
access database by Ha Nguygen. Student identity was by use of the study number only.
We measured physical and mental functions by asking questions about walking distance,
perceived ability to concentrate, whether the student left the house when unwell and whether
they got washed and dressed during their most severe symptoms. In addition students
completed questions about the duration of time spent sleeping, studying, attending
university, exercising, and on non-exercise related social activities (see "Physical Function
and Fatigue", Appendix 12.1). A numerical rating scale from zero "no fatigue" to ten "as
bad as you can imagine" based on the brief fatigue inventory gave a numerical score to the
student's perception of their fatigue severity at each visit (Mendoza et al, 1999).
Students were reviewed as soon as possible after diagnosis, at two months and again at 6
months after diagnosis. As the parental homes ofmost students were distant from Edinburgh
considerable flexibility was needed because of vacations and students returning to the
parental home to recuperate. Students that had not recovered by six months after diagnosis
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were contacted by email or telephone to determine the dates of return to social activities,
exercise and the duration of their fatigue.
5.7 Sample Processing
5.7.1 Peripheral Blood
Up to 18 ml of peripheral blood was drawn into EDTA containing tubes (Sarstedt) and
separated into plasma and peripheral blood mononuclear cells (PBMC) by density gradient
centrifugation. The PBMC were used for flow cytometry and a portion was stored at -70 °C
as a source ofDNA for viral load estimation and strain typing.
The EDTA whole blood was layered over an equal volume of Ficoll (Histopaque_1077,
Sigma) as described by Boyum (Boyum, 1968) in 50 ml conical-bottomed tubes (Falcon).
These were centrifuged (MSE [Machine Shop Equipment Ltd.] Mistral 3000i) at 900g for 15
minutes at 20°C. After separation by centrifugation 3 ml of plasma was retained for
serological testing. The layer of peripheral blood mononuclear cells, located between the
plasma and the Ficoll, was removed by aspiration, placed in a second conical-bottomed tube
and washed, in Flanks balanced salt solution [without calcium and magnesium] (HBSS)
(Gibco), by spinning at 270g for 7 minutes at 4°C. This supernatant was discarded and the
cells were re-suspended in fresh HBSS. Viable cell counts were performed by mixing an
aliquot of the re-suspended cells with an equal volume of 0.4% trypan blue (MP
Biomedicals) and counting cells excluding blue dye using a haemocytometer (Improved
Neubauer, BDH Ltd.). The concentration of cells was adjusted to lxl 06 per ml of tissue
culture medium with a portion used for flow cytometry, and the remainder stored in aliquots
of 5 xlO6 cells which were kept in eppendorfs at -70 °C as a source ofDNA for viral load
and typing assays.
5.7.2 Throat Wash
Throat wash samples were collected by gargling with 10 mis 0.9% sterile saline for 30
seconds. The specimen was centrifuged at 760 g for 10 minutes at 4 °C and the supernatant
discarded. The pellet was re-suspended in 3 mis of sterile PBS in a sterile eppendorf and
micro-centrifuged (Micro Centaur, MSE) at 1900g for 5 minutes. The dry pellet was stored




Plasma was tested for the presence of heterophile antibody using a rapid slide agglutination
test (Microgen i.m. absorption kit). 25 pi of plasma was added to one drop each of ox cell
and guinea pig antigen suspensions supplied and mixed thoroughly on a clean glass tile. One
drop of the positive control was also mixed with each of the antigen suspensions above. One
drop of horse red blood cell suspension was added to each of the 4 ovals on the tile and
mixed well. Agglutination in the guinea pig oval, with none in the ox cell oval, at one
minute indicates a positive heterophile antibody test.
5.8.2 Detection of anti-VCA IgG and IgM
Serological testing using plasma (Davidson & Main, 1971) was performed after heat
inactivation to 56 °C for 30 minutes. IgG and IgM to EBV VCA were detected by indirect
immunofluorescence (Henle & Henle, 1966). Slides for the detection of IgG to VCA were
prepared in-house using the EBV positive cell line P3HR-1 (Hinuma et dl, 1967). 105 cells
were dispensed onto each well of 12 well slides (BDH), dried and fixed in acetone for 10
minutes. Serial dilutions of plasma in phosphate buffered saline (PBS) were made from 1/10
to 1/2560. 20 p.1 of diluted plasma was added to each well of a 12 well slide starting with the
highest dilution. The slides were incubated in a moist chamber for one hour at 37°C and
then washed twice with PBS for ten minutes. 15 pi of FITC-conjugated rabbit-anti human
IgG (Dako) [diluted 1/50 with PBS] was applied to each well and incubated for 45 minutes
at room temperature, before again washing the slides twice in PBS. A negative control and
serial dilutions of a positive control (as per the test sample) were included in every batch.
Antibody detection for IgM was performed at only one dilution (1/10) using the same
method except that commercial slides were used (Bion) and FITC-conjugated rabbit anti-
human IgM (Dako) diluted 1/50 with PBS was used as the second layer antibody. Positive
and negative (EBV VCA IgG positive, IgM negative) controls were included on every slide
at a dilution of 1/10.
Slides were mounted with 50:50 PBS : glycerol and examined under the UV microscope
(Leitz Ortholux II) at x400 for the presence of fluorescing cells. For the detection of IgG
anti-VCA the titre at which the fluorescence diminished was recorded. For IgM anti-VCA
the samples were scored as positive or negative for IgM in comparison with the control
wells. Samples with detectable VCA-IgM were additionally tested for rheumatoid factor.
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5.9 DNA Extraction
DNA extraction from PBMC and throat gargle pellets stored at - 70 °C was performed using
the Invitrogen Easy DNA kit (Invitrogen) according to the manufacturer's instructions.
Frozen cell pellets (approximately 5 x 106 cells) were thawed in a water bath and then re-
suspended in 200pl of PBS. 350 pi of solution A (lysis solution) was added to the cells and
mixed until dispersed. The mixture was incubated for 10 minutes at 65 °C. 150pl of
solution B (precipitation solution) was added to form a precipitate of proteins and lipids.
500pl of chloroform (Sigma) was added and agitated until the solution was homogeneous.
The samples were then micro-centrifuged at 15500 g for 15 minutes at 4 °C which separated
each sample into 3 phases. The uppermost, containing the DNA, was recovered into a fresh
eppendorf and the DNA was precipitated with 1 ml of 100% ethanol (BDH). After overnight
freezing at -20 °C the DNA was micro-centrifuged as before, and the ethanol was removed.
The pellet was mixed with 500 pi of 80% ethanol and micro-centrifuged again for 5 minutes
under the same conditions. The ethanol was removed and the pellet was left to air dry for 5
minutes, and then re-suspended in 50 pi of nuclease free water. The DNA concentration was
measured using a UV spectrophotometer (GeneQuant, GE Elealthcare) and aliquots prepared
for storage at -20 °C until used.
5.10 PCR
All PCR work was carried out by Karen McAulay. DNA was diluted with nuclease free
water to l OOng mf' for use in PCR and all PCR was carried out on a T3 Thermocycler
(Biometra) or a Robocycler 96 (Stratagene). Promega and GE Elealthcare reagents were
used unless otherwise stated and all primers were obtained from Sigma Genosys. PCR of the
P-globin gene was undertaken to verify the quality of DNA extraction. Positive and negative
controls were used in all reactions. PCR products were run on 2% agarose gels containing
ethidium bromide and visualised under a UV light source (UVP transilluminator, Ultra
Violet Products).
5.10.1 Viral Load
Viral load estimation of PBMC stored at - 70 °C was carried out using a quantitative
competitive PCR technique following the method of Stevens et a! (1999). This method is
based on competitive co-amplification of a highly conserved 213 bp region of the EBNA1
open reading frame together with an internal standard with an identical amplification
efficiency added in known concentrations (Stevens et al, 1999). DNA was amplified in a
50pl reaction containing 50mM KC1, 1.5mM MgCl2, lOmM Tris-HCl (pH 9.0), 0.1% triton
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X-100, 25 pmol of each primer (5'-GCC GGT GTG TTC GTA TAT GG-3" and the biotin
labelled 5'-CAA AAC CTC AGC AAA TAT ATG AG-3\ 200 pM of each deoxynucleoside
triphosphate and 2U of Taq polymerase (Promega). For each sample tested a series of wells
were set up containing decreasing numbers of the internal standard (106, 105, 104, 1O3,102, 10
and 1 EBV genome copy). The cycling conditions were 5 minutes at 95 °C, 40 cycles of 95
°C for 1 minute, 55 °C for 1 minute and 72 °C for 1 minute, and finally 5 minutes at 72 °C.
The PCR products were quantified by enzyme linked immunoassay. Five pi of each product
was added to 45pl of PCR buffer in two separate streptavidin coated microtitre plates
(Roche) and incubated for 60 minutes at 37 °C. The plates were washed five times with PCR
buffer, the DNA was then denatured with 0.2M sodium hydroxide for 15 minutes at room
temperature and the plates were washed again twice. The plates were incubated with 50pmol
ml"1 of the digoxigenin labelled (Roche) wild type probe (5'-TCT CCC CTT TGG AAT
GGC CCC TG-3') or the internal standard probe (5'-CTA TAT GCC TGC TTC CTC CGG
CG-3') for 60 minutes at 37 °C and then washed three times. The plate was incubated with
anti-digoxigenin alkaline phosphatase and incubated for one hour at 37°C. After washing
three times the plate was incubated with nitrophenyl phosphate (Sigma) for one hour at 37°C.
Optical density was read at 405 nm using a plate reader (MRX1I, Dynex). EBV copy
number was calculated by plotting the log optical density of the wild type/internal standard
against the log of the number of the internal standard copies. The EBV copy number in the
sample is taken as the figure where the x-axis is intercepted (see Figure 1).
—1>— EBVcontrol 1 (103 copies)
Figure 1 Estimation of EBV copy number
Figure from Karen McAulay:
Log OD [wild type/internal standard] versus internal standard copy number for duplicate EBV control samples
containing 10' copies of the EBV genome. Linear regression was performed to calculate x-intercept and the copy
number calculated as the inverse log of the x-intercept.
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5.10.2 Type 1 and 2 Strain Typing
DNA was extracted from stored PBMC as above. The type of EBV in each sample was
determined by nested PCR across a type specific region of the EBNA 3C gene (Brooks et al,
2000; Sample et al, 1990). 500ng -lpg of DNA was amplified in a primary reaction mix
containing lx PCR reaction buffer (50 mM KC1, 10 mM Tris-HCl (pH 8.3) and gelatin
0.01%) together with 1.5 mM MgCl2, 200pM of each deoxynucleotide, 0.1 pM of each
primer (5' CAC AGA GCA CCC CTG AAA GG-3' and 5'-GGC TCG TTT TTG ACG TCG
GC-3') and 1 unit of Taq polymerase (Promega). The cycling conditions were 1 cycle of
94°C for 5 minutes; 40 cycles of 94 °C for 30 seconds, 90 seconds at 45 °C and 120 seconds
at 72°C; followed by a final incubation of 72°C for 5 minutes. The primary product (2.5-5
pi) was further amplified in a second reaction mixture with the secondary primers (5'-AGA
AGG GGA GCG TGT GTT GT-3' and 5'-GTC TTG ATG TTT CCG ATG TGG CTT A-3')
under exactly the same conditions as before. Ten pi of the final products were separated on
a 2 % agarose gel (Bioline Ltd) containing ethidium bromide (Sigma) and visualised under
UV light (Ultra Violet Products Ltd). The gel was Southern blotted and probed with the
digoxigenin labelled 5'-GAA GAT TCA TCG TCA GTG TC-3' (type 1) or 5'-CCG TGA
TTT CTA CCG GGA GT-3' (type 2) (Roche).
5.10.3 Strain Typing LMP1 and EBNA3C Repeats
Strain typing was performed by examining the numbers of repeats in two regions each
known to carry variable numbers of repeats the 39 bp region of EBNA3C and the 33 bp
repeat region of LMP1.
EBNA 3C 39 bp repeat region PCR
The number of repeats in the EBNA3C region varies from 3 to 12 which can be used to
demonstrate variation between EBV isolates. This region was amplified using nested PCR
as described by Haque et al (Haque et al, 1996). 500 ng -1 pg of DNA was amplified in a
50 pi primary reaction mix containing lOmM Tris-HCl (pH 8.3), 50 mM KC1, 1 mM MgCl2,
0.01% gelatine together with, 200 pM of each nucleotide, 0.1 pM of each primer (5'-ACA
CTT GAG TTC CAT GTC GC-3' and 5'-TGT AAT CAC TGG CAA AGG GC-3') and 1
unit of Taq polymerase (Promega). The cycling conditions were denaturation at 94°C for 5
minutes, 30 cycles of denaturation at 94 °C for 30 seconds, annealing at 55 °C for 60 seconds
and extension at 72°C for 90 seconds, with a final incubation at 72°C for 10 minutes. 2.5 pi
of the product was re-amplified in a 50pl reaction volume using the inner primers 5'-TAT
CGC ACG AAG AAC AAC CCC-3' and 5'-AGA TGT GGG AAC TGG GAG ACC-3' for
30 cycles as above except that an annealing temperature of 65 °C was used. Ten pi of the
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nested product was run on a 2% agarose gel (Bioline Ltd.), Southern blotted and hybridised
with a digoxigenin labelled probe 5'-CAC GGG CTC CAA TCA TCT TC-3'. The number
of repeats was compared with known standards previously determined by sequencing.
LMP133 bp repeat region PCR
The LMP1 gene contains a variable number of 33 bp repeat sequences which have been used
to characterize variation between isolates (Miller et al, 1994). The repeat region in the
LMP1 gene was amplified following the method of Khanim et al using the primers 3'-TTT
CCA GCA GAG TCG CTA GG-5' and 5'-GGC GCA CCT GGA GGT GGT CC-3'
(Khanim et al, 1996). 500 ng-1 pg ofDNA was amplified in a 50 pi reaction containing 10
mM Tris-HCl (pH 8.3), 50 mM KC1, 0.01% gelatin, 1.5 mM MgCl2, 200 pM of each
deoxynucleoside, 1 pM of each primer and 1 unit of Taq polymerase (Promega). The
conditions were 5 minutes at 94°C, followed by 35 cycles of denaturation at 94 °C for 30 s,
annealing at 50 °C for 45 s and extension at 72°C for 90 s, with a final incubation of 72°C for
10 minutes. Twenty pi of product was separated on a 2% agarose gel and Southern blotted.
A digoxigenin labeled probe 5'-AGG ACC CTG ACA ACA CTG AT-3' was used to
identify the LMP1 repeats and the number was compared with known standards (previously
determined by sequencing).
Sequencing
In instances where the number of repeats of a given isolate could not be determined on the
Southern blot then sequencing was undertaken. PCR products were excised from the gel
using QIAquick gel extraction kit (Qiagen). Direct sequencing of the product was performed
commercially by MWG Research using the forward primer.
5.11 Flow Cytometry
The following cellular populations were studied: CD87CD3+, CD47CD3+, CD56/CD3",
CD19 /CD3" and CD37y8+.
Immunostaining ofmononuclear cells, harvested as above, was performed by aliquoting 2 x
lO5 cells in polystyrene tubes (Becton Dickinson, [BD]) on ice. Ten pi of the required
monoclonal antibody (BD) was added to each tube, vortexed, and incubated for 15 minutes
in the dark at 4°C. The cells were washed twice with flow cytometry (FCM) buffer by
spinning at 200g at 4°C for 5 minutes (MSE Mistral 3000i). Unstained cells and cells mixed
with fluorochrome isotype controls (BD) were included for every individual.
Flow cytometry was performed within 4 hours of staining using a BD Facs Caliber (BD).
The lymphocyte population was identified on the basis of forward and side scatter
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characteristics (see Figure 2). This was then used to identify a population of cells for
analysis - a so-called "gate". For each sample 10,000 cells were accumulated into the
lymphocyte gate. Data analysis was performed using Cell Quest acquisition and analysis
software (BD). The lymphocyte subset composition of each sample was determined by
analysing each cell population in turn e.g. CD4" vs. CD3+ to assess the proportion of cells
positive for both markers. Actual lymphocyte numbers for each subset were calculated from
the peripheral blood total lymphocyte count obtained at the same time and performed at the
Department of Flaematology Edinburgh Royal Infirmary using an automated counter (SE-
9000, Sysmex).
5.12 Ethics
Ethical committee approval was obtained for LCS, the case control study, and the use of
remainder samples from the Lothian Region Ethics Committee. In addition the consent was
obtained from the Edinburgh University Students Ethics Committee for the LCS and the case
control study. All students participating in the studies received a verbal explanation about
the aims of the study and a written information sheet, and then signed a consent form.
5.13 Statistical Methods
The Mann Whitney U test was used to compare median values of quantitative variables
using Minitab version 13 and GraphPad PRISM software version 4, 2003. Two sample t
tests were used to compare the pulse and blood pressure of cases and controls. The
Spearman correlation coefficient was used to examine the relationship between two
continuous variables using GraphPad PRISM software version 4, 2003. All significance
tests are two sided. Two discontinuous variables were compared using the Chi square test if
numbers permitted (Minitab version 13) or the Fisher's exact test if any variable had a value
of 5 or less (www.langsrud.com/fisher.htm). Multivariate analysis was undertaken by Craig
Higgins using a multivariate Poisson model where a number of potential risk factors for
EBV seropositivity were included together to determine prevalence ratios (Fliggins et al,
2007). The prevalence ratios were used to establish which factors were independently




















6 Longitudinal Cohort Study
6.1 Recruitment
Students were recruited to the four year LCS at the start of two consecutive academic years,
1999 and 2000. Overall 2048 students were recruited to the LCS of which serology was
successfully performed on 2006 (98%). This represents just over half of the 4000 students
that registered with the UHC at the start of these two academic years. Students following
courses lasting less than four years were ineligible. Of the 42 students that were recruited
but could not join the study 3 withdrew from their university course, demographic
information and consent forms were incomplete in 4, questionnaires were not completed in 2
and the blood sample was not obtained or was insufficient in 33. The age range was 17.0 to
42.7 with a median age of 18.7 years. Sixty three percent (1258) of the recruits were female.
6.1.1 EBV Baseline Serology by Age and Sex
Of the 2006, 75% (1499) had detectable EBV anti-VCA IgG. The median age of the
seropositive students was 18.8 years (range 17.0-42.7), which was greater than that of the
seronegative students (18.6 years, range 17.4-31.4, p<0.001). A significantly higher
proportion of female students, 79% (987/1258) were seropositive, as compared with 69% of
the males (512/748, p<0.001).
6.1.2 Ethnicity
Analysis of ethnicity by white and non-white groups did not shown any significant
difference in the proportion of students that were EBV seropositive; 75% (1409/1887) of
white students and 76% (86/113) of non-white students had EBV antibodies, (p=0.73, Table
6). As there were only 113 non-white students numbers were too small for further analysis.
6.1.3 Residence in a Tropical Country
Students that had resided in a tropical country before university were much more likely to be
seropositive (276/341, 81%) than those who had not (1184/1616, 73%, p=0.003) (Table 6).
For those born in a tropical country the EBV seroprevalence was slightly higher (84%).
6.1.4 Household Crowding
Students were asked to record the number of bedrooms and living rooms in their home prior
to university and the number of people sharing these rooms. From this information the
average number of rooms per person in the household was calculated for each student. No
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association between household crowding and EBV status was detected; the median number
of rooms per person for both EBV positive and negative students was 1.8. Students were
also asked if they shared a bedroom as a child. There was no difference in the proportions of
seronegative or seropositive students that had shared a bedroom prior to university
(p=0.110).
6.1.5 Siblings
Seventy five percent (1422/1888) of students with siblings were seropositive as opposed to
66% of those without (75/114, p=0.023). (Table 6)
6.1.6 Breast Feeding
The cohort of students recruited in 2000 were asked how they had been fed as infants. A
large proportion (91%) reported that they had been breast fed. No association with EBV
status was found (Table 6).









1934 1003 75 931 75 p=0.674
Breast fed 823 753 75 70 73 p=0.633
Non-white ethnicity 2000 113 76 1887 75 p=0.733
Residence in tropical
country
1957 341 81 1616 73 p=0.003
Born in tropical
country
2006 127 84 1879 74 p=0.011
History of smoking 1976 443 82 1533 73 p=0.001
Consumes alcohol 1981 1534 76 447 70 p=0.009
n Number of students
Table 6 EBV seroprevalence and baseline characteristics
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6.1.7 Previous IM
Eleven percent (213/2006) of students gave a history of prior IM at university entrance. All
were EBV seropositive.
6.1.8 Sexual Behaviour
Students that reported a sexual relationship before arrival at university were significantly
more likely to be seropositive (944/1133, 83%) than those who had never been sexually
active (547/862, 64%, p<0.001). There was no significant difference in the proportion of
males (55%) and females (58%) that had been sexually active before university (p=0.143).
Among the 213 students with a previous history of IM 77% had been sexually active, whilst
among the seropositive students without a history of IM this figure was 61%, and in the
seronegatives 38% had been sexually active. The likelihood of being seropositive was
increased with increasing numbers of sexual partners; 78% of students (328/422) with 1 prior
sexual partner were seropositive; 85% of students (397/467) with 2-4 sexual partners were
seropositive and 91% of students (213/235) with 5 or more sexual partners were
seropositive, (p trend <0.001) (Table 7). On initial analysis there appeared to be an
association between age at first sexual intercourse and the likelihood of EBV seropositivity
(Table 7). After stratification of the seroprevalence results by numbers of sexual partners the
significant association between age at first sexual intercourse and EBV status was no longer
seen (Figure 3).
Condom use
Among the sexually active students those that "always" used a condom were less likely to be
seropositive (506/624, 81.1%) than those that "seldom or never" used a condom (404/465,
86.9%, p=0.011). (Table 7)
Sexually transmitted infection
Among those who were sexually active 45 (4%) gave a history of a prior sexually
transmitted infection. These students were significantly more likely to be seropositive (93%)
than other sexually active students (p=0.018).
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EBV negative (%) EBV positive (%) p value
Sexually active n=1995
no 315 (37) 547 (63)
yes 189(17) 944 (83) pO.OOl
Number of sexual partners n=1986
0 315 (37) 547 (63)
1 94 (22) 328 (78)
2-4 70(15) 397 (85)
>5 22 (9) 213 (91) p<0.001
Age at first sexual intercourse n=1989
Never 315 (37) 547 (63)
<16 24(12) 178 (88)
16-17 97(16) 492 (84)
> 18 65(19) 271 (81) p<0.001
Condom use n=1951
not sexually active 315 (37) 547 (63)
never/seldom 61(13) 404 (87)
always 118(19) 506 (81) p=0.011













age at first sexual intercourse
<15
>5 partners
2 - 4 partners
1 partner
□ 1 partner D2 - 4 partners B>5 partners
Figure 3 EBV seroprevalence by age at first intercourse and number of sexual partners
6.1.9 Smoking
Students that smoked were more likely to be seropositive 365/443, 83% than those who did
not 1111/1533, 73% (p<0.001), however after adjusting for sexual behaviour the results were
no longer significant.
6.1.10 Alcohol
Students that consumed alcohol were more likely to be seropositive 1168/1534, 76% than
non-drinkers 313/447, 70%, (p=0.009), however after adjusting for sexual behavior the
results were no longer significant.
6.1.11 EBV Strain Types 1 and 2
DNA was successfully amplified using PBMC stored at recruitment in 625 of 1499 (42%)
seropositive students. Type 1 EBV was detected in 483 (77%), type 2 was present in 108
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(17%) and both types were detected in 34 (5%).
6.2 Serological Follow-up of the Longitudinal Cohort
A total of 842 students donated a follow-up blood sample (443 from the 1999 cohort and 399
from the 2000 cohort) after 3 years at University. Of the initially 510 seronegative students,
241 (47%) completed a further questionnaire about their lifestyle at university and gave a
blood sample. Amongst the 241, 38% (91) were male and 62% (150) were female (see
Table 8). This is almost identical to the proportions ofmales and females recruited to the
initial cohort overall (37% male, 63% female) but because more males than females were
originally seronegative this means that a higher proportion of female seronegative students
returned for follow-up, (p<0.001). Considering the originally seronegative students there
was no significant difference in the sexual behaviour before university between the returning
and non-returning students (p=0.128).
Total Male Female
Recruited 2006 748 (37%) 1258 (63%)
Seronegative at
recruitment
507 236 (47%) 271 (54%)
Seronegative students
returned for follow-up







Table 8 EBV Seroconversion at university
6.2.1 EBV Seroconversion and IM at University
Of the 241 students that returned after 3 years 110 (46%) had acquired EBV whilst at
university, indicating an annual seroconversion rate of 15%. The likelihood of
seroconverting was not significantly different between male and female students (44% vs.
47%, p=0.682). The median age of those that seroconverted and those that remained
seronegative was 21.6 years. The proportion that had symptomatic acquisition of EBV,
diagnosed as IM, was 27/110 (25%) which gives an annual IM rate of 3.8% in seronegatives.
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Twelve of the IM cases were male (44%) and 15 (56%) were female, (p=0.447).
6.2.2 Sexual Behaviour at University
Almost all (95%) of the seronegative students that returned for follow-up had some form of
sexual experience during three years at University. The median number of sexual partners
was 2.5. In 185 of the 241 (77%) this included penetrative intercourse, and these students
were significantly more likely to have seroconverted to EBV (51% vs. 29%, p=0.003).
Amongst the 185, those that "always" used a condom were less likely to have acquired EBV
(42/91, 46%) than those who reported "seldom or never" using a condom (52/92, 55%),
although this did not attain significance (p=0.213). Sexually active students who had
seroconverted reported a significantly greater number of sexual partners (median 3) than
sexually active students who had remained EBV seronegative (median 2, p=0.030).
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7 Results Case Control Study
7.1 Recruitment to the Case Control Study
Sixty cases of IM, 28 males and 32 females, were recruited to the case control study via the
UHC. The general practitioners at the UHC ordered diagnostic tests (generally specific EBV
serology and a full blood count [FBC]) when they saw a student with suspected IM. Eight
students had diagnostic serology performed without a FBC, three had a FBC and rapid IM
slide test for heterophile antibody without specific EBV serology, and three had diagnostic
tests out with the UHC but belonged to the LCS. Of the 60 cases recruited, negative baseline
serology was available for 28 who were already taking part in the LCS. Approximately 50%
of all IM cases diagnosed at the UHC were recruited to the case control study. Reasons for
non-participation included failure of the GP to give the student the study information leaflet,
a student might also express an unwillingness to participate at this stage, return to the
parental home to recuperate and a lack of telephone contact details.
Fifty eight seronegative students responded to a request by personal letter and acted as
controls. The median age of the IM cases and controls was 20.1 years. (See Table 9).
IM cases Controls p value
Number 60 58
Male: Female 28:32 23:35 0.442
Median age years 20.1 20.1 0.981
Age Range years 18.2-27.3 18.6-23.8
Table 9 Characteristics of IM cases and controls
Analysis by gender
Variables that showed significant differences by gender have been reported separately
(fatigue duration, fatigue score, blood pressure, haemoglobin, gamma glutamyl transferase
(GGT), and bilirubin).
7.2 Clinical Presentation and Symptoms
7.2.1 Presenting Symptoms
Students were asked which symptoms had caused them to seek medical attention. Usually
students gave 3 symptoms (range 1-5). Sore throat was the commonest presenting symptom
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Figure 4 Presenting symptoms in IM
Tiredness, exhaustion or fatigue was the second most common presenting symptom if these
terms were combined (38/60, 63%), followed by enlarged glands (28/60, 47%). Students
were asked directly about the presence of sore throat, enlarged glands, fever, sweating, loss
of appetite, headaches, pain in muscles or joints, and rash. Thus students had experienced
additional symptoms without them being the precipitant for a visit to the GP. Asked in this
way all but two of the 60 IM cases had experienced a sore throat as part of their illness, and
all but two students had been aware of having enlarged glands (58/60, 97%). Forty percent
of students (24/60) had to alter their diet because of their sore throat with 18/60 (30%)
unable to swallow soft foods. One student, unable to swallow liquids or saliva, was admitted
to hospital, another attended the casualty department and another was prescribed
prednisolone by the GP. Students were asked about the duration of their severe symptoms




which lasted a median of 7 days for both genders. In the control group 6/58 (10%) had had a
sore throat when seen, or in the preceding week, but none needed to modify their diet. Eight
students (13%) developed a rash at some point during acute IM. In 6/8 cases (75%) this was
not related to antibiotic therapy. Five students described urticarial rashes, and another
student admitted to hospital with jaundice later developed a petechial rash. Two students
developed rashes after antibiotics which had been prescribed by doctors out with the UHC.
Only one of the two students with antibiotic-associated rash was able to recall his drug
treatment which was sequential azithromycin, co-amoxiclav and penicillin. Forty seven of
sixty (78%) students complained of reduced appetite, 46/60 (78%) thought that their
temperature had been raised, although only one student had measured this, 45/60 (75%) had
noticed sweating, 39/60 (65%) complained of headaches, and 33/60 (55%) had muscle or
joint pains. Other symptoms elicited on direct questioning were fainting, near fainting or
dizziness 11/60 (18%), altered sleep pattern 7/60 (12%), abdominal pain 7/60 (12%), nausea
7/60 (12%), vomiting 7/60 (12%), mouth ulcers 3/60 (5%) and a feeling of "vagueness",
"muzziness" or being unable to concentrate 3/60 (5%). Four of the seven students (57%)
that complained of nausea were taking antibiotics, whilst none of the students that
complained of vomiting without nausea were so doing. Overall 14 students were prescribed
antibiotics (23%). In two cases the students appeared to have an additional site of infection
(dental abscess and lower respiratory tract infection). In four instances the antibiotic therapy
was instigated by a medical practitioner out with the UHC.
7.2.2 Examination Findings
Of 45 students reviewed in the first month following diagnosis 10 (22%) had enlarged
tonsils, and five (11%) had a tonsillar exudate. One "healthy" control was observed to have
a tonsillar exudate presumably not related to EBV, as serology remained negative, and 6/58
(10%) had enlarged tonsils. Periorbital swelling was noted in two students with IM, but
subjectively students' facial appearance had often appeared "slimmed down" at follow-up
and therefore subtle facial swelling is probably common. The majority (53/60, 88%) of the
IM cases had palpable lymphadenopathy at their first review, even if this visit occurred later
than one month after diagnosis. This was significantly more often than the frequency of
palpable nodes on the control group (23%, p<0.001). Amongst students with IM seen within
a month of diagnosis 40/45 (89%) had palpable lymphadenopathy and eight (18%) had
axillary as well as cervical lymphadenopathy. Of the 13 controls with palpable cervical
lymphadenopathy two (4%) also had palpable axillary lymphadenopathy. Controls with
palpable nodes were not more likely to have had a recent sore throat, however, a higher
proportion showed evidence of seroconversion to anti-VCA IgG (7/13, 57%) compared to
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those without lymphadenopathy (14/44, 32%, p=0.148). Of note, both controls with axillary
lymphadenopathy had serological evidence of recent EBV infection with positive anti-VCA
IgM. Amongst the IM cases, palpable splenomegaly was closely related to the time elapsed
since diagnosis. Six of 57 IM cases (11%) had hepatosplenomegaly at their first visit, four
(7%) had splenomegaly only, and 7 had isolated hepatomegaly (12%) (data was not recorded
in three cases). All but one of the IM cases with splenomegaly or hepatosplenomegaly were
seen within two weeks of diagnosis. In the students seen within two weeks of diagnosis, the
proportion of students with hepatosplenomegaly, splenomegaly or isolated hepatomegaly
was 11/26 (42%). In IM cases both splenomegaly (p=0.012) and hepatomegaly (p=0.022)
were significantly associated with an elevated alanine transaminase. Seven of 52 controls
(14%) had a palpable liver edge which was not considered pathological; (data were not
recorded in six cases). Hepatomegaly in controls was not associated with abnormalities in
liver function. Seven of 57 IM cases (12%, data not recorded in three) had isolated
hepatomegaly, which is similar to the proportion seen in controls. None of the controls had
splenomegaly. The pulse rate of the 45 IM cases seen within a month of diagnosis was
greater (mean 74) than that of the control group (mean 69, p=0.02). No difference was
detected when the systolic and diastolic pressures of cases and controls were compared,
although both
diastolic and systolic reading were lower in female controls than males (see Table 10).
Number Mean Range
Male systolic 23 129 97-148
Female systolic 35 1 16 89-137
p value p<0.001
Male diastolic 23 74 54-88
Female diastolic 35 70 56-86
p value p=0.048
Table 10 Blood pressure in male and female controls
7.2.3 Hospital Admission
Two male students were admitted to hospital as mentioned in the clinical presentation
section 7.2.1 above. Briefly, one student developed jaundice, and the other was unable to
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swallow fluids or saliva. A further student, also male, attended the accident and emergency
department with symptoms of tonsillar swelling, and was prescribed prednisolone, but was
not admitted.
7.3 Haematology Results
A full blood count was performed at each visit made by the 1M cases and at the visit of each
control student. Full blood counts were performed by the Department of Haematology,
Royal Infirmary of Edinburgh, using an automated counter (SE-9000, Sysmex), at the same
time as diagnostic EBV serology at the discretion of the GP. Forty seven of the 60 IM cases
had a full blood count performed by the GP at the time of diagnosis. Normal ranges are
those set by The Department of Haematology, Royal Infirmary of Edinburgh.
7.3.1 Lymphocyte Counts
Forty seven students had a lymphocyte count performed at the time of diagnosis. In 35 cases
(75%) the result exceeded the upper limit of the normal range (1.5-4.0 xl 09 F1) and was
below the lower limit in one. Thus 23% of students had a lymphocyte count in the normal
range at the time of diagnosis. (See Table 11). None of the controls had a lymphocytosis;
almost half (46%) were classified as being lymphopenia according to the normal range set
by the haematology laboratory, although only two had lymphocyte counts less than 1.0
xl09r'. The timing of the full blood count in IM cases with normal lymphocyte counts was
not significantly different from students with abnormal results with respect to the timing of
their most severe symptoms (which had occurred a median of four days previously and 6.5
days previously respectively). The lymphocyte count of the IM group significantly exceeded
that of the control group in the first month after diagnosis and again in cases reviewed
between 2 and 4 months after IM (See Figure 5).
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Time since Diagnosis <15 15-30 1-2 2-4 >5 Control
diagnosis days days months months months




Lymphocytes 5.8 2.3 2.0 1.7 2.1 1.6 1.6
x 109 r1 p<0.001 p<0.001 p<0.001 p=0.22 p=0.001 p=0.09
Monocytes 1.4 0.5 0.4 0.4 0.5 0.4 0.4
x io9 r1 p<0.001 p=0.032 p=0.86 p=0.11 p=0.26 p=0.27
Neutrophils 2.8 2.7 2.6 2.4 3.0 3.1 3.3
x 1091"' p=0.015 p<0.001 p=0.001 p<0.001 p=0.30 p=0.57
Platelets 188 258 235 235 242 222 252
x 1091"1 p<0.001 p=0.70 p=0.09 p=0.12 p=0.35 p=0.045
Hb g r1 (n=23) (n=8) (n-16) (n=9) (11=7) (n=15) (n=22)
(male) 142.0 141.0 140.5 147.0 154.0 153.0 154.0
p=0.004 p=0.002 p<0.001 p=0.10 p=1.0 p=0.58
Hbgl"1 (n=24) (n=18) (n=21) (n=17) (n=12) (n=20) (n=32)
(female) 131.5 129.5 127.0 127.0 129.0 130.5 132.5
p=0.68 p=0.31 p=0.052 p=0.079 p=0.24 p=0.53
g gram 1 litre
















The normal range (1.5-4.0 xlO9 I"1) is shown by the faint dotted line
Figure 5 Total lymphocyte count in IM at diagnosis, during convalescence and in controls
7.3.2 Monocyte Counts
At diagnosis 37/47 (79%) of students had an elevated monocyte count (>0.8 xlO9 f1) and 2
(4%) had a reduced count (<0.2 xlO91"'). The median monocyte counts at the time of
diagnosis and for students with blood collected within 15 days of diagnosis were
significantly greater than that of the control group median (p<0.001 and p=0.032
respectively) as shown in Table 11 and Figure 6. Monocyte counts later in the clinical













































The normal range (0.2-0.8 xlO9 l"') is shown by the faint dotted line
Figure 6 Monocyte count in IM at diagnosis, during convalescence and in controls
7.3.3 Neutrophil Counts
At the time of diagnosis the neutrophil count in IM cases was reduced (median 2.8 xlO91"')
when compared with healthy controls (median 3.3 xlO91"', p=0.015) (Table 11). Twelve of
47 IM cases (26%) had a neutrophil count below the lower limit of the normal range (2.0-7.5
xlO91"1) at diagnosis and in 4 (9%) the neutrophil count was less than 1.0 xlO9 1"'. None had
an elevated neutrophil count at the time of diagnosis. In IM cases the neutrophil count
shows a statistically significant increase with time elapsed since diagnosis, (Spearman
correlation p=0.035). The neutrophil counts of IM cases remained significantly lower than
that of controls until 2 months after diagnosis, as shown in Table 11 and Figure 7. Male
control students had a lower median neutrophil count (2.94 xlO91"') than female controls





































The normal range (2.0-7.5 xlO91"') is shown by the faint dotted line
Figure 7 Neutrophil count in 1M at diagnosis, during convalescence and in controls
7.3.4 Platelet Counts
Platelet counts were significantly reduced at diagnosis when compared with controls (IM
median 188 x 1091_1, control median 252 x 109f', p<0.001) as shown in Table 11 and Figure
8). Ten of 47 IM cases (21%) had a platelet count below the normal range (150-350 xlO9 l"1)
at the time of diagnosis. None were less than 100 x 109 1"', and all were asymptomatic. All
but one of 43 retested with a month had a platelet count above the lower limit of the normal
range. Platelet counts of convalescent students did not differ significantly from those of the
controls (except the late follow-up group (>5 months) where the median platelet count in the

























The normal range (150-350 xlO9 l"1) is shown by the faint dotted line
Figure 8 Platelet count in IM at diagnosis, during convalescence and in controls
7.3.5 Haemoglobin
Haemoglobin values differed between males and females and were therefore analysed
separately as shown in Table 11. In male IM cases haemoglobin values at diagnosis (median
142 g l"1) were significantly lower than those of the male control group (median 154 g f1,
p=0.004). Significantly lower values were seen in male cases compared with controls for
one month after diagnosis. In female IM cases median haemoglobin values were lower than
those of the female control group (control group median 132.5 g 1"') at all time points. These
results bordered on significance for the groups seen between 15 and 30 days after diagnosis
(127 g l"1, p=0.052) and 1 to 2 months (127 g 1"', p=0.079) after IM.
7.4 Liver Function Tests
Liver function tests (alanine transaminase (ALT), alkaline phosphatase (ALKP), gamma
glutamyl transferase (GGT) and bilirubin) were measured using an automated analyser
(Olympus AU640, Watford) by the Department of Clinical Biochemistry, Edinburgh Royal
Infirmary, and compared to the normal range set by that Department.
LFTs are not routinely performed at diagnosis by general practitioners at the UHC. Seven
students (2 male, 5 female) were incidentally found to have had these performed. The
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reasons that they were performed are not known and therefore some clinical bias is possible.
The LFTs were performed by 4 GPs from the 8 doctor practice. Students that joined the case
control study had LFT performed at their first study visit. Students with abnormal results
had their LFTs repeated at follow-up visits until their results (except bilirubin) returned to
the normal range. Control students had LFTs performed once. Two control students (one
with polycystic renal disease) were found to have LFT results out with the "normal range"
provided by Edinburgh Royal Infirmary. No gender difference in LFT was observed for
ALT or ALKP. Bilirubin and GGT differed by gender and were analysed separately.
Time Diagnosis <15 15-30 1-2 2-4 >5 Control
since days days months months months
diagnosis




ALT 135 74 32 14 20 16 16
ur1 p<0.001 p<0.001 p<0.001 p=0.32 p=0.28 p=0.69
ALKP 103 99 83 65 59 71 69
ur1 p=0.002 p<0.001 p=0.02 p=0.87 p=0.54 p=0.64
GGT (n=2) (n=V) (n=12) (11=2) (n=2) (n=3) (n=21)
(male) 90 39 31 14 44 18 14
ur1 p=0.042 p<0.001 p<0.001 p=0.78 p=0.15 p=0.43
GTT (n=5) (n=16) (n=6) (n=5) (n=2) (n=1) 10 (n=32)
(female) 50 39 22 12 18 insufficient data 12
ur1 p=0.040 p<0.001 p=0.013 p=0.89 p=0.06
Bilirubin (n=2) (n=9) (n=12) (n=2) (n=2) (n=3) (n=21)
(male) 20 10 17 14 15 13 16
pmol r1 p=0.33 p=0.036 p=0.74 p=0.55 p=1.0 p=0.73
but < controls
Bilirubin (n=5) (n=16) (n=6J (n=5) (n=2) (n-l) (n=32)
(female) 7 8 13 10 13 12 9
pmol r1 p=0.18 p=0.12 p=0.011 p=0.86 p=0.63 insufficient data
U unit 1 litre
Table 12 Liver function tests at visit one by time elapsed since diagnosis in IM cases, and controls
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7.4.1 Alanine Transaminase
IM cases that had LFT performed within in one month of diagnosis had significantly raised
ALT values compared with control students as shown in Table 12. Eight of twelve (67%)
cases with hepatomegaly had a raised ALT compared with 13 of 43 (30%) cases that did not
have a palpable liver (p=0.022). None of the control students had an elevated ALT. Of 27
cases with ALT performed in the first two weeks of illness 24/27 (89%) were raised, 41%
were more than twice the upper limit of normal and 19% were more 5 times the upper limit
of normal.
7.4.2 Alkaline Phosphatase
ALKP values in students with IM were significantly elevated when compared to control
values in the first month after diagnosis as shown in Table 12. ALKP was less likely to be
elevated in acute IM than ALT. Of 27 cases with ALKP performed in the first two weeks of
illness 5/27 (19%) were raised, and all students with an abnormal ALKP also had a raised
ALT. Of students reviewed in the first month after diagnosis 6/7 (86%) with a raised ALKP
had a palpable liver whereas only 1/31 (3%) without a hepatomegaly had an abnormal ALKP
(p<0.001). None of the controls had an elevated ALKP.
7.4.3 Gamma Glutamyl Transferase
The normal range ofGGT values given by Edinburgh Royal Infirmary is lower in females,
than males, which was affirmed by analysis ofGGT values obtained from male and female
controls enrolled in the study. The median value in males (14 U 1"') was significantly higher
than that in females (12 U 1p=0.023). An elevated GGT was found in 16/58 (28%) IM
cases at their first visit and in 2/53 (4%) controls but was not found to be a significant
marker of organomegaly in either group, (see Table 12).
7.4.4 Bilirubin
Bilirubin values in male controls exceeded those of female controls. The "normal" range is
given as 2-17 pmol 1for both sexes by Edinburgh Royal Infirmary, however, the results
have been analysed by gender in view of the significantly greater values for bilirubin in male
controls (median 16 prnol 1 _1) than female controls (median 9 pmol 1 , p<0.001) (Table
12). Elevation of bilirubin was not significantly related to enlargement of the liver or spleen
in cases or controls.
7.5 Antibody to Epstein-Barr Viral Capsid Antigen and Heterophile
Antibody
Serological tests for IgG and IgM antibodies to VCA and heterophile antibody were
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performed on plasma from all controls (n=58), and from 1M cases (n=60) at diagnosis where
a sample was submitted by the GP (n=52) and at subsequent follow up visits. The diagnosis
of IM was based on the presence of anti-VCA IgM, or, the presence of a positive heterophile
antibody test and the demonstration of anti-VCA IgG seroconversion.
7.5.1 Heterophile Antibody
Heterophile antibody was detected in 51/52 (98%) cases where a diagnostic sample was sent
by the GP. The IM case with the initially negative heterophile result had a positive result
when reviewed after 3 weeks. IM cases reviewed within 2 weeks of diagnosis had a positive
result in 28/29 (97%), at four weeks this had fallen to 89% (32/36), at 1-2 months 69%
(18/26), 47% (9/19) at 2-4 months and 22% (7/32) in those seen after 5 months still had a
positive result (Figure 9). Two of the 58 control students (3%) had a positive heterophile
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Figure 9 Heterophile antibody in IM at diagnosis, during convalescence and in controls
7.5.2 IgM Antibodies to Viral Capsid Antigen
IgM antibodies to VCA were detected in 48/52 (92%) of the IM cases where a diagnostic
sample was sent by the GP. Amongst the 46 IM cases reviewed within one month of their
initial diagnosis 45 (98%) had anti-VCA IgM. Two IM cases never showed a positive anti-
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VCA IgM test. Anti-VCA IgM antibodies declined over time from diagnosis with 69%
(18/26) positive at 1-2 months, 37% (7/19) at 2-4 months and 13% (4/32) after 5 months.
Three of 58 (5%) controls had detectable anti-VCA IgM; all had seroconverted to anti-VCA
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Figure 10 Anti-VCA IgM in IM at diagnosis, during convalescence and in controls
7.5.3 IgG Antibodies to Viral Capsid Antigen
IgG anti-VCA antibodies were detected in 51/52 (98%) samples submitted at diagnosis of
IM. The IM case with no detectable anti-VCA IgG at diagnosis did have detectable anti-
VCA IgG when reviewed 8 days later. Antibody titres in IM cases varied throughout the
study with a tendency to fall during the convalescent period (Figure 11). However in 6 cases
with low or absent (1 case) anti-VCA IgG at diagnosis; increased titres were seen in later
samples. At diagnosis 29% (15/52) of IM samples showed antibody levels above the test
normal range (<1:640), and this figure reduced to 26% (5/19) at follow-up between 2 and 4
months, and 19% (6/32) at follow-up 5 or more months after diagnosis. Twenty two of the
58 controls (38%) had detectable anti-VCA IgG indicating silent seroconversion, and of
these one had detectable IgM and heterophile antibody, 2 had anti-VCA IgM alone, and 1









Figure 11 Anti-VCA IgG in IM at diagnosis, during convalescence and in controls
7.6 Viral Load
The viral load was measured by a semi quantitative technique, by Dr. K. McAulay
(University of Edinburgh), on 46/60 (77%) students at the time of diagnosis (no diagnostic
sample in eight, no stored DNA in 4 early samples and insufficient in two). Viral load
quantification at follow-up visits was performed on 133/150 (89%) occasions. There was a
highly significant reduction in viral load with days elapsed since diagnosis (p<0.001)(see
Figure 12).
Overall, at the time of the diagnostic sample students had been unwell for a median of 5 days
(maximum 46 days). Four students complaining of vomiting had a significantly higher viral
load (median, 72, 225 genomes per 106 cells) than those without vomiting (5807, p=0.005).
The association between the presence of other symptoms and the viral load at diagnosis was
investigated. Students with some types of symptoms consistent with a more severe illness
(e.g. fever, sweating, myalgia, severe sore throat resulting in modified diet, reduced walking
distance) did often have a higher median viral load at diagnosis, but these did not attain
statistical significance in the numbers of students studied (Table 13). Students suffering
from persistent fatigue at six months after diagnosis also had a higher median viral load at
diagnosis (12, 400 genomes per 106 cells) than students that had made a complete recovery
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by this time (5773 genomes per 106 cells) but this did not attain statistical significance, nor
was the viral load at diagnosis correlated with the duration of fatigue in males or females.
Fatigue is discussed in more detail in section 7.8.9. No significant correlation between the
viral load at diagnosis and duration of severe symptoms, or the initial total white cell count,

















Median VL at diagnosis if
variable present (Range)
copies per 106 cells
Median VL at diagnosis if
variable absent (Range)
copies per 106 cells
P
Fever 37/46 7800 (0-318300) 7366 (82-147850) 0.890
Sweating 36/46 8283 (0-318300) 5201 (82-147850) 0.842
Muscle aches 28/46 8825 (0-417850) 4636 (161-318300) 0.492
Headache 29/46 3500 (0-147850) 10,466(161-318300) 0.387
Anorexia 36/46 6604 (0-318300) 8870 (161-33783) 1.0
Nausea 6/46 2563 (59-16840) 8283 (0-318300) 0.463
Vomiting 4/46 72225 (16840-318300) 5807 (0-147850) p=0.005
Rash 7/46 2673 (59-33783) 8766 (0-318,300) 0.275
Unable to follow
usual diet
19/46 8883 (0-54300) 3036 (0-318300) 0.446
Unable to tolerate
soft diet




19/46 8766 (82-147850) 5841 (0-318300) 0.076
Walking distance
<100m at worst
24/46 9692 (82-147850) 2855 (0-318300) 0.063
Fatigue at 6 months 9/40 12,400 (0-48283) 5773 (0-318300) 0.391
Part-time term
employment
9/43 8883 (82-54300) 6604 (0-318300) 0.870
Impaired
concentration
38/46 8283 (0-318300) 4933 (483-16166) 0.460
Table 13 Clinical features of IM cases and viral load at diagnosis
7.7 EBV Strain Typing
7.7.1 EBV Strain Typing (type 1 or 2) in Students with IM
In order to determine the relative contribution of type 1 and 2 strains to disease presentation
EBV typing was carried out using PCR which amplified type specific sequences within the
EBNA3C gene (Brooks et al, 2000; Sample et al, 1990). DNA was successfully amplified in
48/53 samples (91%). Forty two isolates were type 1 strains (88%), 3 were type 2 (6%) and
a further 3 (6%) contained both type 1 and type 2 sequences.
7.7.2 EBV type and Lymphocyte Count at Diagnosis
The number of IM cases caused by type 2 strains was insufficient to permit investigation of
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any associations between EBV type and clinical symptoms, laboratory parameters or viral
load. Lymphocyte counts and EBV type were made available to me for an additional ten IM
cases by Drs. R. Thomas and K. McAulay. Interestingly IM caused by EBV type 1 may be
associated with a higher lymphocyte count in the peripheral blood (see Appendix 12.2).
7.7.3 Strain Typing of IM Cases and their Contacts
In order to compare EBV isolates obtained from IM cases and their contacts strain typing
was performed by examining the numbers of repeats in the EBNA 3C and LMP1 regions of
the EBV genome; two regions known to carry variable numbers of repeat sequences, (see
5.10.3).
Samples obtained
Mouth gargle samples and or peripheral blood samples were collected from the partners,
friends and flatmates of students with IM. Overall 61 contact pairs were identified. The
largest group being flatmates (31) followed by partners (20), friends (10), IM cases known to
each other as friends or flatmates (4 pairs) and a sister, who had also contracted IM. The
samples collected were venous blood and throat gargle (31), capillary blood and throat
gargle (1), venous blood alone (8) and mouth wash alone (12). Among the 40 contacts with
serum or plasma available, 35 (88%) were EBV seropositive. Sixteen of the mouthwash
samples were collected in the students' own homes supervised by the student who had
contracted IM. These samples were subject to greater delays in processing and subjectively
the sample quality of some of the throat gargles looked poor, however, the likelihood of
obtaining a typing result was not significantly less than that achieved with the supervised
gargles (31% vs. 44% p=0.50).
Results
If amplification at both loci was successful a discrepancy at one was interpreted as a
mismatch. If, however, only one locus amplified and this matched; this was termed a
"partial match". In 11 partner pairs where amplification was successful, 6 matched at both
loci, 3 showed partial match and 2 were non-identical (18%).
In the non-sexual contacts there were 2 pairs with matches at both loci, 1 partial match, and
14 mis-matched pairs (82%). Thus sexual contacts were significantly more likely than non¬
sexual contacts to share strains (p=0.001).
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7.8 Impact of IM on Studies and Other Activities
7.8.1 Activities of Daily Living
Students were asked if they were able to get up, dress and wash during the worst phase in
their illness. Whilst this might be affected by important study commitments 50/58 (86%)
could wash and dress during their worst symptoms. Data were not recorded by two students.
Students were asked if they were able to leave their home at the worst stage of their illness.
This figure was lower with only 36 of 59 (61%) of students stating that they left home during
their worst symptoms. A related question was how far students were able to walk. Amongst
students with IM that were able to leave their home 23/35 (66%) could not walk as far as
normal. Five students stated that they were unable to walk 100 m and a further 9 estimated
that they were unable to walk 500 m. All but one student stated that they would normally be
able to walk over 2 km (or for longer than 30 minutes at a normal pace). Of the 56 IM cases
completing this question only 12 (21%) were able to walk over 2 km during the acute phase
of their illness.
7.8.2 Hours of Sleep
Hypersomnia is a recognised feature of IM. The reported hours of sleep in cases exceeded
that of controls. This difference was still apparent at review five or more months after
diagnosis when cases continued to sleep for an hour longer than the control group (Table
14). Unfortunately data on hours of sleep prior to the onset of IM did not form part of the
survey although this information was available for 9 students who developed IM. Their pre¬
morbid hours of sleep did not differ from that of the controls (mean 7.4 hours for cases and
7.3 for controls) suggesting that the IM group did not differ from the control group prior to
the onset of their illness.
In addition students with IM reported an increase in hours spent lying down but not asleep.
Students reviewed within the first two weeks of diagnosis spent a median of two hours per
day spent lying down but not sleeping compared with one hour for the control group
(p=0.001) (Table 14).
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Time since Diagnosis <15 15-30 1-2 2-4 >5 Control
diagnosis days days months months months
Number of n=60 n=31 n=37 n=27 n=20 n=34 n=58
cases
Activity
Studying t q n=44 15 n=z/ 22.3 n=J4 24.5 n=24 24.5 n=lb 26 n=2/ 26 n=56
p<0.001 p=0.001 p=0.119 p=0.321 p=0.346 p=0.873
Exercising 0 n=w 0 on=2y | n=20 2 2 2
p<0.001 p<0.001 p<0.001 p=0.038 p=0.945 p=0.864
Social 0 4 5 6 10 8n=3i 12
activities
p<0.001 p<0.001 p<0.001 p=0.004 p=0.220 p=0.004
Sleeping J - 10 g n=36 8 8.5 n=iy 8 y n=57
p<0.001 p<0.001 p=0.002 p<0.001 p<0.001
Resting - 2 n=2/ 1 n=35 | n=25 1 1 l
not
sleeping p=0.001 p=0.093 p=0.525 p=0.864 p=0.371
-
Values expressed as mec ian hours per week, except rours of sleep1 / 24 hours
t Sum of hours of private study and timetabled classes per week
Table 14 Hours spent per week on different activities in IM at diagnosis, during convalescence
and in controls
7.8.3 Concentration
The majority (47/60, 78%) of students thought that IM had affected their ability to
concentrate (see "Physical Function and Fatigue" Appendix 12.1). This perception did not
vary with gender, but was significantly influenced by whether the worst symptoms had
occurred during the holidays. Of the thirteen students who stated that their concentration had
not been affected, six (46%) were on holiday at the time of their most severe symptoms,
whereas, amongst the students stating that their ability to concentrate was impaired, only
15% (7/47) were on vacation at the time of their worst symptoms. This difference was
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statistically significant (p=0.015).
Students that stated their ability to concentrate was impaired estimated the period of time
they could learn new information, either in a lecture or from a textbook. At the time of their
most severe symptoms this was ten minutes or less for 70% (31/44) of the students reporting
impaired concentration. This information was collected in 25 of the control group ofwhom
22/25 (88%) could concentrate for 40 minutes or more. When compared with control
students the IM cases reported a significantly reduced concentration span for one month after
diagnosis.
7.8.4 Hours Attending University
Cases, prior to IM, and controls reported spending similar numbers of hours attending
university (Table 15). Amongst controls no significant gender difference in attendance was
detected.
Cases (before IM) Controls p value
Number 59 58
Attending university 16 (0f-48)n=5y 15(6-40) 0.935
Private study 10 (2-60) 10 (0-50) n=56 0.312
Total study hours 27 (5-66)n=58 26 (8-80) n=56 0.306
Social activities 12(3-25) 12(3-41) 0.571
Exercise 4 (0-20) 2(0-12) p=0.008
Median hours per wee c, range in parentheses; t two PhD students gave University hrs=0
Table 15 Reported weekly hours of study, exercise and social activities in cases prior to IM and
in controls
As expected the development of IM had an adverse effect on students' attendance at
university. An estimation was made at each interview of the actual timetabled hours of
university sessions that the student had been unable to attend on account of IM. Overall the
median number of lost timetabled hours was ten, with a range of none to 300. Seventeen of
60 (28%) lost no university time, although 13 of these 17 were on holiday at the time of their
most severe symptoms. Twenty two (37%) students lost up to 20 hours and six (10%)
missed over 100 hours. Female students reported missing significantly more university
classes than male students, a median of 17 vs. 2 hours, (p=0.004) (Table 16). The
occurrence of a student's most severe symptoms during a holiday period offered significant
protection against missing timetabled university classes (median hours missed if onset during
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vacation 0, onset during term median 15 hours, p=0.001). Onset of illness during a vacation
completely protected male students (7/7) from missing timetabled classes whereas 3/6
female students still missed university time (4, 59 and 126 hours). The five students, all
female, that either left university completely or decided to repeat the year missed between 36
and 300 hours (average 115, median 72).
Number Median Range
Male 28 2 0-80
Female 32 17 0-300
p value p=0.004
Table 16 Hours of timetabled university classes missed through illness in male and female IM
cases
The severity of initial disability predicted the quantity of university classes missed. Students
with IM that could not wash and dress at the worst point of their illness, or that were unable
to leave their house, or reported a reduced walking distance all missed a significantly greater















8/57 56 (0-300) 7(0-126) p=0.009
Males 3/27 39 (20-40) 1 (0-80) p=0.039




23/58 35 (0-300) 3 (0-126) p=0.004
Males 8/27 15.5 (0-80) 0(0-70) 0.182




48/59 15.5 (0-300) 0 (0-46) p=0.005
Males 20/27 4(0-80) 0(0-46) 0.156




28/58 18.5 (0-300) 2.5(0-126) p=0.005
Males 10/27 15.5 (0-80) 0(0-70) 0.078
Females 18/31 44 (0-300) 11 (0-126) 0.128
m meters
Table 17 Severity of initial disability in IM cases and subsequent number of missed timetabled
classes
At interview there was an impression that students studying science subjects missed a greater
number of timetabled university hours, presumably reflecting the significantly greater
number of timetabled hours in their courses overall, however this did not attain statistical












28 20.0 14.5 0-300
Social sciences 16 13.0* 8.0 0-126
Arts courses 15 1 1.5t 5.0 0-115
p value * p<0.001
f p<0.001
all NS
NS not significant n Number of students
Table 18 Timetabled university hours missed through illness by degree type
7.8.5 Hours of Private Study
Students were asked at each visit if their illness was affecting their ability to study. Over
time there was a gradual increase in the proportion of students returning to their pre-illness
study routines (Table 19). At the time of diagnosis reduced private study was almost
universal with only 8% of students able to follow their normal study routine. Counting the
hours of timetabled university classes missed through illness is reasonably objective,
however, estimating the hours that might have been spent in private study, but were not













47 4 9 8
< 15 days 27 4 0 13
15-30 days 22 12 3 35
1 -2 months 7 18 2 72
2-4 months 3 15 4 83
> 5 months 4 27 5 87
Heft university or on vacation
Table 19 Proportion of students with normal study routine by time after IIV1 diagnosis
In addition, for some students the distinction between attending university and private study
was not clear-cut. Three of the students with IM were PhD students, another was writing a
Master in Law and at least three others were undertaking science honours dissertations when
they contracted glandular fever. Furthermore during exam time students may spend many
hours in private study but none in timetabled classes. Hours of private study and the total
hours of study (timetabled classes and private study) in cases prior to IM and in controls are
shown in Table 15.
When cases were compared with control students their total hours of study were significantly
reduced for two weeks after diagnosis (see Table 14).
Since the median duration of severe symptoms was 7 days (see 7.2.1) and study time was
significantly reduced compared with controls for a further 2 weeks (Table 14) an estimation
of the total study hours lost through illness can be made by comparing the reported
behaviours of cases and controls. During the first seven days cases reported that they
undertook no university work at all, whilst controls completed 26 hours. During the
following two weeks cases completed 15 hours (median) per week (11 hours less than the
control students). Thus a very crude estimation of 48 hours of combined university classes
and private study time might be lost for students contacting IM during term time.
7.8.6 Repeat Academic Year / Left University
Five students in this case control study (8%) were known to have discontinued their course
after contracting IM. Two left university completely and three planned to repeat the
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academic year during which they had contracted IM.
7.8.7 Social Activities
Cases when well and controls spent similar amounts of time attending social events (e.g.
pub, club, cinema, going out for a meal, see 12.1) (Table 15). There was no significant
gender difference in the number of hours spent on social activities in control subjects or in
cases prior to the onset of symptoms. After contracting IM cases spent fewer hours on social
activities than controls at all periods during convalescence, and this was significant for all
time periods except for students reviewed between 2 and 4 months. As might be anticipated
the reduction was most marked in the early weeks after diagnosis (see Table 14).
7.8.8 Exercise
Six of 60 IM cases (10%) and 15/58 (26%) controls undertook no vigorous exercise (defined
as getting out of breath e.g. running, cycling, exercise class, swimming, see 12.1) (p=0.222).
Unlike the number of hours that students spent studying or socialising, which did not differ
between cases and controls, the reported hours spent undertaking vigorous exercise (prior to
the onset of IM) was greater in cases (median 4 hours per week) than in control (median 2
hours, p=0.008) (Table 15). There was no significant difference in the number of hours of
exercise per week reported by male (median 3 hours) and female controls (median 2 hours,
p=0.274) or between male (median 3.5 hours) and female IM cases (median 4 hours,
p=0.988) prior to the onset of IM.
In the acute phase of their illness 56/60 (93%) of cases had reduced or ceased their usual
exercise regime, and even 5 months after diagnosis one quarter of cases were taking less
exercise than prior to diagnosis. Comparison with controls shows that cases took
significantly less exercise for up to 2 months following diagnosis (Table 14), but this
comparison is problematic in that controls reported fewer hours of exercise than cases prior
to the onset of IM as discussed above.
7.8.9 Fatigue Score and Duration
Students were asked to rate their feeling of fatigue on a numerical rating scale from zero (no
fatigue) to 10 (as bad as you can imagine). Students reviewed within one month of diagnosis
and students reviewed later did not differ in their rating of fatigue before they had become
unwell. Male and female controls did not show a significant difference in their fatigue score;
similarly male and female cases did not differ significantly in their scoring of fatigue prior to
the onset of their illness. Control students had a higher median fatigue score (median 3.5,
i.e. more fatigued) than the score ascribed by cases prior to the onset of their symptoms
(median 1.5) (p<0.001). Female students with IM (median score of 8) had significantly
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higher fatigue scores than male cases at the time of their most severe symptoms (median 7)
(p=0.011).
Students' assessment of their fatigue duration was available in 52/60 (87%) cases. The
duration of their fatigue ranged from 3 days to 841 * days (* still fatigued at last enquiry).
The median duration of fatigue was 70 days, however, the duration of fatigue was longer in
female students (median 125 days) than males (median 54 days, p=0.002) (Figure 13).
When examined as a categorical variable fatigue at six months was significantly associated
with female gender (p=0.005), but not with a stressful event in the six months before
diagnosis (p=0.335) or with a diagnosis of mental illness in the preceding six months
(p=0.114) (See Table 20). When fatigue is examined as a continuous variable (duration in
days) students who reported a stressful event or mental illness in the 6 months prior to IM
were more likely, although not significantly so, to experience a longer duration of fatigue
(medians 94 days and 72 days respectively) (Table 21). In females this trend was more
pronounced, with a median duration of 194 days in those reporting a prior stressful event
(p=0.070), and a median duration of 263 days in those with a prior mental health complaint
(p=0.247).
The initial score that students ascribed to the severity of their fatigue was positively
correlated with the subsequent fatigue duration (p=0.021, see Figure 14) and the number of
hours of timetabled university classes missed through illness (p<0.001, see Figure 15). The
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Figure 13 Duration of fatigue by gender
Fatigue at 6 months
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Prior mental illness 5 7 p=0.114
Prior stressful event 6 14 p=0.335
Table 20 Fatigue at six months
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Figure 15 Initial fatigue score correlates with the number of hours of missed timetabled classes
p<0.001
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Correlates of Fatigue duration
The presence of headache predicted a significantly longer duration of fatigue (median 94
days) than that observed in students without (median 48 days, p=0.009). A reported exercise
tolerance of less than 100 meters at the time of the worst symptoms also predicted a longer
duration of fatigue (medians 107 and 55 days, p=0.019) (see Table 21). Other features
investigated did not attain statistical significance. When males and females were analysed
together there was no significant correlation between the duration of fatigue and the viral
load at diagnosis, the lymphocyte count at diagnosis, the reported weekly hours of exercise
prior to 1M and the number of days with symptoms prior to a diagnosis being made. There
was a significant association between the duration of fatigue and the number of hours missed
from university (p = 0.003), although this was more evident among females (p=0.011) than
males (p=0.341) (Figure 16).
When males and females were analysed separately higher reported pre-morbid weekly hours








Median duration of fatigue if
variable absent
p value
Fever 40/52 71 (5-841) 62 (3-367) 0.254
Sweating 38/52 71 (5-841) 62 (3-367) 0.392
Muscle aches 28/52 70(17-525) 75 (3-841) 0.949
Headache 33/52 94 (17-841) 48 (3-427) p=0.009
Anorexia 41/52 72 (5-841) 66 (3-367) 0.911
Nausea 7/52 51 (42-841) 70 (3-525) 0.872
Vomiting 7/52 160 (55-841) 66 (3-525) 0.099
Rash 7/52 80 (29-367) 70 (3-841) 0.758
Unable to follow
usual diet
21/52 125 (5-427) 63 (3-841) 0.417
Unable to tolerate
soft diet




20/52 109 (21-841) 56 (3-525) p=0.056
Walking distance
<100m at worst
23/51 107 (21-841) 55 (3-367) p=0.019
Onset of IM in
vacation
12/52 130(3-332) 68 (5-841) 0.837
Part-time term
employment
10/45 75 (17-841) 70 (3-427) 0.702
Impaired
concentration
40/52 71 (17-841) 59 (3-427) 0.318
Prior stressful
event
19/52 94 (3-525) 66 (5-841) 0.556
Prior mental
illness
11/52 72 (21-525) 69 (3-841) 0.453
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Figure 17 Weekly pre-morbid hours of exercise in males correlates with fatigue duration
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7.9 Medical, Lifestyle and Behavioural Characteristics
The lifestyle and behavioural characteristics of cases and controls were compared to look for
factors associated with IM.
7.9.1 Tonsillectomy
There was no significant difference in the proportion of cases and controls that had a prior
history of tonsillectomy (p=0.666).
Tonsillectomy No history of
tonsillectomy
Totals
Case 2 57 59
Control 3 50 53
Totals 5 107 112
Table 22 Tonsillectomy in IM cases and in controls
7.9.2 Psychological Illness
It has been suggested that psychological factors may be important in determining
susceptibility or recovery in IM (Greenfield et al, 1959; Kasl et al, 1979). In view of this,
cases and controls were asked if they had experienced a psychological or mental illness in
the preceding six months. Thirteen (6M1, 7F2) of 60 (22%) IM cases and 8 (3M, 5F) of 57
(14%) control students reported some form of psychiatric illness (p=0.282). Three students
with IM and three control students had required treatment (depression 3, depression and
overdose 1, depression and stress 1, stress 1).
7.9.3 Stressful Events
Students were asked if they had experienced any stressful events in the preceding six
months, examples were: the death of or serious illness in a parent, partner, sibling or child;
breaking off a marriage or steady relationship; a major financial crisis; financial pressure
leading to part-time employment; or major problems with studies. Twenty five (14M, 1 IF)
of the 60 of the IM cases (42%) had experienced a stressful event compared with 13 (4M,
9F) of 58 controls (22%) (p=0.025).
7.9.4 Paid Term-Time Employment





undertaking part-time paid employment during term-time. Thirty percent (17/57) of controls
undertook paid work as did 26% (13/51) of the IM group (p=0.616). The IM cases worked a
greater number of hours per week (median 15 hours) than the controls (median 11 hours) but
this did not attain statistical significance (p=0.149).
7.9.5 Smoking and Alcohol Habits
There was no statistically significance difference in the proportion of cases or controls that
stated they smoked or consumed alcohol.
Case Control p value
Smoker 11 9 0.684
Non-smoker 49 49
Consumes alcohol 59 53 0.111
Does not consume alcohol 1 5
Number of alcoholic drinks
per week
13.0 13.5 0.374
Table 23 Smoking and alcohol habits of cases and controls
7.9.6 Exercise
Six of 60 IM cases (10%) and 15/58 (26%) controls undertook no "vigorous" exercise
(p=0.222). There was no significant difference in the number of hours of exercise per week
reported by male (median 3 hours) and female controls (median 2 hours, p=0.274) or
between male (median 3.5 hours) and female IM cases (median 4 hours, p=0.988) prior to
the onset of IM. When the hours of exercise per week were compared in cases and controls,
students that had developed IM reported a significantly greater number of exercise hours per
week (before becoming unwell) than controls as discussed in 7.8.8.
7.9.7 Contact with Other Cases of IM
Students were asked if they knew anyone who had had glandular fever in the preceding three
months. Twenty one of the 60 IM cases (35%) and 15 of 58 (26%) controls recalled such
contact (p=0.281). In the IM group 5 of these contacts were partners, whereas none of the
contacts recalled by the control group were partners.
7.9.8 Relationships
Cases and controls were asked about the total number of relationships or brief contacts,
including kissing, they had had in the preceding three months. All cases (n=59,
questionnaire incomplete for one case), but only 38/58 (66%) of the control group students
had had a sexual relationship of any kind (including kissing) in the preceding three months
(p<0.001). Six (10%) of the control group reported no previous sexual contact of any type
including kissing at any time (p=0.013). Six cases (3 male and 3 female) and 2 controls
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(both male) reported same sex relationships. Restricting the analysis to students reporting a
relationship in the preceding 3 months revealed that, students with IM had, on average, a
greater number of partners (mean 2.5) than the control group of students (mean 1.4),
although the median number of contacts for both groups was one, (p=0.02 [Mann Whitney
U]). The contact involved kissing only for 6 of 59 (10%) IM cases and 10/38 (26%) controls
(p=0.036). In 20/59 (34%) students with IM and 4/38 (11%) controls the relationship had
involved genital or orogenital contact, but not vaginal or anal intercourse (p=0.009).
Amongst students that were sexually active, the proportions that had had penetrative sexual
intercourse were similar: IM 33/59 (56%) and controls 24/38 (63%) (p=0.48).
7.9.9 Travel and Vaccination
The proportion of cases (30/60, 50%), and controls (30/58, 52%) that had travelled outside
the UK in the last six months were similar, (p=0.851). There was no significant difference in
the proportion of students that had received any form of vaccination in the preceding six
months (cases 11/58, 19%, controls 18/58, 31%, p=0.133).
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8 Analysis of Lymphocyte Subsets in Acute IM,
Convalescence and IM-like Illness
In order to investigate the immune response to primary EBV infection the numbers and
proportions of different lymphocyte subsets were studied using flow cytometry during acute
and convalescent periods. These results were compared with data obtained from healthy
control students and from students with "IM-like" symptoms. The latter were students
thought to have symptoms consistent with acute IM by their GP but whose serology was
negative for anti-VCA IgM and heterophile antibodies. Lymphocyte subset analysis was
carried out on 73 occasions on 25 IM patients enrolled in the case control study, 12 controls,
and 9 students with "IM-like" illness.
All of the acute IM cases had detectable anti-VCA IgM except one who had detectable
heterophile antibody and had demonstrated anti-VCA IgG seroconversion. None of the
controls or "IM-like" group had detectable anti-VCA IgM or detectable heterophile
antibody. The results are summarised in Table 24. The results obtained from healthy
controls in the current study are in line with other published data (see Appendix 12.4).
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Time since Diagnosis <15 15-30 1-2 2-4 >5 "IM- Control
diagnosis days days months months months like"
Number of cases n=14 n=6 n=6 n=5 n=8 n=13 n=9 n=12
Median count
Total 7.00 2.16 1.67 1.61 1.87 1.56 1.54 1.39
lymphocytes p=<0.001 p=0.001 p=0.053 p=0.430 p=0.021 p=0.058 p=0.789
xlO9 r1
CD3+ xlO91"1 5.15 1.46 1.0 1.12 1.19 1.26 0.79 1.02
(T-cells) p=<0.001 p=0.035 p=0.963 p=0.493 p=0.177 p=0.077 p=0.303
CD8+xl09l'' 4.53 0.57 0.4 0.39 0.52 0.48 0.36 0.41
(CD8+ T-cells) p=<0.001 p=0.028 p=0.888 p=0.874 p=0.232 p=0.165 p=0.374
CD4+ xlO9 r1 0.92 (n=13> 0.46 0.41 0.63 0.60 0.70 0.54 0.75
(T-helper cells) p=0.370 p=0.101 p=0.068 p=0.370 p=0.563 p=0.849 p=0.110
y5 xlO91'1 0.46 (n=U) 0.32 0.20 0.15 0.32 0.15 0.11 0.08
(y8 lymphocytes) p<0.001 p=0.001 p=0.006 p=0.044 p<0.001 p=0.036 p=0.526
CD56+CD3~ 1.00 <n=I3) 0.50 0.33 0.22 0.31 0.22 0.21 0.14
xlO9 r1 p=<0.001 p=0.008 p=0.013 p=0.126 p=0.028 p=0.087 p=0.145
(NK cells)
CD19+xlOyl"' 0.26 0.14 0.17 0.13 0.27 0.21 0.26 0.27
(B cells) p=0.857 p=0.325 p=0.147 p=0.031 p=0.729 p=0.242 p=0.749
CD4%/CD8% 0.18 0.70 1.27 1.23 1.19 1.31 1.41 1.57
p=<0.001 p=0.006 p=0.211 p=0.726 p=0.129 p=0.311 p=0.643
Table 24 Lymphocyte subset analysis in acute IM, convalescents, controls and IM-like illness
8.1.1 Total Lymphocyte Counts
The median total lymphocyte counts of the acute IM group (7.0 xlOV) was significantly
greater than that of the control group (1.39 xl09f', p<0.001), (see Table 24 and Figure 18).
The median lymphocyte count of the heterophile negative, "IM-like" group (1.54 xl09f')
was significantly less than that of the acute IM group (p<0.001) but was not significantly
different from the control group (p=0.789). The median lymphocyte counts of convalescing
IM cases continued to exceed that of the control group at all time points (see Figure 18).
This difference was statistically significant in the first 15 days (2.16 xl09l"', p=0.001), 15-30
days (1.67 xlO9!"1 p=0.05) and also in the group collected between 2 and 4 months after
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Figure 18 Total lymphocyte numbers in IM, convalescents, controls and IM-like illness
8.1.2 T-lymphocytes (CD3+)
T-lymphocyte numbers in the acute IM group (median 5.15 xlO9!"') significantly exceeded
those of the control group (1.02 xl09r', p<0.001) and those of the "IM-like" group (0.79
xlO9!"1, p<0.001) (see Table 24 and Figure 19). The median CD3+ T-cell count of the "IM-
like" group did not differ significantly from that of the control group. Samples from six
students convalescing from IM who were seen within two weeks of diagnosis, had T-cell
numbers greater than those of the control group (1.46 xl09l_1, p=0.035). After this period



















Figure 19 T-lymphocyte numbers in IM, convalescents, controls and lM-like illness
8.1.3 CD8+ T-cells
CD8+ T-cell numbers at diagnosis (median 4.53 xl09f') were significantly greater than those
of the control group (0.41 xl09l_1, p<0.001) and those of the "IM-like" group (0.36 xlO9!"1,
p<0.001) (see Table 24, Figure 20 and Figure 21). Only one IM sample fell within the range
of the control group (IM range 0.65-9.08 xl09l"', control range 0.21 - 0.95 xl09f'). The
median CD8+ count of the "IM-like" group (0.36 xlOV) did not differ significantly from
that of the control group. For a group of six cases, where samples were collected within 15
days of diagnosis, the median CD8+ T-cell count (0.57 x 109 1"' ') was significantly greater
than that of the control group, (p=0.028). The convalescent data demonstrate that CD8" T-











































8.1.4 T-helper cells (CD4+CD3+)
CD4' T-cell numbers of the acute IM group (median 0.92 xl09f') did not differ from those
of the control group (median 0.75 xl09f') (see Table 24, Figure 22 and Figure 23). Figure
23 demonstrates the importance of measuring actual lymphocyte subset numbers in acute
IM, because the different lymphocyte populations are not altered equally. Thus the
proportion of T-cells that are CD4+ falls whilst the actual numbers of these cells remains
almost constant. The median CD4+ counts of the convalescent IM groups and the "IM-like"
(0.54 xlO'l"1) were all less than the control group, but this did not attain significance for any
of the groups, although the median CD4+ count of students seen between 15 and 30 days








































Gamma-delta T-cell numbers at diagnosis (median 0.46 xl09l_1) were significantly greater
than in the control group (0.08 x 1091"', p<0.001) and the "IM-like" group (0.11 xlO'f1,
p=0.004) (Table 24). The y8 T-cell numbers of the "IM-like" group and the control group
did not differ significantly. Gamma-delta T-cell numbers of the IM group remained
significantly greater than those in the control group at all time points when the convalescent
group was divided up according to the time elapsed since diagnosis (see Table 24 and Figure
24). Samples from thirteen students, taken at least 5 months after the diagnosis of IM

































8.1,6 Natural Killer cells (CD56+CD3)
NK cells were identified as staining positively for CD56 but negatively for CD3 (see Figure
27). The results (Table 24 and Figure 26) exclude the small population of cells positive for
both markers. NK cell numbers at diagnosis in IM (median 1.0 x109F') were greater than
those ofthe control group (0.14 xlO'l"1, p<0.001) and the "IM-like" group (0.21 x109F!,
p<0.001). NK cell numbers of the "IM-like" group did not differ significantly from those of
the control group. NK cell numbers exceeded those of the control group at all time points
after diagnosis, and this difference was significant for samples collected from students within
15 days of diagnosis (0.5 xl09f', p=0.008), 15-30 days (0.33 xl09f', p=0.013) and 2-4
months after diagnosis (0.31 xlO9!"1, p=0.028).
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B-cell numbers at diagnosis (0.26 xl09f') and in the "IM-like" group (0.26 xl09l_1) did not
differ significantly from the control group (0.27 xl09f'). B-cell numbers were reduced in the
convalescent period up to 2 months after IM when compared with controls (Table 24 and
Figure 28). This difference was significant for a group of 5 samples collected at 1-2 months































Figure 28 B-cell numbers in IM, convalescents, controls and IM-like illness
8.1.8 CD4/CD8 Ratio
At the time of IM diagnosis the number of CD8+ T-cells was generally greatly increased
whilst the number of CD4T T-cells was maintained at normal levels, which resulted in
inversion of the normal ratio of CD4T to CD8 T-lymphocytes. The ratio of CD4^ to CD8
T-cells in controls gave a ratio of 1.57, whilst at IM diagnosis the ratio was 0.18 (p<0.001),
(see Table 24 and Figure 29). The abnormal ratio persisted for 2 weeks after diagnosis.
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Figure 29 CD4/CD8 Ratio in IM, convalescents, controls and IM-like illness
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9 Discussion
After Epstein-Barr virus was recognised as the cause of infectious mononucleosis in 1968
(Henle et al, 1968) several studies were undertaken to investigate the epidemiology of EBV
infection and IM (Anon., 1971; Biggar et al, 1978; Dan & Chang, 1990; de-Thq et al, 1978;
Hallec et al, 1974; Kafuko et al, 1972; Lehane, 1970; Niederman et al, 1970; Sawyer et al,
1971). These showed that the annual rate of seroconversion in seronegative populations
ranged between 2% (troops in Vietnam) and 27% (peace corps volunteers). The proportion
experiencing symptomatic seroconversion also ranged widely between none (students
attending the Chinese University of Hong Kong and a study including peace corps
volunteers) and 74% (students at Yale University). The clinical features of IM were studied
at this time but these observations were based on distinct populations of hospitalised college
students or military personnel that were comprised almost entirely ofmales (Dalrymple,
1964; Finkel et al, 1964; Hallee et al, 1974; Hoagland, 1960). Additionally some clinical
studies, notably those of Hoagland, predated the discovery of EBV and its association with
IM, and confirmation of IM diagnosis included strict haematological criteria of 50%
lymphocytosis with atypical lymphocytosis of 10%, as well as the presence of heterophile
antibody (Hoagland, 1960; McCarthy & Hoagland, 1964). Later commentators have found
that these criteria only have a sensitivity of between 39 and 43% for a single blood count
(Fleisher et al, 1983; McNeely, 1991). Thus some cases may have been excluded from
earlier descriptions, particularly those with mild or atypical symptoms, although the numbers
potentially excluded are probably not as high as 60% because the patients were hospitalised
and serial blood counts were performed. In recent years three clinical studies discussing the
clinical features of IM have been published, one conducted by The Israeli Defence Force
Medical Corps, another based in a large health maintenance organisation in Seattle, US,
which included 2 hospitals and 23 outpatient clinics, and most recently a small study of 25
cases also from the US (Balfour et al, 2005; Grotto et al, 2003; Rea et al, 2001). Of note,
two thirds of the cases in the Seattle based study were students perhaps emphasising the
importance of this group in the disease epidemiology overall.
The recognition that EBV is associated with a number of malignancies particularly
nasopharyngeal carcinoma, Burkitf s lymphoma, post transplant lymphoproliferative disease
and Hodgkin's Disease, and that in addition IM is a recognised risk factor for the latter
condition (Hjalgrim et al, 2003; Robertson, 2005) has reawakened interest in immunisation
to prevent IM and malignancy (Balfour, 2007; Moss et al, 1998; Sokal et al, 2007;
Thompson & Kurzrock, 2004). The present study was undertaken to investigate the current
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epidemiology ofEBV, the risk factors for symptomatic seroconversion and the clinical and
social impact of symptomatic infection.
Baseline Serological Characteristics
A total of 2006 first year university students were recruited at the start of the academic years
1999 and 2000. These students underwent serological testing for EBV and answered an
epidemiological questionnaire. After 3 years of study all students were invited to attend for
follow-up serological testing and to complete a further questionnaire. At initial recruitment
75% of the cohort, which had a median age of 18.8 years, were EBV seropositive. Male
students were more likely to be seronegative (31%) than female students (21%). A cross-
sectional survey ofEBV serostatus in England and Wales reported a similar findings, with
males in the 10-14 and 15-19 age groups having a lower seroprevalence than females,
however, this differential was not found in the 20-24 group (Morris et al, 2002). The reason
for the delayed acquisition in males is not known but would appear not to be explained by
earlier sexual activity in females. The National Survey ofSexual Attitudes and Lifestyles
found an earlier age of "any type of experience of a sexual kind - for example, kissing,
cuddling, petting" in males (median 13 years in males and 14 years in females in the cohort
aged 16-24) and a higher proportion of males experiencing first sexual intercourse before 16
years (28% for males and 19% for females in the cohort aged 16-24), however, the median
age of first sexual intercourse was 17 years for both genders in the same cohort (Wellings et
al, 1994). Several potential explanations exist for this later acquisition of antibody in males;
females are known to select male partners older than themselves (Johnson et al, 1990;
Wadsworth et al, 1993), who as a consequence of being older are more likely to be
seropositive; alternatively the difference may reflect other social or behavioural differences
in male and female adolescents; or, if vaginal sexual intercourse is a significant route of
transmission then it is also possible that women may be more likely to acquire EBV sexually
than men (as has been observed in Western studies ofHIV seroconversion in couples with
discordant HIV status (Mastro & Kitayaporn, 1998; Nicolosi et al, 1994), and also in
seroprevalence surveys ofHSV-2 (Gibson et al, 1990; Morris et al, 2002; Pebody et al,
2004; Slomka et al, 2002; Vyse et al, 2000)).
The baseline lifestyle questionnaire in the current LCS did show that having acquired EBV
at the time of university entrance was strongly associated with prior sexual intercourse,
however, there was no difference in the proportion of male and female students that had been
sexually active prior to university. The likelihood of having acquired EBV increased with
increasing numbers of previous sexual relationships; from 63% EBV seroprevalence for
students who had never been sexually active to 91% seroprevalence in students reporting 5
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or more previous sexual partners. Those students reporting prior IM were more likely to
have had sexual intercourse prior to university, than students who were seropositive without
experiencing IM, or students who were seronegative.
EBV DNA has been detected in breast milk (Junker et al, 1991), however, the transplacental
transmission of maternal antibodies to EBV would appear to protect infants against early
infection as evidenced by the abrupt onset of seroconversion after 8 months of age (Chan et
al, 2001), perhaps explaining the absence of an association between EBV and breast feeding.
In the current seroepidemiological study there was no association with breast feeding,
however, the proportion of students reporting that they were breast fed seems improbably
high at 92%. A survey conducted in 2005 found that only 7% ofUK infants were
exclusively breast fed until 4 months of age, whilst comparable rates in Norway are 64%
(Hoddinott et al, 2008).
Those who had resided in a tropical country were significantly more likely to have acquired
EBV (81%) compared with those who had not (73%). The association was stronger for
students born in a tropical country, 84% ofwhom were EBV seropositive. These finding are
in keeping with epidemiological studies conducted in Africa (Biggar et al, 1981; Kafuko et
al, 1972), China (Wang & Evans, 1986), and India (Venkitaraman et al, 1985), showing a
high sero-prevalence of EBV in early childhood. No significant association was found
between ethnicity and EBV seroprevalence in our study although it should be noted that the
cohort was 94% Caucasian, resulting in small numbers for the comparison.
As in a prior epidemiological investigation (Lai et al, 1975) those with siblings were
significantly more likely to be seropositive (75%) than those without (66%), although not all
workers have found this association (Dan & Chang, 1990).
No association was found between EBV seropositivity and sharing a bed room or household
crowding (as measured by the average number of rooms per person in the household prior to
university). Previous seroepidemiological surveys have yielded mixed results. Crowcrofit et
al (1998) found that sharing a bed room was associated with EBV seropositivity after
multivariate analysis, but that the effect was most marked in families of lower socio¬
economic status. Household size was not significantly associated with EBV seropositivity
after multivariate analysis. Another study found no consistent relationship between EBV
seropositivity, household size and other measures of crowding (Sumaya et al, 1975). Two
further prospective studies of IM found no association with household crowding (Dan &
Chang, 1990; Hallee et al, 1974).
EBV Seroconversion at University
Eight hundred and forty two students returned for follow-up at the end of the study including
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241 (47%) of the initially seronegative students. Of the seronegative students that returned
110 (46%) had seroconverted, and 27 (25%) of these had contracted IM. This is at the lower
end of earlier higher education institution based studies in the UK and US where the
proportion of symptomatic EBV seroconversion ranged between 28 and 74% (Anon., 1971;
Hallet et al, 1974; Niederman et al, 1970; Sawyer et al, 1971) (see Table 2). In a study
based in the University of Hong Kong all EBV seroconversions were asymptomatic, and
studies in American military personnel found either no cases of IM or a low rate based on
hospitalisation of cases (Dan & Chang, 1990; Lehane, 1970; Niederman et al, 1970). In our
cohort there was an annual EBV seroconversion rate of 15% and an annual IM rate of 4%
amongst the seronegative students. These rates are in the range of those noted in previous
studies (see Table 2) where annual seroconversion rates in institutions ranged between 7%
and 27%, and annual IM rates ranged between zero in Hong Kong and 13% in students at
Yale University (Anon., 1971; Dan & Chang, 1990; Hallee et al, 1974; Lehane, 1970;
Niederman et al, 1970; Sawyer et al, 1971). As in the baseline observations of the LCS
EBV seroconversion at university was significantly associated with an increased number of
sexual partners.
In the case control study, cases, before they became unwell, reported a significantly greater
number of hours undertaking vigorous exercise every week than control students. Whilst
this may reflect recall bias by the IM cases there was no difference between cases and
controls in the reported hours spent on social activities or studying. Thus perhaps exercise
may predispose to symptomatic, rather than silent, EBV seroconversion. A parallel can be
drawn with polio where exercise often appeared to precipitate a severe or fatal paralysis, or,
paralysis in which the muscles exercised were more severely affected (Russell, 1949). Polio
that occurred following muscle injury, exercise, or intramuscular injections, was known as
"provocation poliomyelitis", and more recently this form of the disease was studied in a
transgenic mouse model. It is thought that CD155, a cellular receptor of unknown function,
to which Polio virus binds, is upregulated in nerve endings following minor trauma
(Gromeier & Wimmer, 1999).
Presenting Symptoms in IM
The commonest symptoms which caused the students to attend their GP were sore throat,
fatigue and symptoms related to "swollen glands". On direct questioning only two of 60
students did not experience a sore throat, although they were aware of swelling of their
cervical lymph nodes. Hoagland in his review of 200 IM cases found lymph node
enlargement and fatigue in all IM cases but reported that 12% of patients had a "typhoidal"
presentation without pharyngitis or jaundice (Hoagland, 1960). Hoagland also considered
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that certain symptoms including cough, sputum, joint pains, painful or extremely tender
lymph nodes, and severe abdominal pain mitigated "against the diagnosis of uncomplicated
mononucleosis". It should be noted that specific EBV serology was not available to
Hoagland and that the cases described may have been restricted as discussed previously.
More recent studies using specific anti-VCA IgM as the diagnostic criterion have reported
cough in 22% of cases, painful lymphadenopathy in 57%, "nausea/vomiting" in 41%,
headache in 50-83%, and "myalgia / arthralgia" in 32% (Grotto et al, 2003; Rea et al, 2001).
The current study found few students complained of fever (13%), and that some had
presentations which included atypical symptoms including gastrointestinal symptoms 8%
(predominantly vomiting), headache 10%, fainting 10% or cough 7%. Acute symptoms
lasted a median of 7 days in both genders, and were followed by a fatigue state lasting a
median of 70 days, which lasted more than twice as long and was subjectively more severe
in female students (see below).
Examination Findings
The majority of cases (88%) had palpable cervical lymphadenopathy, significantly more than
that detected in control students (23%). Hoagland (1960) found lymph node enlargement in
all his cases, however, as noted earlier his cases were based on different diagnostic criteria
and the patient population comprised young male soldiers. More recent reports noted
cervical lymphadenopathy in 77-89% of cases (Grotto et al, 2003; Rea et al, 2001). In the
present study splenomegaly or hepatosplenomegaly was only found in cases and not in
controls. Of IM cases reviewed within two weeks of diagnosis 35% had splenomegaly or
hepatosplenomegaly, which is in line with the findings of Finkel et al (1964) who found
splenomegaly in 38% of 235 patients. In the current study the proportion of cases (12%) and
controls (14%) that had isolated hepatomegaly was similar. The presence of a palpable liver
or spleen in cases was significantly associated with elevation ofALT, whilst a palpable liver
in controls was not associated with derangement of liver function tests.
Concurrent prescription of ampicillin or amoxicillin is well known to cause rash in IM
(Johannsen et al, 2005), however, of the eight students (13%) that experienced a skin rash as
part of the illness only two were taking antibiotics, demonstrating that rash is regularly a
feature of the illness itself. This study found rash in a greater proportion of cases than the
3% noted by Hoagland (McCarthy & Hoagland, 1964), although other workers have also
recorded rash in 15-17% of IM cases (Balfour et al, 2005; Grotto et al, 2003; Pullen et al,
1967; Rea et al, 2001). Five percent of students suffered very severe acute symptoms
requiring hospital admission or attendance.
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Laboratory Parameters
The diagnosis of acute IM was confirmed with anti-VCA IgM and or a positive heterophile
antibody plus demonstrated anti-VCA IgG seroconversion. The rapid slide test for
heterophile antibody used (Microgen i.m. absorption kit) had excellent sensitivity in this
population with only one test (2%) negative at the time of diagnosis, and this had become
positive on repeat testing three weeks later. Anti-VCA IgM was negative at the time of the
initial sample on four occasions (8%) and became positive on later repeat testing in two, and
remained negative in two. The specificity, and, positive and negative predictive values of
the heterophile antibody test and anti-VCA IgM were not assessed in this study. False
positive and negative heterophile results are well recognised; positive results may occur in
other infections, including HIV (of concern because HIV seroconversion illness may appear
clinically similar to IM), inflammatory conditions and also as an incidental finding (Hendry
& Longmore, 1982; Horwitz et al, 1979; Reed, 1974; Ridker et al, 1990; Seitanidis, 1969;
Vidrih et al, 2001; Wynne Jones et al, 1994). False negative results are particularly
associated with young children (Sumaya & Ench, 1985). Whilst the sensitivity of different
kits varies it is generally accepted that the use of horse RBC is the most sensitive means of
detecting heterophile antibody (Beer, 1936; Evans et al, 1975; Lee et al, 1968b; Linderholm
et al, 1994). In the current study the rapid slide test for heterophile antibody remained
positive for longer than anti-VCA IgM, with 22% of IM cases positive after 5 months, as
opposed to 13% for anti-VCA IgM. This is in keeping with earlier work using a plate
method to detect horse RBC heterophile agglutinins which showed 73% were still positive at
one year whilst only 25% of the anti-VCA IgM remained positive (Evans et al, 1975). Also
in line with our findings a more recent study found that only 13% of IM cases had detectable
anti-VCA IgM at six months (Rea et al, 2001). Anti-VCA IgG was present in all but one
student (98%) at diagnosis and this student had developed anti-VCA IgG on repeat testing 8
days after initial presentation.
Acute IM is typically associated with a marked lymphocytosis and the presence of atypical
lymphocytes on the blood film. In the current study 75% of cases had a lymphocytosis
(defined as > 4x109 F1) at the time of diagnosis, whilst 23% had lymphocyte counts within in
the normal range, and one case had a count below the normal range. None of the healthy
control students had a lymphocytosis, in fact almost half of them were classified as
lymphopenic (<1.5 xlO91"1) according to the laboratory's "normal range". In IM cases the
lymphocyte count remained significantly greater than that of the control students for up to
thirty days following diagnosis.
Twenty six percent of cases and 7% of controls had neutrophil counts less than 2x109 f1,
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which is the lower limit of the normal range. Only IM cases had neutropenia of less than
lxl 091"1 which occurred in four students (9%). When compared with controls, cases had
significant reductions in their median neutrophil count for up to 2 months after diagnosis.
Reduced neutrophil counts were previously reported by Carter who found 4% of 172 acute
IM cases had counts of less than lxlO91"1 (Carter, 1966a). Increased cytokine-induced
apoptosis, direct cell invasion and anti-neutrophil antibodies have been suggested as causes
for the reduced neutrophil count in acute IM (McAulay et al, 2007; Savard & Gosselin,
2006; Schooley et al, 1984).
Thrombocytopenia is also a recognised complication of acute IM and although platelet
counts below the normal range were noted in 21% at diagnosis, none were less than 100xl09
1"' and all were asymptomatic. All but one of 43 retested within a month had a platelet count
above the lower limit of the normal range. Asymptomatic thrombocytopenia has previously
been reported in 24-50% of cases (Cantow & Kostinas, 1966; Carter, 1965) but this has not
been a universal finding (Lofsness et al, 1987). Profound thrombocytopenia with
haemorrhagic manifestations is occasionally seen (Clarke & Davies, 1964; Goldstein &
Porter, 1969; Radel & Schorr, 1963).
In the current study male cases had significantly lower haemoglobin values, than male
controls, at diagnosis and for up to a month later. In females median Hb levels were lower
than in controls at all time points, although this only achieved borderline significance in
students seen between 15 and 30 days after diagnosis. Haemolytic anaemia is a recognised
complication of acute IM, thought to occur in 0.5-3% of cases, usually in the first three
weeks after diagnosis (Johannsen et al, 2005). None of the cases in the current study who
had a FBC taken at the time of diagnosis appeared to have significant haemolysis with only
one male case having a Hb value below 130 g l"1, the lower limit of the normal range for
males supplied by the Haematology Laboratory, however, this excludes a student admitted to
hospital with jaundice whose Hb at diagnosis is unknown.
Abnormality of one or more of the liver function tests was common, affecting 73% of
students reviewed within one month of diagnosis. This in keeping with the 83% prevalence
noted by Finkel et al (1964) and 58% noted by Grotto et al (2003). None of the controls had
elevation ofALT or ALKP. Elevation ofGGT occurred in both cases and controls but was
significantly more common in cases, with only one control having more than a trivial
elevation ofGGT. Amongst cases reviewed within two weeks of diagnosis 41% had ALT
levels more than twice the upper limit of normal and in 19% the elevation was more than 5
times the upper limit of normal. There was no significant difference in the proportion of
cases (22%) or controls (17%) that had an elevated bilirubin. A similar figure of 21% was
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described by Finkel et al (1964) in their IM cases although this study did not have a healthy
control group.
An increased viral load at diagnosis was not generally associated with features that would
suggest more severe clinical disease. Exceptions to this were 4 students with vomiting as
part of their IM presentation, and a trend towards significant associations with both an
exercise tolerance of less than 100m, and being unable to leave the house at the time of the
most severe symptoms. The failure to find an association between viral load and severe
clinical illness is in keeping with the findings of Silins et al (2001) who found that the EBV
viral load in IM and cases undergoing asymptomatic seroconversion was similar. In
contrast, Balfour et al (2005) did find an association between whole blood viral load and
more severe illness, although this was based on an unvalidated scoring system, that ascribed
a numerical score (0-3) for the extent of limitation of physical activity and for the intensity
of pain / symptoms.
The raised lymphocyte count in IM was composed of elevations ofCD8 T-cells, NK cells
and yS T-cells without any significant change in the numbers ofCD4+-T-cells or B-cells.
The total lymphocyte count remained significantly above that of the control students for up
to 15 days, whereas the elevation of yS T-cells persisted at all time periods during
convalescence. NK cell numbers were elevated at all time points up to 5 months, which was
significant for samples taken at diagnosis, in the first month, and between two and four
months after diagnosis. Two previous reports have documented raised y5 T-cells at the time
of diagnosis in IM; one of these also repeated the observations after 4 weeks finding that y8
T-cells remained significantly elevated when compared with the control group (De Paoli et
al, 1990; Hassan et al, 1991). The current results show a long lasting elevation of this
lymphocyte subset together with prolonged NK cells numbers up to 4 months.
Whilst the exact role of yS T-cells in IM is unknown it is interesting to speculate on their
possible functions as these lymphocytes link the innate and adaptive arms of the immune
response. When acting as part of the innate immune system yS T-cells may lyse target cells
and release cytokines and chemokines in response to recognition of non-peptide antigens, but
in addition they can function as conventional aP T-cells recognising peptide antigens, and
more recently a role in antigen presentation, at least in vitro, has been reported (Brandes et
al, 2005; Kaufmann, 1996; Welsh et al, 1997). A role for y8 T-cells has also been proposed
in the resolution of inflammatory states and in anti-cancer surveillance has been proposed
(Chen & Letvin, 2003; Dechanet et al, 1999; Ferrarini et al, 2002; Gao et al, 2003). A
murine study of HSV infection detected y5 T-cells specific for the viral gp gl, a glycoprotein
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which, with gE, forms a viral Fc receptor that binds IgG, facilitating viral cell-cell spread
(Johnson et al, 1992; Roizman et al, 2007). Thus the y8 T-cells in this model targeted a viral
immune evasion mechanism.
It is clear from the current observations of y§ and NK cells, and the work of others, that IM
has prolonged, possibly permanent, effects on the immune system. Acute EBV infection
when manifest as IM, results in massive alterations in lymphocyte specificities with up to
44% of all CD8" T-cells being specific for a single EBV epitope, and huge increases in
lymphocyte numbers, particularly the CD8" population (Callan et al, 1998; Macallan et al,
2003). Although the total numbers of CD8+ cells subside quickly over 2 to 3 weeks there
remain long lasting perturbations of the CD8* T-cell population with an increased proportion
of cells expressing intracellular IFN-y at six months (Attarbaschi et al, 2003). Tan et al
studied donors both with and without a history of IM and found up to 5% ofCD8T cells were
specific for a single EBV epitope many years after primary infection (Tan et al, 1999).
Sauce et al have observed long lasting defects in EBV-specific CD8+ T-cell responses to IL-
7, lasting 2 or more years after IM, and seemingly permanent reductions in IL-15 a receptor
expression on CD4" and CD8+ T-cells and CD56+NK cells following IM (Sauce et al, 2006).
These, or other yet to be described, immunological abnormalities may contribute to the
pathogenesis of Hodgkin's lymphoma, known to occur at an increased frequency for at least
10 years following IM (Hjalgrim et al, 2003), further strengthening the case to prevent
symptomatic primary EBV infection in populations at risk.
Impact on Academic and Social Activities
One of the objectives of the current study was to document the effects of IM on the daily
activities of the students, particularly their studies but also on their domestic and social lives.
The illness, particularly when its onset was in term time, had a profound effect on studies
with a median loss of 10 hours of timetabled university classes per student, and significantly
reduced personal study time resulting in an estimated overall loss of study time of
approximately 48 hours per student. Female students missed significantly more university
classes (median of 17 hours) than males (median 2 hours) and were more likely to
discontinue their studies completely (n=5 versus none). The reason for the greater impact on
female students is not known. Some viral illnesses, notably rubella and parvovirus infection,
are known to exert more severe morbidity in women (Brown, 2005; Gershon, 2005). It is
also known that women have a greater lifetime risk of psychiatric illness than men (Afifi,
2007), and is possible that females are more vulnerable to negative cognitions after IM (e.g.
feelings of low mastery, and more rumination or worry).
The severity of the initial disability predicted the quantity of university classes missed, such
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that students who could not wash and dress at the worst point of their illness, or that were
unable to leave their house, or reported reduced walking distance all missed significantly
more classes than cases who did nor report these symptoms. The initial numerical score that
cases attributed to their fatigue correlated significantly in both genders with the subsequent
number of university classes missed. The majority of IM cases (78%) reported an impaired
ability to concentrate recording a median concentration span of 10 minutes at the time of
their most severe symptoms whilst controls reported a concentration span of 40 minutes.
The perception of impaired concentration was not affected by gender but was significantly
associated with the onset of symptoms in term time. There was evidence that students
prioritised their academic work over exercise and other social activities after diagnosis. The
total study hours (personal and timetabled) were significantly reduced in cases when
compared with controls for a period of only 15 days after diagnosis (although the median
was somewhat reduced until four months), whereas, significant reductions in hours of
exercise persisted for up to 2 months, and hours spent on social activities other than exercise
were significantly reduced when compared with controls 5 or more months after diagnosis.
Hypersomnia is a recognised feature of IM and cases reported increased hours of sleep
compared with controls; a pattern that persisted at 5 months after diagnosis. Non-exercise
related social activities were severely curtailed by IM and were significantly reduced
compared with controls at 5 or more months after diagnosis, at this stage cases spent 4 hours
per week less than controls on social activities, which is in keeping with their reported
requirement for additional sleep.
IM cases reported significantly fewer hours of exercise than controls for up to 2 months after
diagnosis. Whereas cases and controls reported spending similar amounts of time attending
university, studying and socialising, the reported hours of vigorous exercise per week prior
to the onset of IM was significantly greater in cases than that reported by the control
students. It is not clear why exercise alone should be subject to a particular recall bias, and
therefore the possibility exists that higher levels of exercise may itself be a risk factor for IM.
Interestingly, a significant positive correlation between fatigue duration and levels of pre¬
morbid exercise hours was found in male cases. At visits later than 5 months after diagnosis
however the amount of exercise undertaken by cases and controls did not differ significantly.
The possible explanations for this might be that the cases overstated their pre-morbid
exercise hours, or that even though they said that they had recovered they had not taken up
their previous exercise regimes or that the numbers of subjects analysed are inadequate to
show a significant difference. That cases, even ones that said they no longer felt fatigued,
had not regained their previous exercise pattern by 5 or more months after their illness would
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support the idea that subtle effects of IM persist for long periods after the acute illness.
Fatigue
Fatigue was undoubtedly the most long lasting of IM-related symptoms. In other studies of
fatigue following IM there was a marked gender difference with females experiencing more
protracted symptoms (Buchwald et al, 2000; Candy et al, 2003; Petersen et al, 2006; White
et al, 2001). Buchwald et al (2000) found that a greater number of life events in the
preceding six months, and greater family support, also predicted ongoing fatigue at six
months after diagnosis. Petersen et al (2006) found fatigue after IM was associated with
premorbid mood disorders. Interestingly in a primary care study of post-infectious fatigue,
where only 1% of participants had glandular fever and most had prior sore throat or other
upper respiratory tract infections, there was no excess of females in the fatigued group, and
instead a link with previous fatigue and previous psychological disorder was found (Wessely
et al, 1995). In the present study 23% of participants were still fatigued at six months a
proportion somewhat closer to the 12% reported by Buchwald et al (2000) than the 40%
found by White et al (1998). Overall the median duration of fatigue in Edinburgh students
was 70 days, with a median duration of 125 days in females, and 54 days in males. Fatigue
duration was significantly correlated with the number of timetabled classes missed by both
genders overall, and in females. In line with the work of White et al (2001) and Buchwald et
al (2000) students that recalled a stressful event prior to the onset of IM were also at greater
risk of ongoing fatigue at 6 months after diagnosis.
Fatigue, along with the other symptoms of IM, is generally assumed to be caused by
cytokines released by the large numbers of circulating, activated, CD8+ T-cells typically
found in the acute disease (Attarbaschi et al, 2003; Callan et al, 1998; Foss et al, 1994;
White et al, 2001). In this study no association was found between total numbers of
peripheral blood lymphocytes, CD4+, CD8+ or NK lymphocyte subsets and fatigue severity
or duration. In males, but not in females, there was some evidence that a higher monocyte
(p=0.033) and total lymphocyte (p=0.064) count at diagnosis was associated with a greater
number of hours missed from university classes.
Some markers of functional impairment in acute IM were also significantly related to fatigue
duration, especially in females, including inability to leave home and inability to walk 100m
at the worst point of their illness. White et al (2001) also found that "days in bed at onset"
predicted an increased risk of fatigue at 2 months after diagnosis. In the Edinburgh students
the initial numerical score that cases attributed to their fatigue showed a significant
correlation with the duration of subsequent fatigue, and scores were higher in female rather
than male cases. The association between score and subsequent fatigue duration was not
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significant when the genders were analysed separately, suggesting that the fatigue score was
a stronger predictor of missed university classes than fatigue duration.
Candy et al reported that patients with IM often recall being advised to rest by their general
practitioner, however, beyond the most acute symptoms this may unhelpful (Candy et al,
2005). A very early study of predominantly male (91%) students with IM demonstrated that
the group allocated to bed rest suffered from significantly more "prolonged fatigue and
debility" than the group allowed to mobilise freely (Dalrymple, 1964). A more recent pilot
study significantly reduced the incidence of fatigue 6 months after IM by providing a brief
individualised face to face session involving a plan for graded activity and lifestyle advice
(Candy et al, 2004).
Strain Typing
In the LCS, using PBMC collected at recruitment, type 1 EBV was detected in 483 (77%),
type 2 was present in 108 (17%) and both types were detected in 34 (5%). In the case
control study forty two isolates were type 1 strains (88%), 3 were type 2 (6%) and a further 3
(6%) contained both type 1 and type 2 sequences. It can be seen that there is a higher
proportion type 1 strains amongst the IM cases than in the cohort as a whole, however, this
did not attain statistical significance1. It might be expected that IM would be caused by type
1 strains more often than type 2 in view of the differing in vitro behaviour of the two types,
whereby EBV-1 shows greater ability to stimulate B cell activation and immortalisation
(Rickinson et al, 1987). Gratama and Ernberg (1995) previously observed that 7/7 EBV
isolates from IM cases were type A (the old designation for EBV type 1). A larger study
which included the cases documented in the present work, together with additional IM cases,
has demonstrated a significant excess of type 1 in the aetiology of IM, compared with the
background distribution ofEBV types in the same population (Crawford et al, 2006).
The current study has demonstrated that cases and their friends or household contacts were
much more likely to have differing EBV isolates than cases and their partners who had
indistinguishable isolates in 9/11 (82%) pairs. As the number of repeats at each locus
studied is finite, it is possible that isolates could be categorised as indistinguishable but in
fact be different had additional typing been performed. The observation of strain sharing by
sexual partners is further complicated by recent work suggesting that primary infection may
involve the transmission ofmultiple strains (Sitki-Green et al, 2003; Sitki-Green et al, 2004).
In two instances in the current study, (an IM case and his girlfriend, and another case and
their flatmate) there was a match at one locus and a mismatch at the other. These were
3 Fisher exact test of the heterogeneity of proportions (personal communication C. Higgins)
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classified as mismatches for the purposes of the study but could represent the detection of
mixed populations.
Gender Bias
Females were more likely to participate in all parts of this investigation into EBV infection
in Edinburgh University Students. Of the 2006 students recruited to the LCS 63% were
female, which is greater than the proportion of females (53%4) undertaking four year courses
in the years 1999 and 2000, and is closer to the proportion of females that registered with the
UHC (59%5) where the recruitment took place. The higher proportion of females recruited
to the LCS would seem to reflect both the higher health care seeking behaviour ofwomen
(Rickards et al, 2004) and the greater participation ofwomen in studies of this type (Candy
et al, 2003; Stewart-Brown et al, 2000; White et al, 2001). Amongst the 241 seronegative
students that returned for follow-up after three years 62% were female, which represents an
excess as only 54% of the seronegative students were female at recruitment.
The gender bias was less pronounced in recruitment to the case control study where 53% of
participants were female. The higher proportion ofmales in the case control study (47%)
probably reflects the higher seronegative rate in male students entering university, and is
close to the percentage of serology tests consistent with acute IM at the UHC that occurred
in males (49%)6. The recruitment to this part of the study was poorer as it was not
immediate and relied on the GPs in the UHC to give IM cases an information leaflet, seek
permission for the student to be approached, obtain a telephone number and then fax this
information. None-the-less despite this circuitous process the rate of recruitment was in line
with the 45-49% achieved in other studies of student health in primary care (Rea et al, 2001;
Stewart-Brown et al, 2000).
Female cases completed a greater number of follow-up visits than males (mean 2.9 and 2.1
respectively) and were more likely to attend for a final follow-up visit (63% vs. 54%,
p=0.710). As noted above females are more likely to participate in research studies than
males, however, having been recruited their greater likelihood to attend more follow-up
visits may reflect their longer duration of symptoms. Reasons for non-attendance at a final
4 Personal communication, Andrew Quickfall, Governance and Strategic Planning, University of
Edinburgh (see Appendix 12.3)
5 Personal communication, Nadine Harrison, University Health Centre
6
Analysis of the diagnostic serology undertaken for the University Health Centre in the years 2000-
2003 showed that of positive tests, consistent with an IM diagnosis, 49% were in males, and 51% in
females.
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review visit after 5 months included being unable to contact the student by email or
telephone, the student having left the university through illness or completion of their degree,
and the student declining further follow-up.
10 Conclusions
Whilst EBV may be mainly transmitted in saliva rather than in genital secretions the current
investigation has demonstrated that sexually active students are much more likely to have
acquired EBV, and that students presenting with IM are likely to be sexually active. This
has implications for their healthcare as a whole as they may have additional requirements
including contraception and sexual health screening, for infections known to have a high
prevalence in young adults, including Chlamydia trachomatis. The study has demonstrated
long lasting fatigue and functional impairment (academic, social and physical exercise)
following IM indicating that primary preventative strategies, particularly immunisation when
it becomes available, and tertiary preventative strategies to prevent disability, such as the
graded activity and lifestyle management approach piloted by Candy et al (2004), may
reduce morbidity in this population. Females and those recalling a stressful event prior to
the onset of IM are at particular risk of adverse outcome following IM.
11 FurtherWork
The current study demonstrated an association between the numerical score ascribed by
students to the severity of their initial fatigue and subsequent adverse outcomes including
fatigue duration and the number of university classes missed. The prognostic accuracy of
this simple tool deserves further exploration as a means to predict poor outcomes in IM.
Incorporating behavioural measures to encourage activity and prevent physical
deconditioning, thought to worsen fatigue, as piloted by Candy et al (2004), should be
further explored to reduce IM associated morbidity.
IM appears to be associated with failure of course completion in some students. Exit
interviews of all students leaving university without completing their degree could be offered
to investigate the extent of this effect. It is possible that IM may adversely effect the class of
degree that students achieve. This could be investigated by prospectively assessing
academic performance before and after IM.
The role of the y8 T-cells in IM is not known. The current study has demonstrated that they
persist in raised numbers long into the convalescent period. Recent work has demonstrated
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that these cells, in addition to linking the innate and adaptive immune responses, can also act
as antigen presenting cells. The role and specificity of these interesting cells could be further
studied.
Type 1 EBV shows greater ability to stimulate B-cell activation and immortalisation and has
now been shown to be over-represented in the aetiology of IM as compared with type 2 EBV
(Crawford et al, 2006; Rickinson et al, 1987). It is not known if there are differences in the
viral load, clinical manifestations or immune parameters in IM caused by the different types,
although preliminary investigation of the lymphocyte count at the time of diagnosis in this
study suggests that IM caused by type 1 is associated with a higher lymphocyte count than
IM caused by type 2 strains (Appendix 12.2).
There is some evidence to suggest that the epidemiology of herpes viruses, particularly HSV
and EBV, is changing, with acquisition being delayed into teenage years (Morris et al, 2002;
Morris & Edmunds, 2002; Scoular et al, 2002; Takeuchi et al, 2006; Vyse et al, 2000). This
is likely to result in an increased proportion of symptomatic illness and increased rate of
complications and hospitalisations (Auwaerter, 1999; Halevy & Ash, 1988; Horwitz et al,
1983; Morris & Edmunds, 2002; Tattevin et al, 2006). This study has demonstrated the
importance of IM as a cause of morbidity in students and disruption to university studies,
however, the impact of IM on adolescent school children and their studies has not been
addressed. The current study has also shown a high annual rate of EBV seroconversion.
The rate of annual seroconversion in adolescent schoolchildren would need to be determined
in order to offer immunisation at the optimal age.
Study of sexual behaviour has indicated a progressive fall in the age at first sexual
intercourse in the UK during the 1970s and 1980s (Wadsworth et al, 1993; Wellings et al,
1994; Wellings et al, 2001) with 30% ofmale 16-19 year olds and 25% of females reporting
first sexual intercourse before the age of 16. The current study has demonstrated a strong
linkage with sexual behaviour, it therefore follows that the epidemiology of IM may be
affected by changing patterns of sexual behaviour and increasingly become an illness of
adolescent schoolchildren as well as college students. It could be anticipated that
industrialisation and development in other parts of the world where IM was previously rare,
for example Brazil, Thailand and Malaysia, would result in an increase in the population rate
of IM due to delays in the age of primary infection, but as yet no published reports have
appeared. Future seroepidemiological studies and the schedule of any EBV immunisation










Date of questionnaire completion
Day Month Year
Introduction
We are conducting a research study in Edinburgh University students on the ways in which personal
and family background and life-styles relate to getting glandular fever. The information sheet you
have been given describes the study, why we believe it is important and what you would need to do.
We hope that you will be willing to take part. If you have any questions please speak to one of the
attendant staff, or Dr Sheena Sutherland, Department of Medical Microbiology, University of
Edinburgh, Medical School, who is not directly involved in the study.








TfflS QUESTIONNAIRE IS ANONYMOUS SO NONE OF THE ANSWERS YOU GIVE CAN
BE PASSED TO THE UNIVERSITY OR ANYONE ELSE.
YOU ARE UNDER NO OBLIGATION TO TAKE PART IN THIS STUDY OR TO FILL IN
THIS QUESTIONNAIRE NOW - IF YOU WISH WE CAN MAKE ARRANGEMENTS FOR
YOU TO COME BACK ANOTHER TIME.
2
II) Number:
1. PersonalHistory and Family Background
This information will be used to examine the association between spread of infection and living
circumstances, family size, position in the family etc.
1.1 Where were you born?:
Town:
Country:
1.2 When were you born?: □□ □□ □□
day month year















1.5 Are you: male Q]]i femaleD
3
1.6 Are you a: twin| |i triplet | |2 or singleton-born | |3 ?
If twin, is your co-twin male
If triplet, what are the sexes of your co-triplets ?
If you are a twin or triplet, we would like to contact your siblings for this study, to ask them
the same questions we have asked you. It would of course be entirely their choice whether
they wished to participate. If you are agreeable to us contacting them, please could you enter
their name and address:
1 11 or female 1 h
1.7 Do you have any brothers or sisters (including half or step brothers or sisters)?
Yes | [l No 1 I2 If yes:








6. Brother Sister I
(please continue at end ofquestionnaire ifrequired)
1.8 What were your parents' occupation(s) when you were a child (ifmany, state the longest)?
Father's occupation:
Mother's occupation:
1.9 Are you: tick:
Married? 1
Widowed? 2
Divorced or Separated? 3
Cohabiting (living with partner)? 4




1.10 Do you have any children? Yes | |i No [3 If yes:
Sex: Date of Birth:
Male | |i Female 2 □n □□ □□
Day Month Year
Male | |i Female 2 II 1 □□ rin
Day Month Year
Male | |i Female 2 □□ □□
Day Month Year
Male | |i Female 12 □□ □□
Day Month Year
2. Questions About Crowdins and Living Circumstances
This information will be used to determine whether close contact is a riskfactorfor early infection.
2.1 As a child, did you share a bedroom?:
Never, pf almost never
Occasionally, but not continuously
(eg when there were visitors)
Continuously, from ages:
If continuously, with whom did you
share?
If shared continuously on more than one
occasion, please give details
D
D
□□ .0 □□ years
Relationship: Brother [ |i SisterD
Other 1 b please specify
Older than you? 1 |i or younger than you?D
Or same age (twin)? a
2.2 For each school you attended for a year or more, please give details:






Approx. no of children
in the school











(please continue at end ofquestionnaire ifrequired)
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2.3 Where have you lived? Please list each village/town you have lived in for a year or more,























(please continue at end ofquestionnaire ifrequired)
* Ifyouiived in an institution such as a hall of residence, please say so instead of stating the
numbers of rooms and people.
2.4 Have you ever lived in a developing or tropical country? Yes | |i No
If yes:
Where?
From age 1 | 1 to 1 || 1 years
3. MedicalBackeround
Past andpresent medical and growth history may be important in the susceptibility to infection.
3.1. What was your weight at birth?
Kilograms | 1 - 1 li 1 or f ?! !| jj | grammes or lbs| || 1 oz| || |
Ifbirthweight not known, were you at birth:
small 1 |i average 1 h large 1 b don't know 1 [4
Were you breast fed? yes [ |i no 1 b don't know [ |s
3.2 Height/Weight:
Current height






3.3 At primary school were you: tick:
Tall for your age?
Short for your age? . 2
About average? 3
3.4 If female, tick:
- age of first period 1 jl| years or never started
- age regular periods started L ~li ~l years or never became regular





































3.6 Have you had (at any age) any of the following illnesses? If so, at what age?
tick: tick:






Measles l 2 3 4
Mumps l 2 3 4
German measles l 2 3 4
Whooping cough I 2 3 4
Glandular fever (infectious mononucleosis) l 2 3 4
Chickenpox l 2 3 4
Hepatitis A i 2 3 4
Hepatitis B l 2 3 4
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3.7 Do you have, or have you had, any of the following allergies? If yes, was this diagnosis
confirmed by a doctor? Were you treated with any prescribed medications?
Tick: Doctor
diagnosed?:
Were you ever treated with:
(tick)







































































Sexual contacts might be relevant to whetherpeople get infections.
Yesa NoQ3.8 Have you ever been sexually active?
If no: proceed to question 3.10
If yes:
Age of first sexual intercourse
Number of sexual partners, ever
















3.9 Have you ever had a sexually transmitted disease?
If yes, at what age? (first occurrence if several)










3.10 Have you had any other serious or longstanding illnesses or operations: (including all
illnesses for which admitted to hospital)?
YeS | |i No 1 h If yes, please list:





(please continue at end ofquestionnaire ifrequired)
3.11 Have you ever had a blood transfusion?
□
Yes | 1' No 1 b
If yes, on how many different occasions?
When was the first time? 1 I'll 1 (year)
When was the most recent time? (year)
3.12 Are you using any medication (including oral contraceptives and inhalers) now?







(please continue at end ofquestionnaire ifnecessary)
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3.13 Mental illnesses?
Have you ever had a mental/psychological illness/problem: Yes
If yes, was it:






l No | I2
3.14 Have you experienced a major life event in the last year? Yes Noo
For example: month year
Has your parent, child, sibling or spouse YesD No | b If yes when?
died?
Have you broken off a marriage or Yes [3 No [3 If yes when?
steady relationship?
Have you had a major financial crisis? Yes r3 No i I2 If yes when?




4. Smoking, Drinkins and Exercise
Social habits like smoking, and drinking alcohol may effect your susceptibility to infection.
4.1 Smoking:
Do you, or have you ever, regularly smoked tobacco (ie smoked at
least 1 cigarette or cigar or pipe per day, on average, for at least 1
year)?
Yes No | I2
If ves. how old were vou when vou started to smoke regularly?
1 ji J years
During the period when you were a regular smoker, how much, on average, did you smoke?
cigarettes / day I || |
cigars/day I j j
hand rolling tobacco oz / week j j j
pipe tobacco oz / week I !| |
Have you now stopped smoking? Yes | |l No 1 b
If ves. how old were you when you stopped? years
4.2 Alcohol:
Do you or have you drunk alcohol regularly (once / week or more for at least a year)?:
Yes | |i No I I2
If yes, at what age did you start to drink regularly? 1 II 1 year"
tick:
Do you still drink regularly? Yes 1 |t No | |2
During the period when you were a regular drinker, how much, on average, did you drink?
Beer or cider (pints) | | per day or | || | Per week
Wine (glasses) [ J per day or 111 Per week
Spirits (tots) | 1 per day or 111 Per week
11
THANK YOU VERY MUCH FOR HELPING US WITH THIS SURVEY
We appreciate your help, and hope that you have felt able to answer the questions without too much
trouble. If there is anything you would like to add or comment upon, please write it below:-
I DIM}I KC>11 S I I DIM Q1 I S I IONMIRK
GLANDULAR FEVER STUDY
CONFIDENTIAL
ID Number: Male I Female□
Date ofBirth 1 II 1 1 II 1 nn
Day Month Year
Date of Filling in Questionnaire 1 II 1 m 1 II 1
Day Month Year
Introduction
You may recall that when you first arrived at Edinburgh University you filled in a questionnaire and gave a
blood sample as part of a study investigating the ways in which your lifestyle and background relate to your risk
of developing glandular fever. Later on you should have received the result of this blood test from us. Now that
you have been at University for 3 years, we would appreciate it if you would fill in a further questionnaire and
allow us to take some more blood. Once again your replies will be treated confidentially. The information will
not be disclosed to the University or others. Your participation is voluntary and whether you participate or not
will make no difference to your medical care. If you feel that any of the questions are intrusive, please feel ffee
to pass on to the next without answering.
If you wish to discuss any aspects of the study further, please contact Dr. Tanzina Haque, Basic & Clinical
Virology IDG, R(D)VS, Tower Block, Summerhall, Edinburgh EH9 1QH (tel. 0131 650 7941), who is not
directly involved in the study.







1. QUESTIONSABOUT YOUR STUDIES
1.2 What course arc you undertaking?
specify
2. PERSONAL AND FAMILYDETAILS
2.1 If you were regularly looked after outside your own home before attending primary
school, what were the arrangements for looking after you, and from approximately what
age did these apply?
Tick more than one box if appropriate.
Nursery school or reception class
Other day care centre
At childminder's home
Other outside home - please specify










2.2 Do you have any children? Yes [ |i No 2 If yes:
Sex: Date of Birth:
Male | |i Female | [2 • s □□ □□
Day Month Year
Male | |i Female | [2 □□ nn nn
Day Month Year
Male | |i Female | [2 □□ nn nn
Day Month Year
Male | |i Female | [2 □n nn nn
Day Month Year
2
3. QUESTIONS ABOUT YOUR LIVING CIRCUMSTANCES
3
3.1 Please list each residence you have lived in for 3 months or more since coming to
Edinburgh University (excluding your parents' home):
1st RESIDENCE:
(a) fromoo /□□ to oo / on
M YM Y
Villa«!c/to\vn/citv Countrv






















MM Y Y "
Village/town/city Country

















1 II 1 /I II 1 to II 1l/l II 1
MY MY
Village/town/city Country













































fromQUI /□□ to dO / □[
MY MY
Village/town/city Country






















(b) from 1 |/| 11 to
M Y M Y '
Village/town/city Country














3.7 If during the last 6 months you have lived in any residences for 1 month or more that you
have not listed above, please list them here (including parental home):
1st RESIDENCE:
(b) from 1 II 1l/l1 II 1 to II I\! \ II 1
MY MY
Village/town/city Country
Type of accommodation: please tick:




















(b) 1 II 1|/| II 1 10 II 1 /1 II 1
M Y M Y
Village/town/city Country







































(b) from l/l 1 1 to II /1 II 1
M Y M Y
Village/town/city Country
Type of accommodation: please tick:
Halls of residence □
House □
Flat [J
Other 1 1 please specify










4.1 Since coming to University have you been immunised against any of the following?:
Please tick:
Yes No Don't know






Typhoid i 2 |8
i etanus i 2 □«
Hepatitis A □ . 2 □«
Hepatitis B □ . 2 □»
Meningitis □ . 2 o
Yellow Fever C . 2 o
Japanese B Encephalitis C . 2 o
Rabies . 2 o
Diphtheria ■ 2 o
Other I . 2 □.
Other, please state
8
4.2 Since coming to University have you had:
Glandular fever Yes | | No| |
If yes:
Was the diagnosis confirmed by a blood test?
YesO No| |
Did you see die gianuuiur lever study doctor?
Yes 1 1 No| 1
Did you have any illness with sore throat and fatigue for 3 days or more for which you did not
seek medical advice?
Yes []] No| |








4.3 Since coming to University have you had any other physical illnesses that required a visit
to your doctor? (excluding visits for vaccinations, contraception)
YesQ No[ |
Tick: Tick: Tick:
If yes, was the visit for: Yes No Time off study
(days)



















4.4 Have you ever had your tonsils out? Yes













Drug/alcohol related problems □ i












Other, please state ...
4.6 Since coming to University have you experienced any of the following stressful events?
Tick:
Your parent, child, sibling or partner was seriously ill or
died?
You broke off a steady relationship or a marriage?
You had major financial worries?
You had a pregnancy or termination?















4.7 Since coming to University have you used any medication (including oral contraceptives
and inhalers, excluding creams, lotions, drops)? Please state drug type, e.g. antibiotics,
steroids.







(please continue at end ofquestionnaire ifnecessary)
4.8 (a) Whilst you have been at University have you had contact with anyone who has had
glandular fever?
YesD No | [2 If yes, how many?
For each contact please record the details below:
First contact
What was your relationship to the person?
(b) Do/did you live with this person whilst they had glandular fever or during the 3
months preceding their illness?
YesQ NoO
House Yes 1 ♦ No
Flat Yes 1 No
Hall of residence Yes 1 No







(c) How often do/did you see them whilst they had glandular fever? Was it:
Daily Yes | [i No [ [2
12
13
At least weekly Yes




What was your relationship to the person?
(c) Do/did you live with this person whilst they had glandular fever or during the 3
months preceding their illness?
Yesn NoQ



















(d) How often do/did you see them whilst they had glandular fever? Was it:
Daily Yes
At least weekly Yes





What was your relationship to the person?
(d) Do/did you live with this person whilst they had glandular fever or during the 3
months preceding their illness?
Yes 1 |i No 1 I2
Was it in a:
House Yes ! 3 No | I2
Flat YesD No [3
Hall of residence Yes| |i NoD









Daily Yes □1 No
At least weekly Yes LI' No
13
Less than weekly Yes No
4.11 Since you have been at University have you had occurrence of any of the following




































5. SMOKING, DRINKING, EXERCISE AND TRAVEL
5.1 Smoking
Since coming to University have you smoked tobacco (i.e.
smoked at least 1 cigarette or cigar or pipe per day, on
average)?
If yes, how much, on average, did/do you smoke?
Yes[ |i No | [2
cigarettes / day | || |
cigars / day 1 II 1
hand rolling tobacco oz / week [ [[ [ m




Since coining to University have you drunk alcohol?
Yes 1 [i NoD
5fy-;s, how much. \m average. :'.>•> }ou drink? (answer per day or per week, as you fee! most
representative of your consumption)
Beer or cider (pints) | per day or | |( | per week
Wine (glasses) □□ per day or | ][ | per week
Spirits (tots) □□ per day or [ || [ per week
5.3 Exercise
Since coming to University have you regularly (once a week or more) engaged in
active sports or other active exercise sufficient to raise a sweat or get you out of
breath for at least 20 minutes?
Yes 1 ji No 1 b
If yes, number of hours / week on average:
5.4 Travel
Since coming to University have you travelled outside the
UK?
Yes 1 |i No | [2
If yes:
1st TRIP
Which countries? (list names)
When did you go? | || | /1 || |
M Y
1 low long was the trip?
15
Did you suffer from travel-related illness? Yes |i
If yes, please specify
No [3
2nd TRIP
Which countries? (list names)
When did you go?
M Y
How long was the trip?
Did you suffer from travel-related illness? Yes |l NOD
If yes, please specify
3kd TRlp
Which countries? (list names)
When did you go?
M Y
How long was the trip?
Did you suffer from travel-related illness? Yes□ i NoD
If yes, please specify
If you have visited more countries, please continue at end.
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6. SEXUAL RELA TIONSHIPS
Confidentiality:
We are aware that the questions in this section are personal. Your answers will be treated in strict confidence.
If you do not feel happy about answering any or all of these questions that is fine, just leave them out and turn to
page 20. The notes below are to ensure everyone applies the same meaning to certain terms we use. Please read
them carefully before continuing.
NOTES
Genital area
A man's penis or woman's vagina/vulva - that is, sex organs.
(a) Any sexual contact or experience
This is a wider term and can include just kissing or cuddling, but not leading to genital contact or
intercourse.
(b) Genital contact NOT involving intercourse
Forms of contact with the genital area NOT leading to intercourse (vaginal, oral or anal) but intended to
be sexually stimulating, for example, stimulating by hand.
(c) Oral sexual intercourse
A man's or woman's mouth on a partner's genital area.
(d) Penetrative sexual intercourse
Either vaginal or anal sexual intercourse.
Partner/relationship
People who have had sexual experiences together, of any type (a), (b), (c) and (d) referred to above - whether
just once, a few times or as a regular partners, or as married partners.
6.1 Have you ever had any experiences of a sexual kind? E.g. of the various types
described above. These may be brief contacts or longer term relationships.
Yes [3 NoD
If yes, please answer the remaining questions.
If no, turn to page 20.
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(a) Kissing and cuddling but not
genital contact or intercourse Yes 1 |i No| I2
(M neTV.V.v. cor4?.c4 y\ot uiti •reourse 1—li cs | (l 1N0 j 11
(c) Oral sexual intercourse Yes 1 |i No | ?
(d) Penetrative sexual intercourse
Yes | ji No | I2
6.3 We would like to ask you about partners/contacts you have had, however brief, since
coming to University (including during holidays).
How many How many
Was the contact? Yes No
males? females?
(a) Oral sexual intercourse and
penetrative sexual intercourse
□1 a □ □
(b) Penetrative sexual intercourse not
included in (a)
D D □ □
(c) Oral sexual intercourse not included
in (a) or (b)
D 0 □ □
(d) Genital contact not involving
intercourse not included in,(a), (b)
or (c)
D D □ □
(e) Kissing and cuddling but not
leading to genital contact or
□ D □ □
intercourse not included in (a), (b),
(c) or (d)




Always or Occasionally Never or





6.4 Have you had a sexually transmitted disease since coming to University?
Yes□ > NoQ













THANK YOU VERY MUCH FOR HELPING US WITH THIS SURVEY
We appreciate your help, and hope that you have felt able to answer the questions without too much trouble. If
there is anything you would like to add or comment upon, please write it below.
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Visit Number Number MRC/ Date of Visit
Date of Birth Doctor
Clinical assessment - Visit 1
Date of first symptoms (incl "prodrome")
Date ofmost severe symptoms
Duration ofmost severe symptoms (days)
Unwell for how long (days)
Presenting features and how long experienced for at
time ofpresentation to GP









Are you able to attend all your timetabled classes Yes/No
Total hours timetabled per week





Total hours missed due to illness
Is the amount of studying that you do in your own
time normal for you at present?
Yes/No
Are you able to undertake your normal social life? Yes/No
Are you able to undertake your normal exercise
pattern ?
Yes/No
Do you have a part-time job? Yes/No
Hours per week
If yes, give dates absent, or "none" for no time off
1
Physical features
Sore throat Have you experienced
this ever during your
illness
No, not at any point
during illness
Unable to swallow saliva YES/NO
Unable to swallow liquids YES/NO
Unable to swallow soft diet YES/NO


















Do you have any other medical
conditions, the glandular fever
has affected?
Alcohol - units in last week
Alcohol - usual per week
Admitted to hospital / seen in A+E / out-patients?





Temperature student will be given chart and









Spleen size Not palpable Tip Fingers below costal margin
Liver Not palpable Edge Fingers below costal margin
Palpable glands YES/NO cervical Right left both
supraclavicular Right left both
Submandibular Right left both
axilliary Right left both
inguinal Right left both
Tonsils enlarged YES /NO Grade 1 2 3
Visit Number Number MRC/ Date of Visit







PHYSICAL FUNCTION AND FATIGUE
The following items are about activities you might do during a typical
day and how your health now limits you in these activities.
1. Please rate your fatigue (weariness, tiredness) by circling the number that best
describes your fatigue in the last week:
0 1 2 3 4 5
No fatigue
6 7 8 9 10
As bad as you can imagine
When your illness was at it's worst:
0 1 2 3 4 5
No fatigue
6 7 8 9 10
As bad as you can imagine
And before this current illness:
0 1 2 3 4 5
No fatigue
6 7 8 9 10
As bad as you can imagine
2. Record how many hours you spent on average per 24 hours in the last week:
(a) lying down but not asleep hrs
(b) and asleep hrs
3. We want to assess how much your illness has affected your physical function:
(a) Could you wash and dress at worst point in illness? YES/NO
Can you wash and dress now? YES/NO
(b) Could you leave your home at worst point in illness? YES/NO
Are you well enough to leave your home? YES/NO
(c) If you were able to leave home, please record how far you could walk easily






















4. Please record how many hours per week you spend doing vigorous activity
(enough to get out of breath) e.g. running, cycling, exercise class, swimming
at worst point in illness in last week and when well
5. Please record the number of hours per week you spent attending university
sessions e.g. tutorials/lectures/ practical work
at worst point in illness in last week and when well
6. Please record hours per week you spent in private study (not including time
recorded in question 5)
at worst point in illness in last week and when well
7. Has your illness affected your ability to concentrate? YES □ NO □
If yes please complete parts a-b, if no proceed to question 8
(a) Circle the one number that describes best how your illness has interfered
with your ability to concentrate (e.g. keeping attentive over the course of a
lecture or reading )
At the worst point in your illness:
0 12 3 4
No difficulty
5 6 7 8 9 10
Unable to concentrate
During the last week:
0 12 3 4
No difficulty
5 6 7 8 9 10
Unable to concentrate
Circle the one number that describes your ability to concentrate before you
became unwell:
0 12 3 4
No difficulty
5 6 7 8 9 10
Unable to concentrate
(b) Again imagine you are in a lecture or reading a textbook: How long can
you concentrate and learn new information for?
At the worst point in your illness? (circle)
5 minutes 10 minutes 20 minutes 40 minutes Over 1 hour
Now?
5 minutes 10 minutes 20 minutes 40 minutes Over 1 hour
8, Please record how many hours per week you spent going out to social events
(such as seeing a film, going out to a pub, club, or out for a meal)
at worst point in illness in last week and when well
2
Clinical assessment- visits 2, 3 etc Date ofvisit Date
MRC Number Visit number
Do you feel you are still experiencing your
worst symptoms
YES/NO
If no when were you most unwell (in days after first became unwell) Amount in days
Activities
Date Returned
Are you able to attend all your timetabled classes Yes/No






Has the amount of studying that you do in your own time
returned to normal?
Yes/No
Has your social life returned to normal Yes/No
Has your exercise pattern returned to normal Yes/No
Do you have a part-time job Yes/No
If yes have you returned? (Date)
Physical features
Sore throat Have you experienced
this since your last visit
No not since last seen
Unable to swallow saliva YES/NO
Able to swallow liquids YES/NO
Able to swallow soft diet YES/NO
Able to swallow but painful YES/NO














Do you have any other medical
conditions, the glandular fever
has affected?




Temperature student will be given chart and









Spleen size Not palpable Tip Fingers below costal margin
Liver Not palpable Edge Fingers below costal margin
Palpable glands YES/NO cervical Right left both
supraclavicular Right left both
submandibular Right left both
axilliary Right left both
inguinal Right left both
Tonsils enlarged YES /NO Grade 1 2 3
Visit Number Number MRC/ Date of Visit






PHYSICAL FUNCTION AND FATIGUE
The following items are about activities you might do during a typical
day and how your health now limits you in these activities.
1. Please rate your fatigue (weariness, tiredness) by circling the number that best
describes your fatigue over the last week?
0 1 2 3 4 5 6 7 8 9 10
No fatigue As bad as you can imagine
2. Record how many hours you spent on average per 24 hours in the last week:
(a) lying down but not asleep hrs
(b) and asleep hrs
3. We want to assess how much your illness has affected your physical function-.
(a) Can you wash and dress now? YES/NO
(b) Are you well enough to leave your home? YES/NO
(c) If you are able to leave home, please circle how far you could walk easily
e.g. a walk to the shops or college. (An average walking speed is 1 km in 15 mins)
Less than 100m 100-500m 500m to 1km 1-2km Over 2km
4. Please record how many hours per week you spend doing vigorous activity
(Enough to get out of breath - e.g. running, cycling, exercise class)
• in the last week hrs
5. Please record the number of hours per week you spent attending university
sessions e.g. tutorials/lectures/ practical work
in the last week hrs
6. Please record hours per week you spent in private study (not including time
recorded in question 5)




7. Has your illness affected your ability to concentrate? YES □ NO □
If yes please complete parts a-b, If no proceed to question 8
(a) Circle the one number that describes best how your illness has interfered
with your ability to concentrate (e.g. keeping attentive over the course of a
lecture or reading)
During the last week:
0 1 2 3 4 5 6 7 8 9 10
No difficulty Unable to concentrate
(b) Again imagine you are in a lecture or reading a textbook: How long can you
concentrate and learn new information for?
In the last week:
5 minutes 10 minutes 20 minutes 40 minutes Over 1 hour
8. Please record how many hours per week you spent going out to social events
(such as seeing a film, going out to a pub, club, or out for a meal)
in the last week hrs
2
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GLANDULAR FEVER FORM
CONFIDENTIAL
ID Number: Male | | FemaleQ1
-





1 II 1 nn 1 II 1
Day Month Year
Introduction
You may recall that at the beginning of your course you filled in a questionnaire and gave a blood
sample as part of a study investigating the ways in which your lifestyle and background relate to your
risk of developing glandular fever. Now that you have glandular fever, we would appreciate it if you
would fill in a further questionnaire and allow us to take some more blood. Once again your replies
will be treated confidentially. The information will not be disclosed to the University or others. Your
participation is voluntary and whether you participate or not will make no difference to your medical
care whilst at the University. If there are some questions that you would prefer not to answer, that is
fine - just leave a blank. If you wish to discuss any aspect of the study further please contact Dr
Tanzina Haque*, Lecturer in Virology, who is not directly involved in the study.
Thank you, in anticipation, for your help.
DorothyH Crawford Dr Nadine Harrison
Professor ofMedical Microbiology University Health Service
University ofEdinburgh University ofEdinburgh
* Dr. Tanzina Haque, Lecturer in Virology, Tower Block, Summerhall, University of Edinburgh
(0131-650-7941).
I. QUESTIONSABOUT YOUR STUDIES
1.1 When did you start at Edinburgh University?
13 What course are you undertaking?
Please specify
13 In the past 6 months have you:
Yes No
Changed course □ □
Taken exams □ □
Undertaken work contributing to your final degree mark □ □
L PERSONALAND FAMILYDETAILS
Prior to attending primary school, what were the arrangements for looking after yon, and for




Nursery school or reception class U □ U □
Other day care centre □ □ □ □
At home with mother or carer □ □ □ □
At childminder's home □ □ □ □
Other outside home - please specify n □
2.1 Are you: tick:
Married? | [t
Widowed? [ j2
Divorced or Separated? [ j3
Cohabiting (living with partner)? [ |4
In a relationship, but not living with partner? [ j5
Single? Q6
Has this changed in the past 6 months? Yes QJi No | I2
3
Do you have any children? Yes | |i No | I2 Ifyes:
Sex: Date ofBirth:
Male | |i Female | I2 □□ □□ 1 II 1
Day Month Year
Male 1 |i Female | (2 □□ □□ 1 II 1
Day Month Year
Male [ |i Female [ I2 1 1! 1 1 II 1
Day Month Year
Male | |i Female | [2 □□ □□ 1 II 1
Day Month Year
QUESTIONSABOUT YOUR LIVING CIRCUMSTANCES
3.1 Please list each residence you have lived in for 1 month or more during the past 6
months:
I STT" RESIDENCE:
(a) fromCD /CD t0 CD I I II I
MY MY
Village/town/city Country
Type of accommodation: please tick:
Halls of residence [_ j
House j J
Mat [ j
Other 1 | please specify














(b) fromOO /OO t0 □□ / □□
MY MY
Village/town/city Country
Type of accommodation: please tick:
Halls of residence [ J
House □
Flat | J
Other 1 1 please specify










(c) fromOO /OO to DO /
MY MY
Village/town/city Country
Type of accommodation: please tick:
Halls of residence j j
House I j
Flat ! j
Other 1 1 please specify
With how many adults and how many children on average did you share the
following rooms?:
Adults Children
Kitchen | 1 1 1
Bathroom j j j !
Bedroom j I j
Living room | j j !
If you require more space please continue at the end of the questionnaire.
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4. MEDICAL BACKGROUND
4.1 During the past 6 months have you been immunised against?:
please tick:
Yes No Don't know
Polio D O D
Rubella D D O
TB (BCG) D O D
Typhoid D o O
Tetanus D Q
Hepatitis A □> O O
Hepatitis B O D □«
Meningitis D D O
Yellow Fever D D D
Japanese B Encephalitis D O D
Rabies D D O
Diphtheria □. D O
Other D O O
Other, please state.
4.2 Have you had any illnesses during the past 6 months, apart from your present glandular
fever that required a visit to your doctor?
Yes□ NoD
If yes, was the visit for:












On-going medical condition (eg diabetes)
Please specify o □
Other illness
Please specify □. o □
6




Yes No Yes No
Depression Q Q, Q Q2





Schizophrenia Qj, Q2 Q | |2
Drug/alcohol related problems | [t | |p j ^ [ j2
Stress-related problems [ j, [ [2 | ^ [ |2
Other, please state





Your parent, child, sibling or partner was seriously ill or | j
died?
You broke off a marriage or steady relationship? | || | |2
You had a major financial crisis? | |t | |2
Financial pressure led to you taking a part-time job? | |, | |2
Major problems with your studies/exams? [^J, | |2
Other, please state
4.5 Have you used any medication (including oral contraceptives and inhalers) during the
three months before you got glandular fever?
2.





(please continue at end ofquestionnaire ifnecessary)
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4.6 (a) Do you know anyone who has had glandular fever in the last 3 months?
Yes | |i No 1 I2 If yes, how many? £
(If you have had contact with more than one person please record the first contact here and the second
in the next section below)
What was your relationship to the person?
Please specify
(b) Do/did you live with this person whilst they had glandular fever or during the 3
months preceding their illness?
Yes [3 No [3
Was it in a:
House Yes [3 No | I2
Flat YesQ No | |2
Hall of residence Yes 1 [i No | [2
Did you share a:
Bedroom Yes | |i NoQj
Kitchen Yes 1 |i No Q J
Bathroom Yes 1 ]i No [[ ]
(c) How often do/did you see them whilst they had glandular fever? Was it:
Daily Yes 1 [i No 1 I2
At least Weekly Yes 1 |i No [ [2
Less than weekly Yes 1 [i No | [2
8
Please complete this if you have had contact with a second person who has had glandular fever in the last 3
months
4.6 Second contact
What was your relationship to the person?
Please specify.
(c) Do/did you live with this person whilst they had glandular fever or during the 3
months preceding their illness?
Yes [^]i No | I2
Was it in a:
House Yes[^]i No 1 (2
Flat Yes No 1 [2
Hall of residence Yes [ |) No [ [2
Did you share a:
Bedroom Yes [ [i No | [2
Kitchen Yes 1 !■ No | [2
Bathroom Yes [ [i No | [2
(d) How often do/did you see them whilst they had glandular fever? Was it:
Daily Yes | li No [ [2
At least Weekly Yes 1 It No [ I2
Less than weekly Yes 1 [i No 1 [2
4.7 Have you had your tonsils out? Yes 1 li No[ [2
If so, at what age?
9
5. SMOKING. DRINKING. EXERCISEAND TRAVEL
5.1 Smoking
Have you smoked tobacco (ie smoked at least 1 cigarette or yes | |i No | [2
cigar or pipe per day, on average) during the last 6 1
months?
If yes, how, much, on average, did you smoke before you
got glandular fever?
cigarettes / day [ j! j
cigars / day [ }j ]
hand rolling tobacco oz / week ( jj J
pipe tobacco oz / week [ j[ j
5.2 Alcohol
Had you drunk alcohol during the past 6 months before you got glandular fever?
Yes 1 [i No | [2
Ifyes, how much, on average, did you drink before your present illness?
Beer or cider (pints)
Wine (glasses)
Spirits (tots)
LJU per day or L || | per week
| [ | | per day or [ j| ~\ per week
| || | per day or | || ] per week
5.3 Exercise
During the past 6 months (but before your present illness) have you regularly (once a
week or more) engaged in active sports or other active exercise sufficient to raise a
sweat or get you out of breath for at least 20 minutes ?
Yes |^]i No | [2
If yes, number of hours / week on average: [ IP j
5.4 Travel
Have you travelled outside the UK in the past 6 months? yes | |i No | [2
1st VISIT
Which country? (name)
When did you go to the country?
How long was the visit?




When was the visit?
How long was the visit?
Did you suffer from travel-related illness? Yes [^]i No ] [2
If yes, please specify
3rd visit
Which country? (name)
When was the visit?
How long was the visit?
Did you suffer from travel-related illness? Yes [ |i No [ I2
If yes, please specify
If you have visited more countries, please continue at end.
6. SEXUAL RELA TIONSHIPS
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Glandular fever is passed on by close contact, and so it is useful for us to know
about your sexual relationships.
Confidentiality:
We are aware that the questions in this section are personal. Your answers will be
treated in strict confidence; the doctor will not see them. When you have finished put the
questionnaire in the envelope, your name will not be on the questionnaire or envelope.
If you do not feel happy about answering these questions that is fine, just leave them
out. We have given you some notes, to ensure everyone applies the same meaning to
certain terms we use. Please read the appendix before continuing.
6.1 Have you ever had any experiences of a sexual kind? E.g. of the various types described
in the appendix . These may be brief contacts or longer term relationships.
Yes[[]Ji No | [2
If yes, please answer the remaining questions.
6.2 If yes, when was the first time you ever had a relationship that involved :
Age (or
"never")
Was this in the last
three months
(a) Kissing and cuddling but not
genital contact or intercourse Yes 1 ]» No[ (2
(b) Genital contact not involving intercourse Yes 1 [i No [ [2
(c) Oral sexual intercourse Yes 1 [i No | I2
(d) Penetrative sexual intercourse
Yes | [i No | [2
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6.2. Have you had any sexual relationships in the last 3 months before you developed
glandular fever? If yes, we would like to ask you some questions about the
relationship^), however brief:
Number of relationships in past 3 months? [ ! I j
Number ofMales?
Number ofFemales?
If you have had 1 or 2 relationships please in the last 3 months complete section 6.2 only. If there
were more than 2, please complete sections 6.2 and 6.3.
RELATIONSHIP 1
What sex was the person? Male Q J
Was the contact?
(a) Kissing and cuddling but not leading
to genital contact or intercourse
(b) Genital contact not involving
intercourse
(c) Oral sexual intercourse
(d) Penetrative sexual intercourse.
(e) Oral sexual intercourse and
penetrative sexual intercourse






If yes on how many
occasions in the last three












What sex was the person? Male [ | Female [J |
If yes on how many
occasions in the last three
Was the contact? Yes No months did this occur?
(b) Kissing and cuddling but not leading Q D
to genital contact or intercourse
(b) Genital contact not involving D D
intercourse
(c) Oral sexual intercourse D O
(f) Penetrative sexual intercourse. D D
(g) Oral sexual intercourse and D D
penetrative sexual intercourse
If you had penetrative sexual intercourse, did you use:
Always Occasionally Never
A male condom: [_ j □ □
A female condom: j j □ □
A cap/diaphragm: j_ J □ □
Contact Code
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6.3 Have you had any other relationships however brief in the last 3 months before your
illness? If yes, we would like to ask you some questions about these relationships.
If yes, with how many
people in the last three
months did this occur?
(not including relationship 1
& 2)
How many How many
males? females?
Was the contact?
(a) Kissing and cuddling but not
leading to genital contact or
intercourse
(b) Genital contact not involving
intercourse
(c) Oral sexual intercourse
(d) Penetrative sexual intercourse.
(e) Oral sexual intercourse and
penetrative sexual intercourse
If you had penetrative sexual intei
Always Occasionally Never
A male condom: □ □ □
A female condom: □ □ □
A cap/diaphragm: □ □ □
Yes No
D O □ □
Q O □ □
D Q □ □
D 13 □ □
O O □ □
rcourse, did you use:
6.4 Have you had a sexually transmitted disease during the past 6 months?
Yes 1 |i No | I2
If yes, which of the following have you had?: Tick:
Yes No
Gonorrhoea j |t j j2
Syphilis QJ, | [2









THANK YOU VERYMUCH FOR HELPING US WITH THIS SURVEY
We appreciate your help, and hope that you have felt able to answer the questions without too much
trouble. If there is anything you would like to add or comment upon, please write it below:-
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APPENDIX
Please read these notes before answering the questions:
They are just to make sure everyone applies the same meaning to certain terms we have used.
Genital area
A man's penis or woman's vagina- that is sex organs.
(a) Any sexual contact or experience
That is a wider term and can include just kissing or cuddling, but not leading to genital
contact or intercourse
(b) Genital contact NOT involving intercourse
Forms of contact with the genital area NOT leading to intercourse (vaginal, oral or anal) but
intended to be sexually stimulating, for example, stimulating by hand.
(c) Oral sexual intercourse
A man's or woman's mouth on a partner's genital area
(d) Penetrative sexual intercourse
Either vaginal or anal sexual intercourse
Partner/relationship
People who have had sexual experiences together, of any type (a), (b), (c) and (d) referred to above -
whether just once, a few times or as a regular partners, or as married partners.
12.2 EBV Type and Lymphocyte Count at Diagnosis
The number of IM cases caused by type 2 strains was insufficient to permit investigation of
any associations between EBV type and clinical symptoms, laboratory parameters or viral
load. Lymphocyte counts and EBV type were made available to me for an additional ten IM
cases by Drs. R. Thomas and K. McAulay. Interestingly IM caused by type l may be
associated with a higher lymphocyte count in the peripheral blood
EBV type n Median lymphocyte count at diagnosis xlO91"1 p value
l 44 5.77 -
2 4 2.86 p=0.022
Both types 4 6.03 0.837
n Number of students
Includes data from an additional 10 IM cases supplied by Drs. Thomas and McAulay.
Table 25 EBV type and Lymphocyte count at Diagnosis
12.3 Gender Composition of University Students
The gender composition of the student body eligible to enter the study was estimated from
the following information kindly made available by Andrew Quickfall in The Governance
and Strategic Planning Department of University of Edinburgh. In 1999-2000 there were
3851 undergraduates ofwhom 54% were female, and 596 PhD students ofwhom 47% were
female. In the year 2000-2001 there were 3988 undergraduates ofwhom 54% were female
and 626 PhD students ofwhom 46% were female. Overall this means that 53% of eligible
students in the university as a whole were female in these two years.
12.4 Comparison of Lymphocyte Subset Ranges for Controls with
Published Data
The results of lymphocyte subset percentages obtained for the healthy control group in this
study are in line with other published data as shown in Table 26. The results are presented as
average (mean) parentages as this allows comparison with the published data. Actual
lymphocyte numbers rather than percentages were used in the current study as the use of
percentages to describe lymphocyte changes may be misleading, and this is particularly true
in IM where the acute lymphocytosis does not affect the lymphocyte subsets equally.
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Reichert Howard Bofill Williams Mean of
etal (1991) et al{1996) et al{\ 992) et al (1983) control
18-70 years 18-67 years 11-79 years 21-53 years group
(4 centres) (Caucasian) Edinburgh
n=261 n=79 n=600 n=20 n=15
CD3% 69.9-74.1 72.9 76.3 74.8 71.6
CD8% 31.4-36.1 24.7 29.5 27.4 29.2
CD4% 42.9-45.0 46.8 43.6 52.5 45.0
CD 19% 12.8-14.6 - - - 17.7
CD56% 12.9-16.9 - - - 10.7
CD4%/CD8% 1.28-1.56 2.1 1.50 1.92 (calc) 1.67
calc calculatec
Table 26 Comparison of lymphocyte subset ranges in controls with other published data
Reichert et al compared results from healthy adults aged 18 to 70 years at four centres
(Reichert et al, 1991). Data from persons aged 18 to 30 years made up 24% of the samples,
but unfortunately the results were not presented by age. A number of age related changes in
lymphocyte subset percentages have been described including a 1% rise in the percentages of
NK and CD4+ cells per decade and a 1% fall in CD8+ percentage per decade (Bofdl et al,
1992; Reichert et al, 1991). This illustrates the importance of the use of age-matched
controls in this study. The rise in NK percentage with age may explain the lowerNK
percentage in controls in the current study (10.7%), where all participants were less than 30
years of age, than in the study by Reichert et al (1991) who reported a range of 12.9 to
16.9% NK cells. Howard et al. compared data from Asians and other ethnic groups. Their
results from Caucasians are shown in Table 26 above, together with data from Reichert et al,
a study performed at The Royal Free Hospital, UK, and, a small study from New Mexico
(Bofdl et al, 1992; Howard et al, 1996; Reichert et al, 1991; Williams et al, 1983). In health
the number ofCD4+ T-cells is greater than that of the CD8+ T-cells such that the ratio of
CD4:CD8 T-cells is at least 1.0. Study of control students in Edinburgh University are in
line with this finding, with an overall CD4:CD8 ratio for 15 controls of 1.57. Ten to 20
percent of normal controls have been noted to have CD4:CD8 ratios less than 1 but the
magnitude of the shortfall was not documented (Bofill et al, 1992; Reichert et al, 1991). In
the current study three controls had CD4:CD8 ratios of less than 1, although the actual
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values were very close to 1 (0.97, 0.95 and 0.96). Overall, these comparisons show that the
control data in this study is in line with other published data.
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